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Die Bildung infektiöser Viruspartikel des humanen Zytomegalievirus (HCMV) ist ein 
mehrstufiger Prozess. Sie beginnt mit der Verpackung der DNA in die Kapside im Kern, 
gefolgt von weiterer Reifung während des Transports durch das Zytoplasma und der 
abschließenden Freisetzung aus der Zelle. Im Zuge dieser Arbeit wurden zwei Proteine, die 
Einfluss auf die ebengenannten Prozesse haben, analysiert.  
Der erste Teil der Arbeit befasst sich mit der funktionellen Charakterisierung des HCMV 
Proteins pUL77. Es ist bekannt, dass das homologe Protein pUL25 in -Herpesvirinae 
essentiell für die DNA-Verpackung ist. Zunächst konnte das Protein als Kapsid-assoziiertes 
strukturelles Protein identifiziert werden. Es wurden Interaktionen von pUL77 mit DNA-
Verpackungs- und Kapsidproteinen gezeigt. Weiterhin wurde die DNA-Bindungsfähigkeit von 
pUL77 in verschiedenen „in vitro“-Experimenten untersucht. Zusammengefasst weisen 
unsere Ergebnisse auf eine Funktion von HCMV pUL77 bei der DNA-Verpackung hin. 
Im zweiten Teil der Arbeit wurde das HCMV Protein pUL71 charakterisiert, das in allen 
Herpesviren konserviert vorkommt, dessen Funktion jedoch nicht charakterisiert ist. Zunächst 
wurde das Protein als strukturelles Tegumentprotein mit “early-late“ Expressionskinetik 
klassifiziert. Weiterhin wurden die subzelluläre Lokalisation sowie virale und zelluläre 
Interaktionspartner untersucht. Die Ergebnisse weisen auf eine Funktion von HCMV pUL71 
bei der Reifung und beim Transport der Virionen im Zytoplasma hin. „In silico“-Vorhersagen 
zeigten ein „Leuzin Zipper“-Motiv in pUL71, das als mögliche Oligomerisationsdomäne 
dienen könnte. Mutationen wurden in dieses Motiv eingebracht und die resultierenden 
Proteine auf ihre Oligomerisationsfähigkeit mit „in vitro“-Methoden und in rekombinanten 
Viren untersucht. Zusammenfassend konnten wir zeigen, dass das „Leuzin Zipper“-Motiv 
wichtig für die Funktion von pUL71 ist und diese mit einer unbeeinträchtigten 
Oligomerisation des Proteins zusammen hängt. 
 
Schlagwörter: 





The morphogenesis of Human cytomegalovirus (HCMV) virions starts with the capsid 
assembly and DNA insertion in the nucleus followed by maturation during transport through 
the cytoplasm prior to release of virus progeny. In this study we are functionally 
characterising two proteins that are involved in those steps.  
The function of essential HCMV protein pUL77 is characterised in the first part of the study. 
HCMV pUL77 was shown to be a structural protein associated with capsids. Furthermore, our 
experiments demonstrated that HCMV pUL77 interacts with DNA packaging motor 
components and capsid proteins. The ability of HCMV pUL77 to bind double-stranded DNA 
was studied in “in vitro” assays designed for this study. The homologue α-Herpesvirinae 
protein pUL25 is described to be involved in processes connected with DNA packaging. Data 
obtained in this study demonstrates that HCMV pUL77 might serve a similar function. 
In the second part of the study HCMV pUL71, conserved throughout the Herpesvirus family 
but to date unclassified, was functionally characterised. HCMV pUL71 was defined a 
structural tegument protein with early-late expression kinetics. We studied the sub-cellular 
localisation and interactions of pUL71 with a subset of cellular and viral proteins. Thereby we 
could show that HCMV pUL71 function might be connected with processes of viral egress. 
By in silico analyses we identified a leucine zipper motif in pUL71 that might serve as a 
putative oligomerisation domain. In order to investigate the function of the leucine zipper 
motif, we performed in vitro assays and investigated the alterations of the motif in the viral 
context. Taken together we can conclude that (i) an intact leucine zipper motif is crucial for 
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1.1 HCMV and the Herpesviridae 
The human cytomegalovirus (HCMV) is taxonomically classified in the family of 
Herpesviridae according to the international committee on virus taxonomy (=ICTV) (194). 
Characteristics Herpesviridae comprise are (i) structural similarities like composition of the 
virus particle (1.1.1.) as well as (ii) encoding their own viral DNA-polymerase and (iii) 
establishment of a life-long persistence in their host. (2) 
Taking biologic properties such as host range and growth kinetics into account the 
Herpesviridae can be subclassified into three subfamilies: -, β- and γ-Herpesvirinae. 
- Herpesvirinae are characterised by common features like broad host range, a 
comparatively short replication cycle (<1 day) and fast cell-to-cell spread. Persistence takes 
place in sensory neurons. Members of this subfamily causing pathogenicity in humans are 
herpes simplex virus type 1 and 2 (HSV-1, HSV-2) as well as varizella zoster virus (VZV) (2, 
194). 
β- Herpesvirinae are characterised by a narrow host range, comparatively long replication 
cycles (>1 day) and slow cell-to-cell spread. Persistence takes place in lymphotropic organs, 
secretory glands and renal tissue. Human pathogenic members of this subfamily are HCMV, 
human herpes virus type 6 (HHV-6) and human herpes virus type 7 (HHV-7) (2, 194). 
γ- Herpesvirinae are characterised by a strict host range and even restricted towards B- and T-
cells. Furthermore they are convincingly linked to oncogenesis. Human pathogenic members 
of this subfamily are Epstein-Barr virus (EBV) and human herpes virus type 8 (HHV-8) (2, 
194). 
HCMV infection of host cells is characterised by a strong cytopathic effect causing 
enlargement of the cells, eponymously called cytomegaly. Considering the characteristics for 
β-Herpesvirinae mentioned above HCMV can infect a remarkably broad range of cells within 
its human host, including parenchymal cells and connective tissue cells of virtually any organ 
and various hematopoietic cell types. Epithelial cells, endothelial cells, fibroblasts and smooth 
muscle cells are the predominant targets for virus replication (214). 
Following primary infection, HCMV establishes lifelong latency and periodically reactivates 
without causing symptoms in healthy individuals (7, 61, 117). In the absence of an adequate 
host-derived immune response, like in prenatal and postnatal infants (40, 75, 191), patients 
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receiving organ transplants (197) or such suffering from AIDS (55), HCMV can subsequently 
cause invasive disease (65). 
Although the exact mode of HCMV infection is still unknown, it is assumed to be through 
direct contact with body fluids from an infected person (1). Putative routes of transmission are 
via sexual contacts through saliva, sperm and cervix fluid (86), from mother to child 
congenitally (97) or later through breast feeding (147) and via blood transfusions and organ 
transplants (197). 
HCMV is world-widely endemic but persistence in the population differs between 
economically well developed countries of northern Europe (40% seropositive adults) to 
developing countries were almost 100% of adults are seropositive (7, 28). 
 
1.1.1 The viral particles 
One common feature of the Herpesviridae is the composition of its virions. 
For HCMV the virion is between 150-200 nm in diameter in total. From the inside to the 
outside composed of the genome surrounded by a protein matrix in its centre (core), 
encapsidated by a protein shell (capsid), covered by an amorphous protein layer (tegument) 
and a host-derived lipid bilayer with inserted viral glycoproteins (envelope) (91, Figure 1). 
 
Figure 1: Composition of the virion (A) EM analysis of a mature extracellular virion from 
HCMV (TB40E). Sample was embedded and ultra thin sectioned prior analysis by 
transmission electron microscopy (TEM). Magnifications are indicated by the bar. (B) 
Schematically drawing of the virion. Capsid, tegument and envelope layers are indicated 
by red arrows in both representations. 
 
The central core is composed of the linear dsDNA genome and a fibrillic protein matrix. 
(249). Together core and capsid are termed nucleocapsid. 
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The capsid has an icosahedral symmetry (T=16) composed of 162 capsomers. These 
capsomers itself are build up from a subset of structural proteins including the major capsid 
protein (MCP), minor capsid protein (mCP), minor capsid binding protein (mC-BP), smallest 
capsid protein (SCP) as well as parts of the DNA packaging machinery with portal protein 
(pUL104) and large terminase subunit (pUL56). (91) 
Capsid assembly has been studied in -Herpesvirinae in in vitro cell free assembly assays of 
HSV-1 capsids (164). Many HSV-1 capsid proteins share structural and functional homology 
to HCMV capsid proteins and cryo-electron microscopic analysis of both viruses suggests 
similar, but not identical, capsid structure (44, 54, 95, 234, 255, 256). 
The tegument is composed of a number of phosphor proteins. This arrangement does not seem 
to follow any obvious symmetry and is therefore called amorphous (38). So far 20 proteins 
are assigned to the tegument that facilitates important functions during viral replication (112). 
For example they facilitate morphogenesis during egress (e.g. pp150 (26, 156)), viral 
transport (pUL47, pUL48 (136, 216), immune evasion (e.g. pp65 , pIRS1/pTRS1 (41, 58) as 
well as regulation of early gene expression by transactivation (e.g. pp71, pUL69, (133, 247)). 
In comparison to other Herpesvirinae the most structurally diverse region of the HCMV virion 
seems to be the tegument which is composed of a lot of unique proteins. Although proteins 
with homologous functions localised to the tegument, only a limited number of these proteins 
show significant structural homologies (6). 
The envelope is a host derived lipid-bilayer with inserted viral glycoproteins (185) that are 
arranged in three complexes. Glycoprotein complex I (gCI) is a homodimer predominately 
composed of glycoprotein gB (37, 38). glycoprotein complex II (gCII) is arranged of 
glycoproteins gM and gN (137, 138) and glycoprotein complex III (gCIII) from gH, gL and 
gO (104, 132). These complexes are important for attachment to the host cell and fusion 
between the viral envelope and the plasma membrane for entry into the cell, as well as for the 
induction of neutralising antibodies in the host’s immune response (39). 
Among infectious virions a number of other non-infectious viral particles are build during 
HCMV infections. Though these particles are not infectious for not containing the genome 
they are important for the host’s immune response (178). Examples are dense bodies (DB) 
that are composed of enveloped tegument proteins (204) or so called non-infectious 
enveloped particles (NIEPs), empty capsids that underwent further maturation steps like 
tegumentation and envelopment (108). 
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1.1.2 The viral genome 
The HCMV genome has the largest coding capacity of all Herpesviridae with 230kb in length 
and a molecular weight of 1,5 x 108 Dalton (24, 52). It is comprised of linear double stranded 
(ds) DNA and contains two non repetitive regions that are termed unique long (UL)- and 
unique short (US)-segment, flanked by terminal (TRL, TRS) and internal repeats (IRL, IRS) 
(11). The open reading frames (ORFs) are named and numbered according to their position on 
the genome within one of those regions. 
An important motif for DNA packaging is found in the internal repeat regions, the so called a-
region that encodes the cis-acting packaging elements pac 1 and pac 2 (115, 146, 159, 163). 
These elements are an important trigger for nuclease- and binding activity of the terminase 
during packaging of DNA into preformed capsids, a crucial step in viral maturation (31, 161). 
The lab strain AD169 that is predominantly used in this study is completely sequenced and 
contains 208 ORFs (52). Through passaging mutations in comparison to wild type virus have 
accumulated in AD169 likes frame shifts in genes RL5A, RL13 and UL131A (14, 72, 252) 
and a substitution of gene UL36. Those regions are hypothesised to facilitate pathogenicity 
and cell tropisms in other HCMV strains (48, 143). 
 
1.2 From structural components to infectious particles 
The HCMV lifecycle is determined by four crucial events: (i) the entry into the host cell, (ii) 
the exploiting of the cellular machinery to produce dsDNA and protein, (iii) the assembly of 
the capsids and DNA insertion and (iv) the release of virus progeny from the cell. In the 
following those events will be discussed in more detail. Figure 2 is a schematically drawing of 
the events mapping viral replication steps to cellular compartments. 
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Figure 2: The HCMV life cycle. Processes of HCMV lifecycle are summarised starting 
with attachment and entry, followed by transport to the nucleus. Further synthesis of viral 
components is carried out as well as assembly of capsids in the nucleus prior to packaging 
of DNA into these preformed capsids. Egress starts with perinuclear budding and 
transport to the cytoplasmic cisternae where virions undergo the final envelopment. The 
last step is release of virus progeny by exocytosis. Adapted from E. Bogner (30). 
 
1.2.1 Attachment and virus entry 
The process of HCMV entering the host cell is classified into three events: (i) attachment, (ii) 
receptor binding or activation and (iii) fusion (98). 
Attachment of the virus to the surface of the host cell is the first step in viral replication. On 
the viral side the three glycoprotein complexes I-III (gC I-III) are involved. Not all interaction 
partners in this event are fully characterised to date. Still we know that firstly attachment to 
cell surface is mediated by binding of gB and gM to heparan sulphate proteoglycans (63, 
113). Complexes of gH/gL/UL128-131 are necessary for entry in epithelial cells (198). 
Further a couple of receptors were suggested as HCMV entry receptors. For instance Annexin 
II was described to bind gB and enhances HCMV binding and fusion to phospholipid-
membranes (182, 188). To the contrary, cells that do not express Annexin II are permissive 
for HCMV too (182). Another candidate was human aminopeptidase N (CD13) that was 
discussed to mediate interactions between gH and cell surface (218). Epidermal growth factor 
receptor (EGFR) as another putative HCMV receptor and integrin αvβ3 as a co-receptor were 
described by Wang et al. (242, 243). Still, it is important to note cells that do not express 
EGFR are susceptible for HCMV infection in HELF cells. Taken together, neither one of the 
entry receptors proposed so far are likely to be the HCMV entry receptor nor seem this event 
to be dependent on one receptor alone in all cell types. Therefore further investigations need 
to be carried out to elucidate the underlying mechanism of attachment. 
Still, these processes are followed by membrane fusion between envelope and host cell 
plasma membrane (62). Again glycoproteins seem to be involved but the exact events remain 
poorly understood (34, 114, 190). In the case of HSV-1 the specific mode of entry is cell-type 
dependent. Either the route via direct fusion at the plasma membrane and subsequent release 
of the capsid into the cytosol or endocytosis is used (142, 168). An equivalent scenario is 
likely for HCMV. 
Once the virus has entered the cell its nucleocapsid is transported to the nuclear pore by 
hijacking cellular motor proteins. Kinesin or dynein and dynactin transport capsids on 
microtubules from the plasma membrane to the nuclear pore (76, 80, 187, 217). At the nuclear 
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pore the DNA is released and circulised to ensure proper nuclear import of functional 
genomes (172, 193). 
 
1.2.2 Gene expression and replication 
Once the dsDNA genome has reached the nucleus gene expression will start in a cascade 
manner modulated by multiple transcription activators. Within this cascade proteins are 
characterised according to their expression kinetics in (i) immediate-early, (ii) early and (iii) 
late proteins (244). Within the first three hours of infection immediate early genes (IE1/2 
(221)) are expressed triggered by cellular RNA-Polymerase II together with viral proteins 
pp71 and pUL69 (22, 247). Expression is independent from de novo-synthesised viral 
proteins. Immediate early proteins regulate expression of so called early genes (219). 
Expressed between three and 36 hours post infection (h p.i.) early genes regulate initiation of 
viral replication and expression of the majority of viral proteins so called late proteins that 
often have structural functions (expression 36-72h p.i.) (90). Expression of late proteins starts 
with DNA-synthesis that is carried out following the rolling circle-mechanism (17, 103, 145) 
first described for genome replication in bacteriophage λ (5). DNA-synthesis is restricted to 
centralised areas in the nucleus termed replication centres (73, 74). According to the rolling 
cycle mechanism so called concatamers, linear linkage of several unique-length genomes, are 
synthesised from the circular template that will be later on processed for DNA packaging. 
 
1.2.3 Capsid assembly and DNA packaging 
During the process of capsid assembly three different forms of capsid are described: empty A-
capsids, protein containing B-capsids and DNA filled C-capsids (91, 192). 
Assembly of the capsid takes place in the proximity of viral replication centres in the nucleus 
of host cells. All components needed for assembly are transported inside the nucleus. 
For HSV-1 extensive in vitro cell free assembly assays of capsids have been performed (164) 
to identify important players in this process. For HCMV it was shown that first of all the two 
alternatively translated gene products of UL80 assembly protein precursor (pAP) and 
proteinase precursor (pPR) together with the MCP form higher order complexes in the 
cytoplasm (pAP12-MCP6) (91). Those are transported into the nucleus together with SCP (56, 
127). There they build up the pro-capsids together with mCP and mc-BP (92, 164). Thereby 
pAP and pPR form a so called scaffold to stabilise the structural viral proteins at their correct 
positions during assembly (91). At the same time the portal protein pUL104 (77, 167, 213) is 
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inserted as well. Once assembly is completed capsids are called B-capsid, containing two 
layers of protein one composed of structural components on the outside and the scaffold 
within. 
Before DNA can be packaged the capsid needs to be matured by removing the scaffold by 
proteolytic activity of pPR derived protease PR (192, 245). 
The process of DNA packaging shows homologies to that described for dsDNA 
bacteriophages belonging to the order of Caudovirales (21). As mentioned above DNA is 
synthesised as concatamers that need to be processed in unique length genomes during 
packaging. Seven viral gene products have been indentified due to the homologies between 
bacteriophages and Herpesviridae. For HCMV those are pUL104, pUL93, pUL89, pUL77, 
pUL56, pUL52 und pUL51 (52). The most important among them are the two subunits of the 
terminase pUL56 and pUL89 that specifically bind to the a-sequence of viral DNA, have an 
endonuclease activity and produce energy needed for packaging by ATP-hydrolysis (31, 32, 
105, 206, 207). The terminase translocates the DNA via the portal inside the capsids (77, 78). 
If DNA packaging is successful, the capsids containing the genome are now termed C-capsids 
while abortive packaging leads to so called DNA-free A-capsids (179). 
DNA processing and packaging, as well as the turn over from B to C-capsid is hypothesised to 
be synchronised and conserved in all Herpesviridae (125). 
 
1.2.4 Maturation and egress 
After the capsids have undergone packaging they are interacting with first tegument and 
cellular proteins of the nuclear lamina to drive egress. For example it has been described that 
viral kinase pUL97 in HCMV or pUL31 and pUL34 in α-Herpesvirinae polarise and thereby 
destabilise the nuclear lamina to allow capsids to leave the nucleus (51, 88, 122, 184, 195, 
201). This transport is described as a perinuclear budding event (186). Glycoproteins gB and 
gH (33, 155, 184) facilitate a first temporal envelopment at the inner nuclear membrane 
followed by a de-envelopment at the outer nuclear membrane (8). Further they bud into the 
cytoplasm and get transported to the cytoplasmic cisternae. Morphogenesis of the virions will 
occur on the capsids itself through tegumentation while been transported through the cytosol 
as well (202) as on the future envelopment site (151, 152). The exact underlying mechanisms 
of morphogenesis are controversially discussed in the field. Recently, it was hypothesised that 
the virus reconstructs the cell for its morphogenesis upon infection by inducing formation of a 
compartment that combines endoplasmatic reticulum (ER), Golgi and trans-Golgi network 
(TGN) in close proximity. It has been reported that many vesicles derived from the TGN, 
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secretory, and endosomal pathway (66, 71, 87, 202, 233) concentrate in a junxtanuclear 
position to form a structure termed “assembly compartment” or “assembly complex” (AC) 
(101, 202). Besides these cellular structures, tegument, envelope, and non-structural proteins 
have been found to accumulate in this AC during infection (70, 99, 101, 138, 202, 209, 227). 
Anyhow, ultrastructural analysis of HCMV infected cells revealed that final envelopment 
takes place at the cisternae of the tubular endosomes or TGN (233). There the viral particles 
acquire their final envelope by budding into membrane compartment containing both TGN 
and endosomes (47).  
The cellular processes of membrane budding which are normally part of endosome sorting are 
controlled by the cellular endosomal sorting complex required for transport (ESCRT). Recent 
data showed that ESCRT specific proteins are recruited to the AC thereby suggesting that 
ESCRT machinery is involved in final maturation steps (225) 
After completion of morphogenesis mature virions will leave the cell by exocytosis (151, 152, 
153, 154). 
 
1.3 Aim of the study 
In this study proteins are functionally characterised that are proposed to be involved in two 
important steps of virion morphogenesis. At the beginning of this study and partially still to 
date nothing is described about the function of HCMV essential protein pUL77 and pUL71, 
though being nonessential, its loss causes severe growth impairments (82, 239). Homologues 
in -Herpesvirinae are partially characterised and therefore we tried to draw conclusions from 
these homologies. 
Firstly HCMV pUL77 is analysed in comparison to its -Herpesvirinae homologue pUL25 
(52). This protein is described to have a proposed function as an assisting factor during DNA 
packaging, to generate a headfull signal to stop the packaging process or to function as a cap 
to seal the portal and hold DNA within packaged capsids (15, 118, 144, 171, 235). More 
recently, an additional function early in the viral lifecycle is discussed. HSV-1 pUL25 is 
described to trigger the release of genomic DNA at the nuclear pore during entry (175, 193) 
The 1911 bp long gene product of ORF UL77 is defined as a core gene and situated on 
position 112227 and 114137 in the HCMV genome (NC_006273.2, 81) between UL76 and 
UL78 partially overlapping with the C-Terminus of pUL76. The translated protein is 636 aa in 
length and the calculated molecular weight (MW) and isoelectric point (pI) is 73028.53 (~ 
73kDa) and 5.73, respectively. 
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In this study we hypothesise that HCMV pUL77 shares equivalent properties with its α-
Herpesvirinae homologues and plays a role in similar processes. Therefore we generate a 
specific antibody to analyse the subviral localisation of pUL77, interactions with certain viral 
proteins by ultracentrifugation and various protein-protein interactions in vitro. Furthermore, 
we analyse whether pUL77 has the capacity to bind dsDNA, a prerequisite for the proposed 
functions in DNA packaging or release, by generating a new assay that allows us to use 
defined DNA fragments for our interaction studies. 
The -Herpesvirinae homologue for pUL71 is pUL51 (52). However, HCMV pUL71 and 
HSV-1 pUL51 are not structural homologues, but both are members of the Herpesvirus U44 
superfamily, containing the conserved, but functionally unclassified, U44 domain (140). 
At the beginning of this study, only studies in animal herpesviruses and HSV-1 were 
performed (67, 96, 131). Most of them concentrated on localisation but some also connected 
the protein to processes of egress either at the stage of perinuclear budding or at a later step 
like secondary envelopment (119, 131, 169, 170). 
The 1086 bp long gene product of ORF UL71 is defined as a core gene and situated on 
position 104703 and 105788 in the HCMV genome (NC_006273.2, 81) between UL70 and 
UL72 partially overlapping with the N-terminus of the opposed UL70. The translated protein 
is 361 aa in length and the calculated MW and pI is 39885.86 (~ 40kDa) and 4.99, 
respectively. 
In this study we analyse whether the functions described for -Herpesvirinae are applicable 
for pUL71. Again we start our analysis by generating a specific antibody that will be further 
used to identify subviral localisation and the interaction with other viral and cellular proteins 
in different in vitro protein-protein interaction studies and immunofluorescence. In addition, 
analyses are performed to determine the time point of expression of pUL71 within the HCMV 
transcription cascade and the intracellular distribution of the protein. Oligomerisation of 
pUL71 is analysed by single particle EM analysis, in vitro protein-protein interaction studies 
and in the viral context using recombinant viruses. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals, consumables and equipment 
2.1.1.1 Chemicals 
All chemicals were purchased at highest purity and used according to the manufacturer 
indicated below. Buffers and media for cell culture are indicated in the appropriate section. 
 
Name Manufacturer
Acetone ((CH3)2CO) [Cat. No. 8002] JT Baker, Phillipsburg, NJ
Acrylamide stock [Cat. No. 10687] 
(acrylamide- bis solution (29:1) 30%) 
Serva Electrophoresis, Heidelberg
-Ade/-His/-Leu/-Trp DO Supplement  
[10 g Cat. No. 630428] 
Clontech, Otsu, Japan
Agar (agar-agar bacteriological) [Cat. No. 2266.3]  Carl-Roth, Karlsruhe
Agarose- electrophoresis grade [Cat. No. 15510-027] Invitrogen, Paisley, UK
Ampiciline Na-salt [Cat. No. 13399] Serva Electrophoresis, Heidelberg
APS (ammonium peroxodisulfate) [Cat. No. 09913] Fluka, Steinheim
3-AT (3-amino-1,2,4-triazole) [Cat. No. A-8056-10G] Sigma-Aldrich, St. Louis, MO
Bis-Tris Pufferan [Cat. No. 9140.2] 
(bis-(2-hydroxyethyl)-imino-tris(hydroxymethyl)-methan) 
Carl-Roth, Karlsruhe
Boric acid (H3BO3) [Cat. No. 1.00165.5000] Merck, Darmstadt
Bromephenole blue sodium salt [Cat. No. 32768] Riedel-de Haen, Steinheim
BSA (albumin bovine fraction V) [Cat. No. 11930] Serva Electrophoresis, Heidelberg
CaCl2 (calcium chloride) [Cat. No.C-7902]  Sigma, Deisenhofen
CH3COOH (acetic acid) Rotipuran [Cat. No. 37385] Carl-Roth, Karlsruhe
Chloroform [Cat. No. 1.02431.1000] Merck, Darmstadt
cOmplete Mini, [Cat. No. 04693159001] 
EDTA-free Protease Inhibitor Mix 
Roche Diagnostics, Mannheim
Coomassie brilliant blue R250 [Cat. No. 21553] Merck, Darmstadt
DABCO(1,4-diazabicyclo[2.2.2]octan) [Cat. No. D-2522] Sigma, St.Louis, MO
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Name Manufacturer
DAPI (4',6-diamidino-2-phenylindole) [Cat. No. 6335.1] Carl-Roth, Karlsruhe
DMF (N, N Dimethylformamide) Rotipuran  
[Cat. No. T921.1] 
Carl-Roth, Karlsruhe
dNTP Mix (10mM total) [Cat. No. BIO-39044] Bioline, Luckenwalde
DTT (dithiothreitol) [Cat. No. D-9779] Sigma, St.Louis, MO
EDTA (ethylendiamine tetraacetic acid) [Cat. No. 8040.2] Carl-Roth, Karlsruhe
1,2-Epoxypropane (propylene oxide) [Cat. No. 56671] Carl-Roth, Karlsruhe
Ethanolamine [Cat. No. E-6133] Sigma, St.Louis, MO
EtOHden. (ethanol 96% +MEK 1%) [Cat. No. T171.3] Carl-Roth, Karlsruhe
EtOH (ethanol 96% EMPROVE exp.)  
[Cat. No. 1.00971.1000] 
Merck, Darmstadt
Fluoroprep [Cat. No. REF-75521] bioMerieux, Marcy l'Etoile, France 
Glucose (α-D(+) glucose monohydrate) [Cat. No. 6887.1] Carl-Roth, Karlsruhe
Glutaraldehyd 25% solution [Cat. No. 74157.1] Carl-Roth, Karlsruhe
L-Gluthadione reduced [Cat. No. 6382.2] Carl-Roth, Karlsruhe
Glycerol Rotipuran [Cat. No. 3783.1] Carl-Roth, Karlsruhe
Glycid ether 100 [Cat. No. 8619.1] Carl-Roth, Karlsruhe
Glycine [Cat. No. 3908.3] Carl-Roth, Karlsruhe
Hardener DBA [Cat. No. 8623] Carl-Roth, Karlsruhe
Hardener MNA [Cat. No. 8639] Carl-Roth, Karlsruhe
HEPES Pufferan [Cat. No. 9105.2] 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
Carl-Roth, Karlsruhe
HCl 37% Rotipuran (hydrochloric acid) [Cat. No. 4625.2] Carl-Roth, Karlsruhe
Herring sperm DNA 10mg/ml [Cat. No. D181B] Promega, Madison, WI
IPTG (isopropyl-1-thio-ß-D-galactopyranoside)  
[Cat. No. CN08.2] 
Carl-Roth, Karlsruhe
Isopropyl alcohol (2-propanol) Rotipuran  
[Cat. No.6752.3] 
Carl-Roth, Karlsruhe
Kanamycine sulphate [Cat. No. T832.1] Carl-Roth, Karlsruhe
KCH3CO2 (potassium acetate) [Cat. No. T874.1] Carl-Roth, Karlsruhe
KCl (potassium chloride) [Cat. No. 6781.3] Carl-Roth, Karlsruhe
KH2PO4 (potassium dihydrogen phosphate)  





Lead citrate (Lead(II) citrate tribasic trihydrate)  
[Cat. No. 15326-25G] 
Sigma, St.Louis, MO
L-Leucine [Cat. No. L8000-25G] Sigma, St.Louis, MO
-Leu/-Trp DO supplement (10g Cat No. 630417) Clontech, Otsu, Japan
LiOAc (lithium acetate dehydrate) [Cat. No. 62395] Fluka, Steinheim
β-mercaptoethanole (2-mercaptoethanole)  
[Cat. No. 4227.1] 
Carl-Roth, Karlsruhe
MES  Pufferan [Cat. No. 4256.2] 
(2-(N-morpholino)ethanesulfonic acid) 
Carl-Roth, Karlsruhe
Methocel MC [Cat. No. M-64605-100G-F] Sigma, St.Louis, MO
MgCl2 (magnesium chloride hexahydrate)  
[Cat. No. A450933] 
Merck, Darmstadt
MgSO4 (magnesium sulfate) [Cat. No. 0261.2] Carl-Roth, Karlsruhe
Milk powder- blotting grade [Cat. No. T145.3] Carl-Roth, Karlsruhe
MnCl2 (manganese(II) chloride) [Cat. No. T881.3] Carl-Roth, Karlsruhe
MOPS (3-(N-morpholino) propanesulfonic acid)  
[Cat. No. M-1254] 
Sigma, St.Louis, MO
NaCl (sodium chloride) [Cat. No. 1.06404.5000] Merck, Darmstadt
Na-desoxycholat (sodium desoxycholat)  
[Cat. No. 685304] 
Merck, Darmstadt
Na2HPO4 x 2H2O [Cat. No. K11432680] 
(di-sodium hydrogenphosphate dihydrate) 
Merck, Darmstadt
NaH2PO4 x H2O [Cat. No. A983346807] 
(sodium dihydrogenphosphate monohydrate) 
Merck, Darmstadt
NaN3 (sodium azide) [Cat. No. K305.1] Carl-Roth, Karlsruhe
NaOH (sodium hydroxide) [Cat. No. P031.2] Carl-Roth, Karlsruhe
Na2SO4 (sodium sulphate) [Cat. No. 8560.3] Carl-Roth, Karlsruhe
NH4Cl (ammonium chloride) [Cat. No. P726.1] Carl-Roth, Karlsruhe
(NH4)2SO4 (ammonium sulphate) [Cat. No. 3746.1] Carl-Roth, Karlsruhe
NP-40 (nonidet P-40) non-ionic detergent  
[Cat. No. N-6507] 
Sigma, St.Louis, MO
Osmium tetroxide 4% solution [Cat. No. 8088.1] Carl-Roth, Karlsruhe
PAA (phosphonoacetic acid) [Cat. No. 195425] ICN-Biomedicals INC, Aurora, OH
PEG4000 (polyethylene glycol MW 4000)  
[Cat. No. 0156.1] 
Carl-Roth, Karlsruhe
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Name Manufacturer
Peptone/Tryptone [Cat. No. 211705]  
(bacto-tryptone pancreatic digest of casein) 
BD, Le Ponnt de Claix, France
PFA (paraformaldehyde) [Cat. No. 0335.2] Carl-Roth, Karlsruhe
Phenole (Rotiphenol for separation of DNA/RNA)  
[Cat. No. 0038.2] 
Carl-Roth, Karlsruhe
Ponceau S [Cat. No. 33429] Serva, Boehringer Ingelheim Bioproducts, Heidelberg
RbCl (rubidium chloride)  
[Cat. No. 4471.1]  
Carl-Roth, Karlsruhe
RedSafe [Cat. No. 21141] 
(nucleic acid staining solution) 
Intron Biotechnology, INC. Gyeonggi-do, Korea
[35S] methionine/cystein (10 mCi/ml)  
[Cat. No. IS103/074] 
Hartmann Analytic, Braunschweig
SDS (sodium dodecyl sulfate) pellets  
[Cat. No. CN30.3] 
Carl-Roth, Karlsruhe
Sodium tatrate (di-sodium tartrate dihydrate)  
[Cat. No.T110.1] 
Carl-Roth, Karlsruhe
Sucrose [Cat. No. S-0389] Sigma, St.Louis, MO
Tannin [Cat. No. 4239.1] Carl-Roth, Karlsruhe
TCA (trichloro acidic acid) [Cat. No. 8074.0100] Merck, Darmstadt
TEMED (N,N,N',N'-tetramethyl-ethane-1,2-diamine)  
[Cat. No. T-9281]   
Sigma, St.Louis, MO
Tetracycline hydrochloride [Cat. No. A2228.0025] AppliChem, Darmstadt
Tris Pufferan [Cat. No. 4955.3]  
(2-Amino-2-hydroxymethyl-propane-1,3-diol) 
Carl-Roth, Karlsruhe
Triton X-100 detergent [Cat. No. 648466]  
(Polyethylene glycol mono  
[4-(1,1,3,3-tetramethylbutyl)phenyl] ether) 
Calbiochem, La Jolla, CA
L-Tryptophan [Cat. No. T-0254-5G] Sigma, St.Louis, MO
Tween-20 non ionic detergent [Cat. No. 9127.2] 
(Polyoxyethylene (20) sorbitan monolaurate) 
Carl-Roth, Karlsruhe
Uranyl acetate dihydrate [Cat. No. 19481] Ted Pella INC., Redding, CA
Yeast extract granulated [Cat. No. 2904.2] Carl-Roth, Karlsruhe
Yeast nitrogen base without amino acids  
[Cat. No. HP26.1] 
Carl-Roth, Karlsruhe






Amicon Ultra centrifugal filters Ultracel 30K/50K Millipore, Cork, Ireland
Amicon Ultra centrifugal filters Ultracel 0.5mL 30K/50K Millipore, Cork, Ireland
Botteltop filter 500ml SFCA 0.45µm Nalgene, Rochester, NY
Centrifuge tubes 1x 3 1/2 in. (25x89mm) for SW32Ti Beckmann Coulter, Krefeld
Centrifuge tubes 7/16x 2 3/8 in. (11x60mm) for SW60Ti Beckmann Coulter, Krefeld
Centrifuge tubes 9/16x 3 3/4 in. (14x95mm) for SW40 Beckmann Coulter, Krefeld
Cell culture dishes Falcon 
6 well (1x106 cells per well); 12 well (5x105 cells per well); 
24 well (2x105 cells per well); 96 well (4x104 cells per well) 
BD, Heidelberg
Cell culture flasks Falcon 
25 ml (1x106 cells); 75 ml (1x107 cells); 175 ml (2x107 cells) 
BD, Heidelberg
Conical test tubes 17x120 (15ml) Carl-Roth, Karlsruhe
Conical test tubes 30x115 (50ml) Carl-Roth, Karlsruhe
Econo-Pac 10 disposable columns BioRad Laboratories, Muenchen
Injekt 20ml luer solo syringe Braun, Melsungen
Injekt-F 1ml luer solo syringe Braun, Melsungen
Multiply® -Pro cup PCR tube 0.2ml PP Sarstedt, Nuembrecht
Nitrocellulose membrane 0.2μm Schleicher & Schuell BioScience GmbH, Dassel 
Rotilab reaction tubes 1.5ml Carl-Roth, Karlsruhe
Rotilab syringe filters PVDF 0.22µm Carl-Roth, Karlsruhe
Rotilab syringe filters PVDF 0.45µm Carl-Roth, Karlsruhe
Whatmann blotting paper (WM Whatmann 3MM) GE Healthcare, Freiburg





Benchtop Centrifuge 3K20 
Rotor: #12158 for 1x 3 1/2 in. (25x89mm) 
Sigma Laborzentrifugen GmbH, Osterode 
Eppendorf Centrifuge 5417R Eppendorf, Wesseling-Berzdorf
Rotors: Fixed-angle rotor FA-45-30-11,  
Swing-bucket rotor A-8-11 
Function Line Labofuge 400 
Rotor: Swinging bucket rotor #75008179 
Heraeus, Osterode
Optima L-90K Ultracentrifuge 






Affi Gel® 10 Gel active ester agarose BioRad Laboratories, Hercules, CA 
Affi Gel® 15 Gel active ester agarose BioRad Laboratories, Hercules, CA 
ÄKTA FPLC system  GE Healthcare, Freiburg 
(Elements: CU-950, Frac-920, INV-907, M-925, P-920, UPC-900)  
Deoxyribonucleic acid-cellulose  
(double stranded, from calf thymus DNA) 
Sigma-Aldrich, St Louis, MO
Glutathione Sepharose 4B GE Healthcare, Freiburg
GSTrapTM 1ml column GE Healthcare, Freiburg
HiPrep 16/60 Sephacryl HR column GE Healthcare, Freiburg
HiTrap™ Heparin HP column GE Healthcare, Freiburg
Pierce Avidin Agarose Thermo Scientific, Dreieich
Protein A Sepharose CL-4B GE Healthcare, Freiburg










Biometra BioDoc Analyse Ti5 Biometra Goettingen
CCD-Camera Fusion SL Vilber Lourmat, Eberhardzell
Molecular Dynamics Phosphorimager SI Amersham Pharmacia, Uppsala, Sweden
Generals 
Bronson sonifier II W-450 Heinemann, Schwaebisch Gmuend
Beaker resonator 101-147-046 Heinemann, Schwaebisch Gmuend
Consort EV243 Electrophoresis power supply Carl-Roth, Karlsruhe
Horizontal electrophoresis system university workshop, Erlangen
MC1 precision balance LC420 Satorius, Goettingen
Model 583 Gel Dryer BioRad Laboratories, Muenchen
Sterile safety bench Antair BSK 4MP S/N 8261 Heraeus, Osterode
TE 70XP Semi-Dry Transfer Unit w/built-in Power Supply Hoefer, San Francisco, CA
Thermocycler Primus 25 advanced Peqlab, Erlangen
Vertical electrophoresis system Kreutz Labortechnik, Reiskirchen
Vortex Genie 2 Scientific Industries, INC., Bohemia, NY
Microscopes and Equipment 
Axio-Observer.Z1 fluorescence microscope Carl Zeiss MicroImaging GmbH, Jena
Eclipse A1 laser scanning microscope Nikon Instruments, Tokyo, Japan
Olympus BX60 wide field Olympus, Tokyo, Japan
TEM TecnaiTM G2 FEI Company, Eindhoven
Turbo Carbon Coater 208 Cressington Scientific Instruments Ltd., Watford, UK











Eppendorf Reference 1000 Eppendorf, Wesseling-Berzdorf
Eppendorf Reference 100 Eppendorf, Wesseling-Berzdorf
Eppendorf Research 10 Eppendorf, Wesseling-Berzdorf
Eppendorf Research 2.5 Eppendorf, Wesseling-Berzdorf
Pipetus® Hirschmann Laborgeraete, Eberstadt
Spectrometers 
Nanodrop 1000 Peqlab, Erlangen
Ultraspec 4000 UV/Vis spectrometer Pharmacia Biotech, Uppsala, Sweden
Software 
Axiovision 4.8 software for Zeiss microscopes Carl Zeiss MicroImaging GmbH, Jena
Biometra BioDoc Analyse 2.1 Biometra, Goettingen
Cell D Imaging software for Olympus microscopes Olympus, Tokyo, Japan
ImageJ 1.41o NIH Bethesda, MD
Image Quant for Phosphorimager Amersham Pharmacia, Uppsala Sweden
NIS-Elements software for Nikon microscopes Nikon Instruments, Tokyo, Japan
Unicorn 5.1 for ÄKTA FPLC GE Healtcare, Freiburg
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2.1.2 Enzymes, Markers and Kits 
Name Manufacturer
Enzymes modifying DNA, RNA and proteins 
BamHI [Cat. No. ER0051] Fermentas, Mannheim
BglII [Cat. No. ER0081] Fermentas, Mannheim
DNase Ι from bovine pancreas [Cat. No. 11284932001] Roche Diagnostics, Mannheim
DpnI [Cat. No. ER1701] Fermentas, Mannheim
EcoRI [Cat. No. ER0271] Fermentas, Mannheim
Lysozyme 20 000 U/mg [Cat. No. 8259.3] Carl-Roth, Karlsruhe
NdeI [Cat. No. ER0581] Fermentas, Mannheim
NotI [Cat. No. ER0591] Fermentas, Mannheim
peqGOLD Pwo-DNA-Polymerase [Cat. No. 01-5020] Peqlab, Erlangen
PreScission Protease 500U [Cat. No. 27-0843-01]  GE Healtcare, Freiburg
RNase A 100mg [Cat. No. 740505] Machery-Nagel, Dueren
T4 DNA Ligase 1000 units [Cat. No. EL0011] Fermentas, Mannheim
Taq DNA-Polymerase (recombinant) 100 units [Cat. No.EP0401] Fermentas, Mannheim
XbaI [Cat. No. ER0681] Fermentas, Mannheim
DNA marker 
Generuler TM Low Range DNA Ladder [Cat. No. SM1911] Fermentas, Mannheim
Generuler TM 1kb DNA Ladder [Cat. No. SM0311] Fermentas, Mannheim
Protein marker 
PageRuler TM Prestained Protein Ladder [Cat. No. SM0671] Fermentas, Mannheim












AEC-Staining Kit [Cat. No. AEC101] Sigma-Aldrich, St. Louis, MO
ECL kit [Cat. No. 34075] 
SuperSignal West Dura Extended Duration Substrate 
Thermo Scientific, Dreieich
NucleoSpin Extract II Kit [Cat. No. 740609.250] Machery-Nagel, Dueren
GeneJET™ Plasmid Miniprep kit [Cat. No. K0503] Fermentas, Mannheim
PureLink™ HiPure Plasmid Midiprep kit [Cat. No. K210014] Invitrogen, Karlsruhe
TnT® T7 [Cat. No. L1170] 
Quick Coupled Transcription/Translation System 
Promega, Mannheim
TurboFect™ in vitro Transfection Reagent [Cat. No. R0531] Fermentas, Mannheim
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2.1.3 Bacteria, cells and virus 
 Features reference 
Bacteria (E. coli)   
BL21 






endA1, gyrA96, hsdR17 (rk-, mk+), recA1, relA1, 
supE44 thi-1-,deoR (lacZYA-argF)-U169f80lac M15 
Invitrogen 
XL1-blue 
endA1, gyrA96, hsdR17 (rk-mK+), lac, recA1, relA1, 
supE44, thi, (F´, lacIq, lacZM15, proAB+, tet) Stratagene 
Yeast (Saccharomyces cerevisiae)  
AH109 
MATa, his3-200, leu2-3/ 112, trp1-901, ura3-52; 





MAT, ade2-101, his3-200, leu2-3/ 112, trp1-901, 
ura3-52, gal4, met–, gal80, URA3::GAL1UAS -
GAL1TATA-lacZ, MEL1 
Clontech 
Insect cells   
High5 5B1-4, Trichoplusia ni embryonic cell line Invitrogen 
Sf9 Spodoptera frugiperda ovarian tissue cell line Invitrogen 
Mammalian cells   
Hela human cervix carcinoma cell line ATCC.CCL-2 
HFF 
Primary human foreskin fibroblast isolate passages 
10-15 
T. Stamminger , 
Uni. Erlangen 
293T 
Human Embryonic Kidney (HEK) epithelial cell line 
transformed by human adenovirus 5 + SV40 T-antigen 
ATCC.CRL-
11268, 177 
Viruses (HCMV)   
AD169 
Lab strain, additional 929 bp after nucleotide, 54612 
causing frame shift effecting UL42, UL43 
68, 196 
recombinant BACs  
71_LZ-BAC pTBs-UL71del34-41_res (d3-24) 150, * 
71_L1-BAC pTBs-UL71L34A-L41A_res (I1-15) 150, * 
71_wt-BAC pTB4- HCMV TB40E-4 BAC (endotheliotropic) 215, * 
* Constructed in cooperation with Dr. Jens von Einem, University Hospital Ulm 
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2.1.4 Buffers and media 
Buffers that are specific for certain procedures are directly indicated in the Methods section. 
2.1.4.1 General buffers and solutions (9): 
PBS (phosphate buffered saline)- 137mM NaCl, 2,7mM KCl, 8mM Na2HPO4 x 2 H2O, 
 1.76mM KH2PO4; pH 7.4 
TE (Tris-EDTA) Buffer- 10 mM Tris-HCl, 1mM EDTA; pH 8.0 
Tris-HCl Buffer- Tris is adjusted with HCl to right pH (between 6.8 - 9.0) 
Sodium phosphate buffer (3): e.g. 1L 20mM pH7.4: 19ml 0,2M Na2HPO4 x 2 H2O + 
 81ml 0,2M NaH2PO4 
2.1.4.2 Media and supplements for cultivation of bacteria (E.coli) 
LB Soc I 
10g/L Peptone/Tryptone 
5g/L Yeast extract 
5g/L NaCl 
15g/L Agar (plates) 
pH 7.5 
20g/L Peptone/Tryptone 









Antibiotic working concentration comment 
Ampiciline 100µg/ml in ddH2O, -20°C 
Gentamycine 7µg/ml 4°C 
IPTG 40µg/ml in ddH2O, at -20°C 
Kanamycine 50µg/ml in ddH2O, -20°C 
Tetracycline 10µg/ml in 70% EtOH, light protected, -20°C 
X-Gal 100µg/ml in DMF, light protected, -20°C 
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2.1.4.3 Media and supplements for cultivation of yeast 
YPD Minimal media 
20g/L Peptone/Tryptone 
10g/L Yeast extract 
20g/L Agar (plates) 
2% Glucose 
pH 6.5 






-Leu selective media -Trp- selective media 
Minimal media 
+0.64 g/L-Leu/-Trp DO supplement 
+20µg/L L-Tryptophan 
Minimal media 
+0.64 g/L-Leu/-Trp DO supplement 
+100mg/L L-Leucine 
-Leu/-Trp selective media -Leu/-Trp/-Ade/-His selective media 
Minimal media 
+0.64 g/L-Leu/-Trp DO supplement 
Minimal media 
+0.60 g/L  -Ade/-His/-Leu/-Trp  
                  DO supplement 
 
2.1.4.4 Media and supplements for cultivation of insect cells 
Name Manufacturer 
FCS (fetal calf serum) (#CH 30 160.30) Prebio Science, Bonn 
Gentamycine sulphate 50mg/ml (#17-518 L) Lonza, Basel, Switzerland 
Grace’s Insect Medium suppl. (#11605-045) Gibco-BRL Life Technologies, Eggenstein
 
Sf9 or High5 cells were grown in Grace’s Insect Medium supplemented with 10% FCS and 
50µg/ml Gentamycine sulphate. 
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2.1.4.5 Media and supplements for cultivation of mammalian cells 
Name Manufacturer 
L-alanyl-L-glutamine (#K0302) Biochrom AG, Lankwitz 
FCS (fetal calf serum) (#CH 30 160.30) Prebio Science, Bonn 
Gentamycine sulphate 50mg/ml (#17-518 L) Lonza, Basel, Switzerland 
MEM (Minimum essential Medium Eagle) (#12-136F) Lonza, Basel, Switzerland 
NEAA (non essential amino acids) 100x (#K0293) Biochrom AG, Lankwitz 
OptiMEM I (1x) (#11058-021) Lonza, Basel, Switzerland 
PBS (Phosphate buffered saline) I(#17-512F) Lonza, Basel, Switzerland 
Sodium pyruvate 100x (#L0473) Biochrom AG, Lankwitz 
Trypsin/EDTA 0.25% pH 7,0 (#2500-056) Gibco-BRL Life Technologies, Eggenstein 
 
Growth medium for HFF, 293T Growth medium for Hela 
MEM             500ml 
Supplements: 
Gentamycine sulphate  
 500µl 
L-alanyl-L-glutamine  5ml 
Sodium pyruvate   5ml 
NEAA    5ml 
MEM     500ml 
Supplements: 
Gentamycine sulphate  
 500µl 
L-alanyl-L-glutamine  5ml 
Sodium pyruvate   5ml 
 
 
HFF, Hela or 293T cells were grown in their appropriate media supplemented with 10% FCS. 
For infection and transfection FCS concentration was reduced to 2%, for transfection for 
BiFCs to 0.1%.  Unsupplemented OptiMEM I was used to prepare transfection mixes. 
 
Inhibitors of viral replication: 




Plasmid Features Reference 
bMON14272 
Baculovirus shuttle vector, present in 
DH10Bac™ E. coli, Bacmid 
Invitrogen 
pcDNA-YC 
C-term. YFP (YC) in pcDNA3.1+, for BiFC J. von Einem 
pcDNA3.1+ 
Mammalian expression vector 




GFP in pcDNA3.1+ for assaying expression 
capacity of cells in BiFC 
J. von Einem 
pcDNA3.1-mcherry 
mCherry in pcDNA3.1+ for assaying 
expression capacity of cells in BiFC 
J. von Einem 
pcDNA3.1/HisC 
Mammalian expression vector 
T7prom, f1 ori, pBR322 ori , AmpR, pCMV, 
pSV40, NeoR., 6xHis, Xpress_EK 
Invitrogen 
pcDNA56 UL56wt in pcDNA3.1/HisC E. Bogner 
pcDNA71 UL71wt in pcDNA3.1/HisB This study 
pcDNA71_ΔLZ-YC UL71 Δ34-55 + C-term. YC in pcDNA3.1+ This study 
pcDNA71_L1-YC UL71 L34/41A + C-term. YC in pcDNA3.1+ This study 
pcDNA71_L2-YC 




UL71 L34/41/48/55A + C-term. YC in 
pcDNA3.1+ 
This study 
pcDNA71_wt-YC UL71wt + C-term. YFP (YC) in pcDNA3.1+ This study 
pcDNA71_wt-YN 
BiFC YN-construct 
UL71wt + N-term. YFP (YN) in pcDNA3.1+ 
J. von Einem 
pcDNA71_ΔLZ-myc UL71 Δ34-55 pHM1580 This study 
pcDNA71_L1-myc UL71 L34/41A in pHM1580 This study 
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pcDNA71_L2-myc UL71 L34/41/55A in pHM1580 This study 
pcDNA71_L3-myc UL71 L34/41/48/55A in pHM1580 This study 
pcDNA71-myc UL71wt in pHM1580 E. Bogner 
pcDNA77 UL77wt in pcDNA3.1 HisC E. Bogner 
pcDNA77-myc UL77wt in pHM1580 E. Bogner 
pcDNA89 UL89wt in pcDNA3.1 HisB E. Bogner 
pcDNA104 UL104wt in pcDNA3.1 HisB E. Bogner 
pcDNAMCP UL86wt in pcDNA3.1 HisC E. Bogner 
pCM1029 Cosmid 85 
pGADT-7 
Gal-4 AD Vector for Yeast 
pBR322 ori, AmpR, 2µ ori, LEU2 
57 
pGAD56 UL56wt Gal4-AD construct for Y2H This study 
pGAD71 UL71wt Gal4-AD construct for Y2H This study 
pGAD77 UL77wt Gal4-AD construct for Y2H This study 
pGAD89 UL89wt Gal4-AD construct for Y2H This study 
pGAD104 UL104wt Gal4-AD construct for Y2H This study 
pGADMCP UL86wt Gal4-AD construct for Y2H This study 
pGBKT-7 
DNA-BD Vector for Yeast 
pBR322 ori, KanR, 2µ ori, TRP1 
134 
pGBD71 UL71wt DNA-BD construct for Y2H This study 
pGBD77 UL77wt DNA-BD construct for Y2H This study 
34 
pGBD56 UL56wt DNA-BD construct for Y2H This study 
pGBD89 UL89wt DNA-BD construct for Y2H This study 
pGBD104 UL104wt DNA-BD construct for Y2H This study 
pGBDMCP UL86wt DNA-BD construct for Y2H This study 
pFastBacHT B 
Cloning vector for Baculovirus 
f1ori, pBR322ori, AmpR, PHprom, SV40 pA, 
Tn7-R, Tn7L GentR, 6x His, TEV_EK 
Invitrogen 
pFast71 UL71 in pFastBac HT B This study 
pGEX-6P-1 
E. coli (BL21) expression vector 




pGEX-UL71 UL71wt in pGex6p-1 E. Bogner 
pGEX-UL77 UL77wt in pGex6p-1 E. Bogner 
pHM123 IE1 in pcDNA3 183 
pHM1580 
Mammalian expression vector 
pcDNA3.1+, N-terminal Myc-tag 
100 




The primers were designed with help of Gene Runner Version 3.01 
(http://www.generunner.net) software and received by Invitrogen, Karlsruhe. DNA of cosmids 
(85) and plasmids indicated in the table above were used as template. Constructs were tested 















































bio-pac1 5´ ATTTCACCCCCCCGCTAAAAACACCCCCCCGCCCAC-3´ 
pac1 rev 5´-GTGGGCGGGGGGGTGTTTTTAGCGGGGGGGTGAAAT-3´ 
pUC18-pac 5´-ATTTCACCCCCCCGCTAAAAACTCCGCCCCCCTGACGAG-3´ 
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2.1.7 Used antibodies 
Primary antibodies: 
Primary antibodies for immunofluorescence (IF) were diluted in PBS only, whereas they were 
diluted in PBS + 0.1% Tween-20 +0.3% BSA +0.02% NaN3 for immunostaining (WB), stored 
at 4°C and used multiple times. 
Viral targets 
Cytotect Cytotect CP Biotest, a hyper immune serum against HCMV, 100E/ml  
(PZN-1469325; Biotest Pharma GmbH, Dreieich)  
For WB: [1:5000] 
mAbgB “CMV gB” (1-M-12) mouse mAb against pUL55 = gB  
(sc-52400; Santa Cruz Biotechnology, INC., Heidelberg)  
for IF: [1:75] /for WB: [1:400] 
mAbIE1 mAb63-27 mouse mAb specific for IE1 (183) 
for IF: [conc.] / for WB: [conc.]/ for IP: [1:50] 
mAbMCP mAb28-4 mouse monoclonal antibody (mAb) specific for 
the major capsid protein (MCP) (53) 
for IF: [conc.] / for WB: [1:10]/ for IP: [1:50] 
mAbpp28 “CMV pp28” (5C3) mouse mAb against pUL99 = pp28  
(sc-56975; Santa Cruz Biotechnology, INC., Heidelberg)  
for IF: [1:75] / for WB: [1:250] 
mAbpp150 (XP-1) mouse mAb against pp150 = UL32 (110) 
for IF: [1:10] 
mAbUL44 “CMV pp52” (CH16) mouse mAb against pUL44 = pp52  
(sc-69744; Santa Cruz Biotechnology, INC., Heidelberg)  
for IF: [1:50] / for WB: [1:400] 
pAbUL56 affinity purified from HCMV positive patient Sera (31) 
for WB: F1 [conc.]/ for IP: F1 [1:50] 
pAbUL71 affinity purified from HCMV positive patient Sera (this study)  
for IF: F1 [conc.]/ for WB: F1 [1:20]/ for IP: F1 [1:50] 
pAbUL77 affinity purified from HCMV positive patient Sera (this study)  
for IF: F1 1:5/ for WB: F1 [1:10]/ for IP: [1:50] 
pAbUL104 affinity purified from HCMV positive patient Sera (77)  




mAbGM130 “purified mouse anti-GM130” against Golgi matrix protein GM130  
(#610822; Becton, Dickinson and Company Transduction Laboratories, 
Franklin Lakes, NJ)  
for IF: [1:75] 
mAbp230 “purified mouse anti-Human p230 trans Golgi” against peripheral membrane 
protein associated with cytosolic face of TGN p230 (#611280; Becton, 
Dickinson and Company Transduction Laboratories, Franklin Lakes, NJ)  
for IF: [1:75] 
pAb-actin affinity purified rabbit sera against cellular filament protein -actin 
(#600-401-886; Rockland, Gilbertsville, PA)  
for WB: [1:5000] 
 
Epitope-tags: 
mAbGFP GFP (4B10) mouse mAb (#2955; Cell Signalling, Beverly MA)  
for WB: [1:1000] 
pAbHA HA Epitope-tag affinity purified rabbit sera against synthetic peptide  
(YPYDVPDYA); (#OPA-1-10980; ABR, Golden, CO) 
for WB: [1:200] 
mAbHis His-tag (27E8) mouse mAb against 6x-His (HHHHHH)  
(#2366; Cell Signalling, Beverly MA)  
for WB: [1:1000] 
mAbMyc_m Myc-tag (9B11) mouse mAb against c-Myc (EQKLISEEDL)  
(#2276; Cell Signalling, Beverly MA)  
for WB: [1:1000]/ for IP: [1:500] 
mAbMyc_r Myc-tag (71D10) rabbit mAb against c-Myc (EQKLISEEDL)  
(#2278; Cell Signalling, Beverly MA)  
for WB: [1:1000]/ for IP: [1:200] 
mAbXpress Anti-XpressTM –tag mouse mAb against synthetic peptide (DLYDDDDK)  
(#R910-25; Invitrogen, Karlsruhe)  




Secondary antibodies for immunofluorescence (IF) were diluted together with DAPI 
(1:10.000) in PBS whereas in PBS + 0.1% Tween-20 immunostaining (WB). Both were 
discarded after use. 
 
anti-humangreen DyLightTM488-conjugated AffiniPure F(ab’)2 Fragment Goat Anti-Human 
IgG, Amax=493nm; Emax=518nm  (#109-486-006; Jackson Immuno 
Research Laboratories, INC.; Baltimore, MD)  
for IF: [1:250] 
anti-humanHRP Peroxidase-conjugated AffiniPure Goat Anti-Human IgG (H+L)  
(#109-035-003; Jackson Immuno Research Laboratories, INC., Baltimore, 
MD)  
for WB: [1:5000] 
anti-humanred CyTM3-conjugated AffiniPure F(ab’)2 Fragment Goat Anti-Human IgG  
Amax=550nm, Emax=570nm (#109-166-006; Jackson Immuno Research 
Laboratories, INC., Baltimore, MD)  
for IF: [1:300] 
anti-mouseHRP Peroxidase-conjugated polyclonal Rabbit Anti-Mouse IgG’s  
(#P0161; DakoCytomation, Glostrup, Denmark)  
for WB: [1:5000] 
anti-mousered DyLightTM549-conjugated AffiniPure F(ab’)2 Fragment Goat Anti-Mouse 
IgG, Amax=555nm, Emax=568nm (#115-505-006; Jackson Immuno 
Research Laboratories, INC., Baltimore, MD)  
for IF: [1:350] 
anti-rabbitHRP Stabilised Goat Anti-Rabbit HRP-Conjugated (#1858415, Perbio, Bonn)  
for WB: [1:1000] 
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2.2 Methods 
2.2.1 Cultivation of bacteria (E. coli methods) 
2.2.1.1 MOPS competent cells 
With an overnight (o/n) culture of E. coli strains (DH10Bac, BL21, XL1-blue) 100ml LB 
medium were inoculated. Bacteria were incubated at 37°C until an OD600 of 0.6 was reached 
followed collection by centrifugation (5‘ at 1.000 x g, 4°C). The pellet was resuspended in 
40ml ice cold MOPS I (100mM MOPS, 10mM CaCl2, 10mM RbCl, pH 7.0) and incubated on 
ice for 10‘. Bacteria were centrifuged for 5‘ at 1.000 x g, 4°C and resuspended in 40ml ice 
cold MOPS II (100mM MOPS ,70mM CaCl2, 10mM RbCl, pH 6.5). After incubation for 30’ 
on ice, bacteria were collected by centrifugation (5‘ at 1.000 x g, 4°C). The sediment was 
suspended in 2ml ice cold MOPS IIa (MOPS II + 15% glycerol) and incubated for 10’on ice. 
Afterwards aliquots of 100μl were taken. These were used immediately or stored at -80°C. 
2.2.1.2 Transformation of MOPS competent cells 
To competent cells 1 μl plasmid DNA or 15μl ligation mixture were added. Bacteria were 
incubated for 30’ on ice. Afterwards cells were treated 2’ at 42°C (heat shock), followed by a 
short incubation on ice. Bacteria were regenerated in 300μl LB (XL1-blue) or 1ml SOC I 
(BL21) medium for 30’ or 60’ at 37°C, respectively. Then 100μl batches were plated on LB 
plates with the corresponding antibiotics. The plates were incubated o/n at 37°C. 
2.2.1.3 Overexpression of recombinant proteins in E. coli (BL21) 
For over expression of GST-fusion proteins UL71-GST or UL77-GST, BL21 were 
transformed with constructs pGEX-UL71 and pGEX-UL77, respectively as described above 
(2.2.1.2). A fresh overnight culture was grown in LB media supplemented with 100µg/ml 
ampiciline at 37°C. After an OD600 of 0.3 was reached the GST-protein expression was 
induced by addition of IPTG to a final concentration of 1mM and growth was continued for 
2h at 37°C. Bacteria were harvested by centrifugation (10’ at 1.000 x g, 4°C) and sediments 
stored at -20°C until further usage. 
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2.2.2 Cultivation of yeast cells 
Methods described in the following and for Y2H section (2.2.8.2.3) are modified from 
Sanderson et al. (10), MatchmakerTM GAL4 Two-Hybrid System 3 & Libraries User Manual 
2007, Clontech (12) and Yeast Protocols Handbook 2008, Clontech (13). 
2.2.2.1 Propagation and handling of yeast 
To prepare yeast stains for transfection AH109 and Y187 were grown in YPD full media 
firstly on plates for 3 days and then in liquid media o/n at 30°C. It is very important to work 
with fresh cultures to avoid too thick cell walls that interfere with transfection efficiency. 
2.2.2.2 Transfection of yeast 
10ml YPD media was inoculated with fresh o/n culture of yeast strain AH109 or Y187, 
respectively. Reaching an OD600 of 0.5 cells were harvested by centrifugation (5’, 700 x g, 
RT). The sediment was resuspended in 5ml 100mM LiOAc and again centrifuged (5’, 700 x 
g, RT). After this washing step, cells were well suspended in 230µl PEG 4000 followed by 
addition of 46µl dH2O, 35µl 1M LiOAc and 9µl herring sperm DNA to the mixture. In 
contrast, for gap repair reaction instead of 46µl dH2O, 45µl dH2O and 1µl BamHI digested 
vector were added. 
Mixture was split in 10x 32µl aliquots in PCR tubes and either 4µl constructs or PCR 
products were added. For pGADT-7 constructs mating strain MAT-a AH109 whereas for 
pGBK-T Mat- Y187 was transfected. 
After thoroughly mixing a Thermocycler was used for incubation for 30’ at 30°C, followed by 
25’ at 42°C and finally 1’ at 30°C, followed by plating pGADT-7 constructs (prey) on –Leu 
and pGBKT-7 (bait) on -Trp selective media plates, respectively. After growing for 3-5 days at 
30°C, colonies should be visible that were further tested (i) to confirm insert size by colony 
PCR and (ii) for reactivation by plating them on selective plates lacking both marker amino 
acids leucine and tryptophan. 
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2.2.3 Cultivation of insect cells 
2.2.3.1 Propagation and handling of insect cells 
Two species of insect cells, Sf9 for preparation of recombinant baculoviruses and High5 for 
protein over-expression, were cultivated at 27°C in growth media. 
2.2.3.2 Preparation of recombinant baculovirus 
The gene of interest was inserted into Bacmid bMON14272 by site-specific transposition in 
E.coli prior to transfection into Sf9 cells as described by Luckow et al. (135). Amounts of 
DNA, unsupplemented Grace’s Insect Medium and Turbofect (Fermentas) are outlined in the 
manufacturer’s protocol. After resuspending the mixture was incubated for 15’ at room 
temperature (RT) and drop wisely added on top of the cells. Transfection mixture was 
changed after 5h into growth media. Virus in the supernatant was harvested 48h, sterile 
filtered (0.22µm) and stored at 4°C. 
2.2.3.3 Baculovirus expression system 
For harvesting recombinant baculovirus expressed protein, High5 cells were infected with 
virus harvested above (2.2.3.2). Cells were washed with unsupplemented Grace’s Insect 
Medium prior to infection. Medium was changed into growth media after 5h. Viruses in the 
supernatant as well as cells were harvested after 48h. Supernatant was sterile filtered 
(0.22µm) and stored at 4°C whereas cell extracts were subjected to protein purification 
(2.2.6.3.2). 
 
2.2.4 Cultivation of mammalian cells 
2.2.4.1 Propagation and handling of mammalian cells 
All types of used adherent mammalian cells (Hela, HFF, 293T) were cultivated at 37°C and 
5% CO2 atmosphere. 
Confluent monolayers were passaged after washing with PBS, detached with 0.25% trypsin-
EDTA and taken up in total amount of 10ml growth media containing 10% FCS. After the 
effect of trypsin was reversed by FCS of the media, cells were either counted in a Neubauer 
counting chamber for seeding of distinct cell numbers for transfection or splitted 1:5 in 
growth media for further passaging. 
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2.2.4.2 Propagation and titration of virus 
For AD169 propagation 2 x 107 HFFs were infected at a low multiplicity of infection (MOI) 
of 0.1. Medium was changed after 50% cytopathic effect and virus in the media was harvested 
after 10-12 days. 
Recombinant viruses 71_LZ-BAC and 71_L1-BAC, 71_wt-BAC were propagated similarly to 
AD169 by infecting 2 x 107 HFF at a low MOI of 0.1. In contrast to previous method, infected 
cells were splitted before confluence for propagation. The virus in the media was harvested 21 
days post infection (p.i.). 
Cells and cell fragments were removed by centrifugation (5’, 1.000 x g, 4 °C) and filtration 
(0.45μm), aliquoted and stored at –80°C. 
Viral titres were determined by infection of confluent HFFs in 12 or 96 well dishes with 
logarithmic dilutions (10-2-10-8) following visualisation of infected cells by HCMV specific 
antibodies (mAbIE1) 24h p.i. Cells were fixed with cold EtOH: acetone for 30’ at -20°C prior 
to multiple washing steps and antibody reactions. Infected cells were stained with AEC 
staining kit (Sigma), against anti-mouseHRP and plaques counted under the microscope at 
different dilutions. 
2.2.4.3 Experimental virus infection 
Confluent monolayers of HFF were infected at MOI 1 to 3. Virus was applied in growth 
media without FCS and incubated for 2h at 37°C, 5% CO2. After virus absorption supernatant 
was exchanged with growth media containing 2% FCS. 
If expression of proteins at specific time points of infection is examined inhibitors of viral 
replication will be applied. In this study the chemical inhibitor PAA (2.1.4), a specific 
inhibitor of viral DNA-polymerase, was used. Inhibitor was added during infection and 
propagation in growth media. 
2.2.4.4 Transient expression of viral proteins 
Plasmid DNA was transfected into Hela and 293T cells using Turbofect system (Fermentas) 
according to manufacturers’ protocol. 
Briefly, 4 x 104 Hela or 4 x 105 293T cells were seeded per 12 and 6 well, respectively. For 
biomolecular fluorescence complementation (BiFC) assays, Hela cells were grown in growth 
media supplemented with 0.1% FCS for all other purposes 2% FCS. After confluence of 70-
90% was reached transfection was carried out. Amounts of DNA, Optimem I and Turbofect 
are outlined in “Turbofect
™ 
in vitro Transfection” manual (Fermentas, 
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http://www.fermentas.com/templates/files/tiny_mce/coa_pdf/coa_r0531.pdf). After 
resuspending the mixture was incubated for 17’ at RT and drop wisely added on top of the 
cells. Cells were harvested 14h (Hela for BiFC), 24h (Hela) or 48h (293Ts) after transfection, 
respectively. 
2.2.4.5 Harvesting cell extracts 
Cell monolayers were washed with PBS prior to mechanical detachment. Harvested cells were 
collected by centrifugation (5’, 1.000 x g, 4 °C) and sediments taken up in RIPA-Buffer 
(50mM Tris-HCl pH 7.5, 150mM NaCl, 1% NP-40, 0.5% Na-desoxycholate, 0.1% SDS) prior 
to ultrasonic treatment. Cell debris was removed by centrifugation (30’, 10.000 x g, 4 °C) and 
cell extracts subjected to either co-immunoprecipitation (2.2.8.2.2) or directly to 
polyacrylamide gel electrophoresis (PAGE) (2.2.6.1) followed by immunostaining (2.2.7.3.). 
All Buffers contained Protease Inhibitor mix cOmplete Mini (Roche) as instructed by the 
manufacturer. 
2.2.4.6 Isolation and fragmentation of HCMV extracellular virions 
Extracellular virions of AD169 were separated from dense bodies and non-infectious particles 
96h after infection by sedimentation through a sodium-tartrate gradient according to Talbot 
and Almeida (224). Isolated virions were incubated with non-ionic detergent (1% NP-40) for 
10’ on ice prior to separation through a 15% sucrose cushion in TE buffer (1h, 100.000 x g, 
4°C). The supernatant contained the envelope fraction. The sediment which constituted of the 
capsid/tegument fraction was treated with 1% ß-mercaptoethanol for 10‘ on ice. Following 
this treatment, the capsid/tegument fraction was loaded onto another 15% sucrose cushion and 
separated by centrifugation (1h, 100.000 x g, 4°C). The supernatant contained the tegument 
and the sediment the capsid fraction. The tegument as well as the envelope fraction were 
precipitated with 10% TCA and dissolved in TE buffer. The capsid, tegument and envelope 
fraction as well as extracellular virions were subjected to SDS-PAGE (2.2.6.1.1) prior to 
immunostaining (2.2.7.3). 
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2.2.5 Cloning strategies and molecular biological methods 
2.2.5.1 Plasmid constructions 
Amplification of DNA fragments was carried out as described in 2.2.5.2.1. 
Restriction enzymes as well as T4-DNA Ligase and recommended buffers were obtained from 
Fermentas and used as indicated in manufacturer’s protocols and sections 2.2.5.2.2 or 
2.2.5.2.3, respectively. 
2.2.5.1.1 Constructs for bimolecular fluorescence complementation (BiFC) 
The constructs for BiFC were designed in a two step amplification process; firstly the specific 
UL71 and the fluorophore parts were amplified independently, ligated and amplified as one 
piece prior to ligation into the appropriate vector pcDNA3.1+. 
Briefly, for pcDNA71_wt-YC construct pcDNA71-myc served as a template for PCR using 
the primers BiFC_71_for and BiFC_71_rev resulting in PCR-71. For amplification of the C-
terminal part of the fused fluorophore YFP (YC) pcDNA-YC served as a template and 
BiFC_YC_for and BiFC_YC_rev as primers resulting in PCR-YC. Both PCR fragments were 
digested with restriction endonucleases, PCR-71 with BamHI and PCR-YC with BglII and 
because of the similar restriction sites ligated together resulting in disruption of the site. The 
ligated fragment was amplified using primers BiFC_71_for and BiFC_YC_rev resulting in 
PCR-71-YC. The resulting fragment as well as the cloning plasmid pcDNA3.1+ was digested 
with restriction endonucleases BamHI and NotI, ligated together and transformed into XL1-
blue as described previously. 
Constructs pcDNA71_LZ-YC, pcDNA71_L1-YC, pcDNA71_L2-YC and pcDNA71_L3-
YC were constructed in the same manner using pcDNA71_LZ-myc, pcDNA71_L1-myc, 
pcDNA71_L2-myc and pcDNA71_L3-myc as templates for PCR-71. 
2.2.5.1.2 Constructs for co-immunoprecipitation 
Constructs used for elucidating oligomerisation ability of pUL71 using co-
immunoprecipitation are discussed in the following. The wild type construct with the Myc-tag 
pcDNA71-myc was already in the lab’s collection whereas the Xpress-tagged version 
pcDNA71 needed to be constructed in this study. For PCR pcDNA71-myc served as template 
and 71_Bam_for and 71_Xba_rev served as primers for amplification. The product as well as 
cloning vector pcDNA3.1/HisC was subjected to restriction using BamHI and XbaI, followed 
by ligation and transformed into XL1-blue. 
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For construction of Leucine zipper-like motif deletion mutant 71_LZ-myc a two step 
amplification protocol similar as for BiFC constructs was used to remove aa 34-55 of UL71. 
As a first step aa 1-33 were amplified using pcDNA71-myc as template and 71_Bam_for and 
711-33_Bam_rev as primers resulting in PCR1-33 whereas aa 56-361 using 7156-361_BglII_for 
and 71_Xba_rev resulting in PCR56-361. Both PCR fragments were cut with restriction 
endonucleases, PCR1-33 with BamHI and PCR56-361 with BglII and because of the similar 
restriction sites ligated together resulting in disruption of the site. The resulting fragment was 
amplified using primers 71_Bam_for and 71_Xba_rev. The product as well as cloning vector 
pcDNA3.1/His C was subjected to endonuclease digestion using BamHI and XbaI, followed 
by ligation and transformed into XL1-blue. 
The point mutations in the Leucine zipper motif were constructed using a two step Quick 
change site-directed mutagenesis protocol modified from Stratagene. In the first mutagenesis 
round aa 34 and 41 were exchanged from Leucines (L) to Alanine (A) resulting in no 
alteration of the coiled-coil structure but in hydrophobicity of the motif. As for the other 
constructs pcDNA71-myc served as the template for amplification using primers 
71_L1_QC_for and 71_L1_QC_rev, prior to digest of template using DpnI and transformation 
into XL1-blue resulting in pcDNA71_L1-myc (L34/41A). To mutate aa 48 and 55 in the same 
manner another round of Quick Change mutagenesis was performed using pcDNA71_L1-myc 
as template and primers 71_L2_QC_for and 71_L2_QC_rev proceeding as described above. 
The second mutagenesis resulted in two constructs identified by sequencing, pcDNA71_L2-
myc (L34/41/55A) and pcDNA71_L3-myc (L34/41/48/55A). 
2.2.5.1.3 Constructs for protein purification using baculovirus system 
To construct a recombinant baculovirus expressing the gene of interest pUL71 the Bac-To-
Bac system (Invitrogen) was used according to manufactures protocol. Firstly UL71 needed to 
be cloned into Vector pFastBacHT B carrying the sequences later on needed for site 
recombination by site-specific transposition. In the first step UL71 was amplified from 
cosmid pCM1029 using primers UL71_Eco_for and UL71_Bam_rev prior to digesting both 
vector and insert with BamHI and EcoRI, ligation and transfection into XL1-blue. The 
accurate construct was transfected into DH10Bac, an E.coli strain carrying the baculovirus 
genome in the bacmid bMON14272, where site-specific recombination took place in vivo. The 
bacmid was extracted from the cells using methods described in the following (2.2.5.2.5.1). 
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2.2.5.1.4 Constructs for yeast two hybrid assay (Y2H) 
To construct a viral gene library, genes important for DNA packaging and egress discussed in 
this study were cloned into bait and prey vectors pGBKT-7 and pGADT-7 using same PCR 
products, respectively. 
For construction of UL56 yeast vectors, amplification from pcDNA56 using primers 
UL56_Nde_for and UL56_Eco_rev was performed. The insert as well as both vectors 
pGBKT-7 and pGADT-7 were subjected to restriction using endonucleases NdeI and EcoRI, 
resulting in pGBD56 and pGAD56, respectively. 
The other constructs were designed in the same manner e.g. using primers UL71_Eco_for and 
UL71_Bam_rev and cosmid pCM1029 resulting in pGBD71 and pGAD71, respectively. 
Constructs pGBD77 and pGAD77 were constructed using primers UL77_Nde_for and 
UL77_Eco_rev and pcDNA77; further pGBD89 and pGAD89 were constructed using primers 
UL89_Nde_for and UL89_Bam_rev and pcDNA89; pGBD104 and pGAD104 were 
constructed using primers UL104_Eco_for and UL104_Bam_rev and pcDNA104 and finally 
pGADMCP was constructed using template pcDNAMCP and primers MCP_Nde_for and 
MCP_Eco_rev. The corresponding restriction endonucleases indicated in the primer names 
were subjected for digestion of insert and vector prior to ligation as described previously. For 
pGBD71 and pGAD71 that are EcoRI and BamHI, for pGBD77 and pGAD77 NdeI and 
EcoRI, for pGBD89 and pGAD89 NdeI and BamHI, for pGBD104 and pGAD104 BamHI and 
EcoRI and for pGADMCP NdeI and EcoRI, respectively. 
It was not possible to clone pGBDMCP using conventional methods therefore the yeast based 
gap repair was used amplifying MCP from pcDNAMCP using primers MCP_GR_for and 
MCP_GR_rev encoding motifs for site specific recombination in yeast. In the following, PCR 
product was transfected together with BamHI linearised pGBKT-7 and site specific 
recombination took place in yeast strain Y187. 
2.2.5.2 Molecular biological methods 
2.2.5.2.1 Polymerase chain reaction (PCR) 
This method was used in the following for amplification of certain DNA fragments later on 
used for cloning, identification of proper constructs or recombination reactions of the cells. 
Batches were completed according to the manufacturers’ protocols: 100μl reaction batch for 
preparative usage contained 10 – 15ng DNA template, 500ng of each primer, 20nmol dNTPs 
and 2 units of DNA polymerase plus associated buffers. Half the batch was used for PCRs 
preformed for analytical purpose. Concerning temperature program double strand melting 
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took place at 95°C. Temperature for following annealing process was dependent on used 
primers (5°C below melting point of the primer) and elongation process was dependent on the 
used polymerase in terms of temperature and on length of DNA fragment in terms of time. 
This cycle was repeated until an optimum in accuracy and amount was obtained. PCRs were 
performed using a Thermocycler. 
Either PWO-DNA-Polymerase with proof reading activity (Peqlab) at 72°C or Taq-DNA-
Polymerase (Fermentas) at 68°C elongation temperature were used. 
2.2.5.2.2 Restriction of DNA 
Restriction enzymes from Fermentas were used indicated in the 2.2.5.1 as referred by 
manufacturer’s protocol. Briefly, 1 unit of endonuclease in its supplied reaction buffer was 
incubated with 0.5µg DNA for 3h at 37°C for digestion. Double digests were performed as 
calculated by the Double DigestTM software from Fermentas 
(http://fermentas.com/en/tools/doubledigest/). 
2.2.5.2.3 Ligation of DNA 
For ligation, fragment and vector DNA were set in a ratio of 1: 4. T4 DNA Ligase (Fermentas) 
and associated buffer were added. The reaction batch was incubated 3h at RT or o/n at 16°C. 
2.2.5.2.4 Purification of PCR- and DNA-fragments after Restriction 
The DNA was purified using spin columns from Machery-Nagel following manufacturer’s 
protocol. 
2.2.5.2.5 DNA purification 
The procedures discussed in the following were performed with strain of E. coli. 
Plasmids were purified from growing cultures. The used methods are depended on form and 
size of plasmid and which grade of purity is needed for later on performed procedures, 
respectively. 
2.2.5.2.5.1 Preparation of bacmid DNA 
Colonies positive for insertion of gene of interest into bMON14272 in DH10Bac were tested 
(i) for destruction of LacZ operon and therefore missing -galactosidase activity on LB plates 
containing 50µg/ml kanamycine, 100µg/ml X-Gal, 40µg/ml IPTG, 7µg/ml gentamycin, 
5µg/ml tetracycline and (ii) by PCR using specific primers. 1.5ml of culture was collected by 
centrifugation. Pellet was resuspended in 0.3ml Solution I (25mM Tris-HCl pH 8.0, 50mM 
glucose, 10mM EDTA), prior to addition of 0.3ml Solution II (1% SDS, 0.2M NaOH) and 
gentle mixing. After incubation at RT until suspension became almost translucent, 0.3ml 3M 
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KCH3CO2 pH 5.5 were added and incubated for 10’ on ice. Precipitate was sedimented by 
centrifugation (10’ 14.000 x g, RT) and supernatant was added to 0.8ml isopropyl alcohol. 
Bacmid DNA was precipitated by incubation o/n at -20°C followed by centrifugation step (10’ 
14.000xg, RT). DNA pellet was washed twice with 70% EtOH, dried at RT, suspended in 40µl 
TE buffer and stored at 4°C. 
2.2.5.2.5.2 Preparation of plasmids using kits 
DNA used for cloning in E.coli was purified with Plasmid Miniprep kit (Fermentas), whereas 
for large amounts of transfection grade pure DNA Midiprep kit (Invitrogen) was used both 
according to manufacturers’ protocols. Briefly, pellets were collected and subjected to alkaline 
lysis (9). Firstly pellets were resuspended in 25mM Tris-HCl (pH 8.0)/ 50mM glucose/ 10 
mM EDTA), for lysis 1% SDS/ 0.2M NaOH were added and vigorously mixed prior to 
precipitation of cell debris by addition of 5M KCH3O2 (pH 4.8) and again vigorous mixing. 
The cell debris was removed by centrifugation (10’, 10 000 x g, RT) and supernatant was 
applied to columns purchased from Fermentas and Invitrogen. Plasmid DNA was bound to the 
columns, washed and eluted prior to precipitation with 96% isopropyl alcohol (30’, 15 000 x 
g, 4°C). 
2.2.5.2.5.3 Quick preparation method 
Bacteria (300µl) were collected and resuspended in 5 x DNA sample buffer (25% sucrose, 
0.05% bromphenole blue, 0.1% SDS, 50mM Tris-HCl, pH 8.2). To precipitate proteins 
phenol/chloroform (1:1) were added. The sample was mixed by vortexing followed by 
centrifugation to pellet debris. This method will be used for crude purification to screen for 
positive clones if no other manipulations are performed with the plasmid afterwards. 
2.2.5.2.6 Separation of DNA fragments according to their size 
DNA purified after PCR or enzymatic manipulations (2.2.5.2.4) as well as plasmids 
(2.2.5.2.5) were analysed using the following methods. 
2.2.5.2.6.1 Agarose gel electrophoresis 
Agarose 1% was melted in 1 x TBE (89mM Tris, 89mM boric acid, 2mM EDTA, pH 8.0) in 
the microwave until the solution became clear. For DNA staining 50µl/L RedSafe (Intron 
Biotechnology INC.) were added afterwards. Samples were taken up in 5 x DNA sample 
buffer and loaded onto gel. Electrophoresis was carried out at 100V in a horizontal system. 
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2.2.5.2.6.2 Polyacrylamide electrophoresis 
Acrylamide stock was diluted with 1 x TBE till desired percentage. Polymerisation was 
induced by addition of APS and TEMED. Sample preparation was done corresponding to 
2.2.5.2.6.1.Further separation was carried out in a vertical system at 70V. The DNA was 
stained in an ethidium bromide (0.5g/L) solution. This method using 8.5% polyacrylamide 
was used for separating bands in a range from 30-1000bp. 
2.2.5.2.7 Determination of DNA concentration 
DNA amount was determined by spectroscopic measurements at 260 nm using Nanodrop 
(Peqlab) or quantification of gel bands after separation (2.2.5.2.6) using image processing 
software ImageJ 1.41o (National Institute of Health, USA). 
2.2.5.2.8 In vitro translation. 
The plasmids pcDNAUL77, pcDNAUL56 or pcDNAMCP (1µg each) were incubated with 
[35S] methionine/cystein (10mCi/ml) and 40µl TNT® T7 Quick Master Mix (TNT-T7 Quick 
kit, Promega) in a final volume of 50µl for 1.5h at 30°C. Translation products were analysed 
by SDS-PAGE (2.2.6.1.1) or subjected to Protein-DNA-Interaction studies (2.2.8.1). 
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2.2.6 Protein methods 
2.2.6.1 Polyacrylamide gel electrophoresis (PAGE) 
Used for protein separation according to molecular weight followed by visualisation through 
Coomassie (2.2.6.2) or immunostaining (2.2.7.3). 
2.2.6.1.1 SDS-PAGE (126) 
Composition resolving gel 
8.5-10% 
stacking gel 4% 
Acrylamide stock 1417-1667µl 267µl 
1.5M Tris-HCl, pH 8.8 
0.4% SDS 
1250µl - 
0.5M Tris-HCl, pH 6.8 
0.4% SDS 
- 500µl 
ddH2O xµl 1233µl 
total volume 5000µl 2000µl 
10% APS 60µl 20µl 
TEMED 10µl 5µl 
10-30µl Protein samples were added per slot. SDS running buffer (10 x: 250mM Tris, 1,9M 
glycine, 35mM SDS) was used for separation in a vertical system. Electrophoresis was with 
constant 15mA per gel. 
2.2.6.1.2 NATIVE-PAGE 
Composition resolving gel 
8.5-10% 
stacking gel 4% 
Acrylamide stock 1417-1667µl 267µl 
1.5M Tris-HCl, pH 8.8 1250µl - 
0.5M Tris-HCl, pH 6.8 - 500µl 
ddH2O xµl 1233µl 
total volume 5000µl 2000µl 
10% APS 60µl 20µl 
TEMED 10µl 5µl 
Native running buffer (10 x: 250mM Tris, 1.9M glycine) was used for separation in a vertical 
system. Electrophoresis conditions were used similar to SDS-PAGE (2.2.6.1.1) 
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2.2.6.1.3 Electrophoresis conditions 
Standard SDS-PAGE under denaturating conditions was performed as described by Laemmli 
et al. using SDS- loading buffer (2 x buffer: 0.12mM Tris-HCl pH 6.8, 4% SDS, 17.4% 
glycerol, 2% β-mercaptoethanol, 0.02% bromphenole blue) with boiling for 5’ at 95°C prior 
to loading onto SDS-polyacrylamide gels (126). For SDS-PAGE under non reducing 
conditions (209) samples are taken up in native- loading buffer (2 x buffer: 0.12mM Tris-HCl 
pH6.8, 0.1% SDS, 17.4% glycerol, 0.02 % bromphenole blue) and subjected to SDS-
polyacrylamide gels without boiling. While for NATIVE-PAGE samples were taken up in 
native- loading buffer and directly loaded on native polyacrylamide gel. 
2.2.6.2 Coomassie staining 
To visualise separated proteins on the polyacrylamide gels Coomassie staining was used. Gels 
were incubated in Coomassie staining solution (45% EtOHden., 9% CH3COOH, 0,1% 
Coomassie Brilliant Blue R250) until complete staining. The destaining was carried out in 
two steps; incubation with 45% EtOHden./ 12% CH3COOH for 30’ followed by complete 
destaining with 5% EtOHden./ 5% CH3COOH. After neutralizing in H2O gels were dried in a 
frame between wet cellophane sheets. 
2.2.6.3 Purification of recombinantly expressed proteins 
2.2.6.3.1 Purification of GST-proteins for column affinity chromatography 
Protein production was induced in BL21 as described above (2.2.1.3). Sedimented cells were 
lysed in binding buffer (20mM sodium phosphate buffer pH 7.4, 0.15M NaCl) containing 
250µM MgCl2, 25µM MnCl2, 400µg DNase I and 4mg lysozyme, incubated for 30’ and 
sonicated on ice. Undissolved material was removed by centrifugation at 5.000 x g at 4°C and 
supernatant passed through a 0.22µm filter. 
The purification was performed with ÄKTA FPLC system (GE Healthcare) using a GSTrapTM 
1ml column (GE Healthcare). The column was washed with three bed volumes binding buffer 
prior to loading the proteins. Proteins were eluted from the column with 10 bed volumes of 
elution buffer (50mM Tris-HCl, 10mM glutathione, pH 8.0). 
For usage as antigen in antibody purification GST-tag needs to be removed. For cleavage, 
eluted protein was dialysed in PreScission buffer (50mM Tris-HCl pH 7.0, 150mM NaCl, 
1mM EDTA, 1mM DTT) and incubated with 80 units of PreScission protease (GE 
Healthcare) for 12 h at 4°C. After removal of the GST-tag fraction was supplied to 
Glutathione Sepharose 4B slurry (GE Healthcare) for 16 h at 4°C to bind free GST and 
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uncleaved fusion protein. Supernatant containing the proteins rpUL71_E.coli or 
rpUL77_E.coli were stored at –80 °C. 
2.2.6.3.2 Purification of rpUL71_Bac 
Using the baculovirus expression system (2.2.3.3) intracellular protein from 3.6 x 108 High5 
cells was harvested 48h p.i.. Sedimented cells were lysed in anionic exchange buffer (20mM 
Bis-Tris, 200mM NaCl, pH 6.5) containing 250µM MgCl2, 200µg DNase I, 200µg RNAse A 
and 2.5mM sucrose by sonification on ice. Undissolved material was removed by 
centrifugation (30’, 10.000 x g, 4°C). 
Further as a first purification step supernatant was precipitated with 45% (NH4)2SO4 and 
sediment collected by centrifugation (30’, 10.000 x g, 4°C). The pellet was taken up in 
anionic exchange buffer and dialysed against the very same to remove the salt. Secondly, 
further purification was performed with ÄKTA FPLC system using a Resource QTM 1ml 
column (GE Healthcare). The column was washed with three bed volumes anionic exchange 
buffer prior to loading the proteins. A continuous NaCl gradient (0.2-1M NaCl) was used to 
elute protein from the column. Again salt was removed by dialysis against anionic exchange 
buffer. Thirdly, fractions were subjected to gel filtration with a HiPrep 16/60 Sephacryl HR 
column (GE Healthcare) using ÄKTA FPLC. After equilibration of the column with three bed 
volumes anionic exchange buffer, the pooled fractions from the previous step were loaded. 
Forty fractions were collected. 
All fractions were analysed by SDS-PAGE (2.2.6.1.1) followed by Coomassie (2.2.6.2) or 
immunostaining (2.2.7.3) throughout the whole purification procedure. 
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2.2.7 Immunological Methods 
2.2.7.1 Antibody against pUL71 and pUL77 
2.2.7.1.1 Synthesising matrix for column affinity chromatography 
Purified recombinant protein rpUL71_E.coli or rpUL77_E.coli (see 2.2.6.3.1) was covalently 
coupled to agarose matrix that was later used for column affinity chromatography to purify 
specific IgG’s from patients’ sera. 
As a first step protein used as an antigen was dialysed in coupling buffer (0.1M MES pH 6.5, 
0.02% NaN3) for 16h at 4°C. To prepare the matrix 1 Vol. Affi Gel 10 and 2 Vol. Affi Gel 15 
(BioRad) were washed with ddH2O and coupling buffer prior to incubation with antigen for 
16h at 4°C. The matrix is collected by centrifugation (15’, 2.100 x g, 4°C) and blocked with 
1M Ethanolamin-HCl pH 8.0/ 0.02 % NaN3 for 1h. Further washing with ddH2O and starting 
buffer (50mM Tris pH 8.0, 150mM NaCl, 0.02% NaN3) was performed prior to loading of 
sera from high titre HCMV patients. 
2.2.7.1.2 Affinity purified antibodies 
HCMV pUL71 specific human polyclonal antibody pAbUL71 or HCMV pUL77 specific 
human polyclonal antibody pAbUL77 were purified from HCMV positive patients sera (IgG 
positive selected by HCMV diagnostics, Charité Berlin) by column affinity chromatography. 
Affinity purification was performed as described previously (77). 
Briefly, Sera were diluted 1:4 in starting buffer and incubated with matrix in disposable 
columns (Econo-Pac 10, BioRad) for 16h at 4°C. After incubation matrix was washed in 
washing buffer (50mM Tris-HCl pH 8.0, 300mM NaCl, 0.02% NaN3), in order to remove all 
unspecific interactions. 
Further elution was carried out with acidic elution buffer (0.2M glycine-HCl pH 2.8). The 
fractions were neutralised with 2.5M Tris-HCl pH 8.0 immediately after collecting. In this 
manner three fractions were collected. The specificity of the purified fractions was determined 
using immunoblots loaded with purified rpUL71 or rpUL77, respectively. Immunoblot strips 
were reacted with Cytotect (Biotest), mAbUL44 and pAbUL71 or pAbUL77, respectively. 
2.2.7.2 Immunofluorescence 
For immunofluorescence HFF cells were grown on cover slips (1 x 105). At the appropriate 
time point cells were fixed with 3% PFA for 20’, incubated with 50mM NH4Cl to block 
reactive amino groups and permeabilised with 0.2% Triton X-100 for 5’. Detection of specific 
viral or cellular proteins was carried out using primary antibodies for 45’ at RT prior to further 
incubation for 45’ with fluorophore-labelled secondary antibodies (see 2.1.7). Nuclei were 
55 
stained using DAPI added to secondary antibody mixture. After staining the samples were 
mounted in Fluoroprep (bioMerieux) with 2.5% DABCO and examined either under an 
Olympus BX60 wide field or a Nikon Eclipse A1 laser scanning microscope. 
2.2.7.3 Immunostaining following PAGE 
2.2.7.3.1 Semi-Dry transfer 
All proteins separated on the gel were immobilised onto a nitrocellulose membrane (NC) by 
electro blotting: Firstly, all materials- Whatmann blotting paper (WM), polyacrylamide gel 
(gel) and NC- were soaked in blotting buffer (25mM Tris, 200mM glycine, 20% 
EtOHden.).The blot was assembled between the electrodes (-/WM /gel/NC/ WM /+) and 
transfer was performed in a semi dry blot apparatus under following conditions: 0,8mA/cm2 
blotting area for 60’. The efficiency of protein transfer was analysed by staining NC with a 
Ponceau S solution (0.5% Ponceau S, 3% TCA). 
2.2.7.3.2 Antibody probing 
After transfer, NC was blocked with 5% milk powder in PBS/ 0.1% Tween20, 30’ at RT or o/n 
at 4°C. After the blocking, the blot was washed with PBS/ 0.1% Tween20 and probed with the 
dilution of the primary antibody for 1h at RT or o/n at 4°C. Afterwards, the membrane was 
washed and incubated with the secondary antibody linked to HRP for 1h. After another 
washing step the blot was developed using enhanced chemo luminescence (ECL) kit (ECL kit 
Super Signal, Thermo Scientific) according to the manufacturer and analysed by charge 
coupled device (CCD) Camera (Vilber-Lourmant). 
2.2.7.3.3 Stripping of immunoblots 
To remove antibody probing from the immunoblot incubation in stripping buffer (62.5mM 
Tris-HCl pH 6.8, 2% SDS, 0.7% -mercaptoethanol) for 30’ at 60°C was carried out. The 
stripping buffer was removed by multiple washing steps in PBS/ 0.1% Tween20 and blocking 
in 5% milk powder in PBS/ 0.1% Tween20 for 1h at RT. After this procedure the blot could be 
reused for antibody probing (2.2.7.3.2) 
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2.2.8 Protein interaction studies 
2.2.8.1 Protein-DNA-interactions 
2.2.8.1.1 DNA binding assay 
In vitro DNA binding analysis was performed as described before (77). Briefly, DNA -
cellulose (Sigma-Aldrich) or matrix material from HiTrap™ Heparin HP Columns (GE 
Healthcare) was loaded with [35S]-labelled pUL77 or MCP diluted 1:10 in DNA binding 
buffer (50mM Tris-HCl, 10% glycerol, 1mM DTT, 1mM EDTA, pH 8.0). Bound protein was 
eluted with increasing concentrations of NaCl (200 - 2000mM NaCl gradient). Fractions were 
subjected to SDS-PAGE (2.2.6.1.1) prior to autoradiography. Radioactive signals were 
analysed using a Bioimager (Molecular Dynamics Phosphorimager SI, Amersham Pharmacia) 
and quantified with image processing software ImageJ 1.41o (National Institute of Health, 
USA). 
2.2.8.1.2 Binding to defined double stranded (ds) oligonucleotides. 
This assay is modified from the DNA Binding assay described above. 
50µl Pierce Avidin Agarose (Thermo Scientific) was equilibrated in DB-buffer (PBS +1% 
NP-40) for 2h at room temperature. In the following, biotinylated and their complementary 
oligonucleotides (bio-pac1/pac1_rev) were purified (2.2.5.2.4), combined, denatured and 
annealed (Figure 3. A) for yielding the double stranded 36-mer oligonucleotides bio-pac1. 
Briefly, denaturating (5’ 95°C) and annealing (temperature gradient 80-55°C, 2h) was carried 
out using a Thermocycler. In addition, a 250-, 500- and 1000-mer biotinylated DNA fragment 
containing pac1 motif were obtained by PCR using pUC-aseq as a template and either bio-
250, bio-500 or bio-1000 together with pUC18-pac as forward and reverse primers (Figure 3. 
B). 
A schematically drawing of the method is depicted in Figure 3.C. Briefly, the biotinylated 
double-stranded oligonucleotides were bound to the avidin agarose upon incubation for 30’ at 
RT. For removing excess unbound oligonucleotides avidin agarose was washed twice with 
DB-buffer. The avidin agarose was taken up in 100µl DB-buffer, 20µl of in vitro translated 
protein pUL77, pUL56 or MCP (2.2.5.2.8) were added and incubated o/n at 4°C. After 
additional washing (50mM Tris-HCl, pH 8.8, 10% glycerol, 1mM DTT, 1mM EDTA, 150mM 
NaCl) bound DNA-protein complexes were eluted by a NaCl gradient (200-2000mM NaCl) 
prior to boiling in SDS- loading buffer and analysis by SDS-PAGE followed by 
autoradiography (see 2.2.8.1.1). 
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Figure 3: Binding to defined dsDNA. (A) Nucleotide composition of 36-mer bio-pac 
containing pac1 sequence localised between bp 30-58 in HCMV genome (NC_006273.2 
(81)). Bio-pac contains nucleotides 30-64, the forward primer is not tagged while the 
reverse primer is connected to biotin on its 5’-end. (B) Bio-1000, bio-500 and bio-250 are 
generated by PCR using pUC18-aseq as template. Positions of primers are indicated on 
the vector map on the right. (C) Schematically drawing of the procedure. (I) Biotinylated 
dsDNA is incubated with avidin beads at 20°C. (II) Washing step is applied to remove 
unbound dsDNA prior to (III) addition of in vitro translated [35S]-labelled protein. (IV) 
After serious washing steps (IV) to remove unbound protein a (V) NaCl gradient (200-
2000mM) and a boiling step are applied for elution. (V) Samples are analysed by SDS-





2.2.8.2.1 Biomolecular fluorescence complementation assay (BiFC) 
With this method binary protein-interactions were detected using a two-component-
fluorophore as reporter. Both parts of the fluorophore did not interact and therefore were not 
active on their own. In this study citrin (YFP) served as the fluorophore that was fused to the 
putative interaction partners. It became photo-active upon physical interaction of the fusion 
proteins by bringing the two fluorophore parts in close proximity. 
Hela cells were grown on cover slips to 70% confluence. Prior to transfection cells were 
arrested for 12h in medium containing 0.1% FCS. For transient expression of fluorophores 
cells were transfected with three different constructs. Two of them expressing forms of pUL71 
fused to the N- or C-terminal part of YFP (pcDNA71_wt-YN and pcDNA71_wt-YC, 
pcDNA71_L1-YC, pcDNA71_L2-YC; pcDNA71_L3-YC pcDNA71_LZ-YC) and the third 
construct pcDNA3.1-mCherry expressing mCherry (210, 211, 241). Transfection procedure 
was carried out as described above (2.2.4.4) and cells were grown for 14h at 37°C and 30’ at 
32°C prior fixation. Cells were treated according to method described for 
immunofluorescence (2.2.7.2) with PFA, NH4Cl and Triton X-100. Nuclei were stained with 
DAPI and expression of fluorophores analysed using an Axio-Observer.Z1 fluorescence 
microscope and Axiovision software 4.8 (Carl Zeiss MicroImaging). YFP-Intensity was 
measured relative to mCherry expression to allow quantitative comparison between different 
cells (102). 
2.2.8.2.2 Co-immunoprecipitation 
For co-immunoprecipitation mock-infected or AD169-infected cells were harvested 72h p.i. 
For co-immunoprecipitation in transfected cells 293T cells were transfected with two putative 
binding partners cloned into pcDNA3.1/HisB or C (Xpress-tag) and pHM1580 (Myc-tag) and 
collected 48h after transfection. In detail, (i) pcDNA77-myc was transfected together with 
pcDNA56, pcDNA89, pcDNA104, pcDNAMCP and pHM123, or (ii) pcDNA71 with 
pcDNA71-myc, pcDNA71_LZ-myc, pcDNA71_L1-myc, pcDNA71_L2-myc and 
pcDNA71_L3-myc (iii) or constructs used for BiFC (2.2.8.2.1), respectively. In both cases 
total cell extracts were prepared by solubilisation in immunoprecipitation buffer (20mM Tris-
HCl pH 7.5, 150mM NaCl, 0.5% Tween20, 5mM EDTA, Protease Inhibitor mix Complete 
Mini) as described for 2.2.4.5. Comparable amounts of extracts and specific antibodies were 
used for precipitation. Extracts were loaded onto Protein A Sepharose CL-4B (GE Healthcare) 
and subjected to multiple washing steps in order to remove unspecific binding. 
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Immunoprecipitates were analysed by SDS-PAGE (2.2.6.1.1) prior to immunostaining 
(2.2.7.3). 
2.2.8.2.3 Yeast two hybrid assay (Y2H) 
This screening method was developed to analyse binary protein interactions in vivo using 
yeast as a model organism (84). Two putative interacting proteins are fused as bait and prey to 
the DNA-binding and activation domain of a transcriptional activator of Gal4-reporter-
promoter. Both domains cannot interact independently from binary interactions of the tested 
proteins. If these proteins directly interact Gal4-reporter-promoter-induced gene products will 
be detected. In the following, activation of Gal4 reporter promoter was analysed for growth 
on selective media (2.2.8.2.3.1) and enzymatic activity in a -galactosidase filter shift assay 
(2.2.8.2.3.2). 
2.2.8.2.3.1 Mating and reporter growth assay 
Both prey MAT-a AH109 and bait Mat- Y187 tested positively of accuracy of transfection 
and negatively for reactivation (2.2.2.2), were spotted on YPD plates for mating and 
incubated o/n at 30°C. Spotting matrix was stamped on –Leu/-Trp diploid selective and –
Leu/-Trp/-Ade/-His reporter selective plates using a replicating block and incubating them for 
5 days on 30°C. If growth is observed on –Leu/-Trp/-Ade/-His reporter selective plates this 
will be due to Gal4 promoter activation through binary protein-protein interaction. 
2.2.8.2.3.2 β-Galactosidase filter shift assay 
The –Leu/-Trp diploid selective plates prepared in 2.2.8.2.3.1 were used for transferring 
colonies onto filter paper to generate a cast. The colonies on the filter were lysed in liquid 
nitrogen 3 x for 30s prior to incubating them on filter paper saturated with -Gal reaction mix 
(60mM Na2HPO4, 40mM NaH2PO4, 10mM KCl, 1mM MgSO4, 10mg X-Gal, 0,18% -
mercaptoethanol) and incubating for 3-5h at 37°C or until blue colour develops. 
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2.2.9 Electron microscopy (EM) 
2.2.9.1 Embedding and thin sectioning 
HFF cells (1 x 106) were infected at MOI 3 with recombinant viruses 71_LZ-BAC and 
71_L1-BAC, 71_wt-BAC and harvested 5 days p.i.. Cells were taken up in 2.5% 
glutaraldehyde in HEPES buffer (20mM HEPES, 150mM NaCl pH 7.4) and fixed 
consecutively with 1% osmium tetroxide, 0.1% tannin and 1% Na2SO4 all diluted in HEPES 
buffer. After dehydration with EtOH (50/70/90/100%) and a second staining with 0.2% uranyl 
acetate, cells were transferred to beam capsules and embedded in 1,2-epoxypropane in glycid 
ether 100 after addition of hardeners DBA and MNA. Polymerization was induced by heat for 
3 days at 65°C. Thin Sections were cut with an ultra microtome (Leica) and sections were 
transferred to carbon coated cooper grids (Plano, Wetzlar) prior to final staining with 1% 
uranyl acetate in 40% EtOH and lead citrate. Thin sections were analysed using a TEM 
TecnaiTM G2 (FEI Company, Eindhoven) electron microscope operated at 120 kV. 
2.2.9.2 Staining single particles 
Structural details of purified proteins were analysed on carbon coated cooper grids (Plano, 
Wetzlar) using electron microscopy prior to negatively staining with 2% (w/v) uranyl acetate 
according to Valentine et al. (238). The carbon coating is produced by firstly coating a matrix 
of K2OAl2O3SiO2, so-called mica (4) using a Turbo Carbon Coater 208 (Cressington 
Scientific Instruments Ltd). This carbon–coated mica was loaded with protein by introducing 
it into the sample suspension at an angle of 30°C for 1´. The carbon film floated off and 
particles are being adsorbed. The mica was slowly removed, allowing the carbon to fall back 
in its original position. The same procedure was performed in staining solution whereas a grid 
was placed on the surface of the carbon film and incubated for 20 s. The grid was lifted up an 
excess staining solution was drained of by using filter paper. 
2.2.10 In silico tools 
For determination of putative oligomerisation domains and other specific secondary structures e.g. the 
following prediction programs were used: HeliQuest (http://heliquest.ipmc.cnrs.fr/)(89); Clustalw 
(http://toolkit.tuebingen.mpg.de/clustalw); p-coils (http://toolkit.tuebingen.mpg.de/pcoils); Quick2d 
(http://toolkit.tuebingen.mpg.de/quick2_d); Blastclust (http://toolkit.tuebingen.mpg.de/blastclust) (29) 
and Psi-pred (http://bioinf.cs.ucl.ac.uk/psipred/) (42, 111). 
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3 Results 
3.1 Functional characterisation of HCMV pUL77 
3.1.1 Identification of the protein pUL77 
The antibody purified from patients’ sera using column affinity chromatography was tested 
for monospecificity prior to further usage in this study. To generate pAbUL77 IgGs reactive to 
pUL77 were purified from sera from high titre HCMV patients and tested on immunoblots 
probed with rpUL77_E.coli. 
 
Figure 4: Characterisation of the antibody pAbUL77. (A) Purified rpUL77_E.coli was 
separated by 10% SDS-PAGE and immunostaining was performed with Cytotect 
(HCMV+ Serum, lane 1), mAbUL44 (lane 2) and pAbUL77 (lane 3). (B) Commercially 
available immunoblot stripes (Mikrogen Diagnostics, Neuried) containing recombinant 
immunodominant epitopes of IE1 (53 kDa), pp150 (50 kDa), pUL44/pUL57 (45 kDa), 
pp65 (31 kDa), gB1 (25 KDa) and gB2 (18 kDa) were reacted with Cytotect (HCMV+ 
Serum, lane 1), mAbUL44 (lane 2) and pAbUL77 (lane 3). Positively reacted control 
stripe is shown on the right (lane 4). Arrows on the right side indicate the position of 
pUL77. Molecular weight markers (M) are shown on the left side. 
 
Only Cytotect (Figure 4. A, lane 1) and the purified antibody pAbUL77 (Figure 4. A, lane 3) 
reacted on strips with purified protein, but not mAbUL44 (Figure 4. A, lane 2). As an 
additional control for specificity of pAbUL77 immunostaining of different viral proteins was 
performed. Commercially available immunoblot stripes (Mikrogen Diagnostics, Neuried) 
containing recombinant polypeptides derived from immediate early protein IE1 (53 kDa), 
tegument protein pp150 (50 kDa), polymerase co-factor pUL44, single stranded binding 
protein pUL57 (45 kDa), tegument protein pp65 (31 kDa) and glycoprotein gB (gB1, 25 kDa; 
gB2, 18 kDa) were used. Only Cytotect (Figure 4. B, lane 1) and mAbUL44 (Figure 4. B., 
lane 2) but not pAbUL77 (Figure 4. B, lane 3) reacted on the immunoblot, as expected. Thus, 
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showing that pAbUL77 does not react with other HCMV epitops but pUL77 specific ones. 
Taken together, these results indicate pAbUL77 is a monospecific antibody against pUL77. 
 
Figure 5: Identification of pUL77. (A) Mock-infected (lane 1) and AD169-infected (lane 
2) cells were [35S]-labelled 60h p.i.. Cells were harvested and subjected to 
immunoprecipitation against pAbUL77 prior to 8% SDS-PAGE and autoradiography. (B) 
Extracts from mock-infected (lane 1) or AD169-infected cells (lane 2) were separated by 
8% SDS-PAGE prior to immunostaining with pAbUL77. (C) Extracts from mock-
infected (lane 1) or AD169-infected cells (lane 2) were subjected to 8% NATIVE-PAGE 
followed by immunostaining with pAbUL77. The asterisks (*) indicates degradation 
products. Arrows on the right side indicate the positions of the monomer and dimer of 
pUL77, while molecular weight markers (M) are indicated on the left. Markers for 
NATIVE-PAGE: β-GAL: β-galactosidase 130kDa; PYG: phosphorylase 100kDa; BSA: 
bovine serum albumin 68kDa; OVA: Ovalbumine 45kDa; α-CA: carbonic anhydrase 
35kDa. 
 
The purified antibody pAbUL77 is used to identify pUL77 in the viral context used for 
immunoprecipitation in radio-labelled cells and immunostaining after electrophoresis 
performed under native or denaturating conditions. In immunoprecipitation experiment a band 
of approximately 70kDA, the calculated molecular size of pUL77 is 73kDa, is prominently 
detected (Figure 5. A (c.f. 149)). In immunostaining the antibody was used to visualise 
monomeric and oligomeric forms of pUL77. Under denaturating conditions only the 
monomeric form and faint bands representing degradation products are visible on the blot 
(Figure 5. B (SDS-PAGE)). In contrast, higher molecular weight forms were detected under 
native conditions (Figure 5. C (NATIVE-PAGE)). These results are hinting on an 
oligomerisation potential of pUL77. 
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3.1.2 Association of pUL77 with capsids 
Extracellular virions were isolated from the supernatant of AD169-infected cells 96h p.i and 
subjected to fragmentation using detergent treatment prior to ultracentrifugation steps. The 
content of each fraction was analysed by immunostaining and Coomassie staining. 
 
Figure 6: Association of pUL77 with viral capsids. (A) Mock-infected (lane 1) and 
AD169-infected cell extracts (lane 2) as well as extracellular virions (lane 3), purified 
envelope (lane 4), tegument (lane 5) and capsid (lane 6) fractions were analysed by 
immunostaining using pAbUL77 (pUL77, upper panel). To control purity of each fraction 
antibodies against gB for envelope (gB, second panel), pp28 for tegument (pp28, third 
panel) or MCP for capsid fraction (MCP, lower panel) were reacted as well. (B) To 
control protein content, samples used for immunoblot in Fig. A were subjected to 8% 
SDS-PAGE prior to Coomassie staining. The asterisks (*) indicates degradation products. 
Molecular weight markers (M) are indicated on the left side, putative different weight 
forms of pUL77 are indicated by arrows. 
 
To analyse the association of pUL77 to the virions specific antibodies against pUL77 
(pAbUL77) and marker proteins to test the purity of each fraction (mAbgB for gB, mAbpp28 
for pp28, and mAbMCP for MCP) were used. The immunostaining revealed positively for 
pUL77 in infected cells (Figure 6. A, upper panel, lane 2), extracellular virions (Figure 6. A, 
upper panel, lane 3) and capsid fraction (Figure 6. A, upper panel, lane 6). We detected 
monomeric forms of the protein in all three fractions, but oligomeric forms only in the 
extracellular virions and the capsid fraction that was purified from it. All fractions seem to be 
free of contaminations, containing only the described protein content, tested by staining 
against markers gB for envelope (Figure 6. A, second panel (gB)), pp28 for tegument (Figure 
6. A, third panel (pp28)) and MCP for capsid (Figure 6. A, lower panel (MCP)) fraction. 
Figure 6. B shows the overall protein content of each fraction. 
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Taken together, the results show that pUL77 is a structural capsid-associated HCMV protein. 
 
3.1.3 Interaction of HCMV pUL77 with DNA packaging proteins 
After learning that pUL77 is associated to the capsid as a structural protein we wanted to 
investigate pUL77’s direct interactions to certain other capsid proteins. 
 
Figure 7: Interaction of pUL77 with DNA packaging proteins. (A) Mock-infected or 
AD169-infected HFF lysates at 72h p.i. were precipitated with pAbUL77 and subjected to 
SDS-PAGE prior to immunostaining using antibodies mAbIE1 (IE1), pAbUL56 (pUL56), 
pAbUL104 (pUL104), mAbMCP (MCP) and pAbUL77 (pUL77) as control. Extracts 
(Extr., lane 1-2) as well as precipitates (Co-IP, lane 3-4) from mock-infected (lane 1, 3) 
and AD169-infected (lane 2, 4) cells were analysed. (B) Mock-infected or AD169-
infected HFF lysates at 72h p.i. were precipitated with mAbIE1 (IP-IE1), pAbUL56 (IP-
pUL56), pAbUL104 (IP-pUL104 and mAbMCP (IP-MCP) and subjected to SDS-PAGE. 
Immunostaining was performed using pAbUL77 and as an expression control antibodies 
that were used for precipitation. Immunostaining was performed using antibodies pUL77 
and mAbIE1 (IP-IE1), pAbUL77 and pAbUL56 (IP-pUL56), pAbUL77 and pAbUL104 
(IP-pUL104), and pAbUL77and mAbMCP (IP-MCP). Extracts (Extr., lane 1-2) as well as 
precipitates (Co-IP, lane 3-4) from mock-infected (lane 1, 3) and AD169-infected (lane 2, 
4) cells were analysed. The arrows indicate the positions of the proteins IE1, pUL56, 
MCP, pUL104 and pUL77. The molecular weight markers (M) are indicated on the left. 
 
In this study we tested for interactions with MCP that is one of the major components of the 
capsid (53), pUL104 the portal protein through which the DNA is inserted into the preformed 
capsids (78, 79), pUL56 the large subunit of the terminase involved in DNA packaging (31, 
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93) and the non structural viral replication factor immediate early protein IE1 (148) as a 
negative control. 
For that purpose, HFFs were mock-infected or AD169-infected at a MOI of 2, harvested 72h 
p.i. and subjected to co-immunoprecipitations (Co-IP). In a first experiment we precipitated 
against pUL77 (Figure 7. A (IP-pUL77)) and in an alternate experiment against the proteins 
analysed with immunostaining in the previous experiment, e.g. IE1 (Figure 7. B (IP-IE1)), 
pUL56 (Figure 7. B (IP-pUL56)), pUL104 (Figure 7. B (IP-pUL104)) and MCP (Figure 7. B 
(IP-MCP)). 
In other words, either the monospecific antibody pAbUL77 (Figure 7. A) or mAbIE1 against 
IE1, pAbUL56 against pUL56, pAbUL104 against pUL104 and mAbMCP against MCP 
(Figure 7. B) were used for precipitation. The following immunostaining using the antibodies 
mentioned above detected pUL56 (Figure 7. A (pUL56)), MCP (Figure 7. A (MCP)), the 
pUL104 (Figure 7. A (pUL104)) and pUL77, to analyse the presence of both precipitated 
proteins (Figure 7. A (pUL77)) in HCMV-infected cell extracts and precipitates. No band was 
detected in mock-infected cell extracts or precipitates (Figure 7. A and B, lanes 1, 3) using 
virus specific antibodies mAbIE1, pAbUL77, pAbUL56, pAbUL104 and mAbMCP. 
Immunostaining against IE1 was used as a negative control (Figure 7. A (IE)). In addition, 
using antibodies specific for pUL56, pUL104, MCP and IE1 for precipitation, pUL77 was 
detected in the corresponding manner, thus confirming the interactions (Figure 7. B).  
To further examine whether interactions between pUL77 and packaging proteins are direct, 
without other viral proteins involved, co-immunoprecipitations in 293T-transfected cells were 
performed. Briefly, cells were co-transfected with pcDNA77-myc and pcDNA3.1/HisC 
(Figure 8, lanes 3-4 (vector)), pcDNA77-myc and pHM123 encoding IE1 (Figure 8, lanes 5-6 
(IE1)), pcDNA77-myc and pcDNA56 (Figure 8, lanes 7-8 (pUL56)), pcDNA77-myc and 
pcDNA104 (Figure 8, lanes 9-10 (pUL104)) or pcDNA77-myc and pcDNAMCP (Figure 8, 
lanes 11-12 (MCP)). Cell extracts were harvested 48h after transfection. For precipitation a 
specific antibody against the Myc-tag (E-Q-K-L-I-S-E-E-D-L) of pUL77 prior to 
immunostaining against Xpress-tag (D-L-Y-D-D-D-D-K) of IE1, pUL56, pUL104 and MCP 
was used. In precipitates monomers of pUL56, pUL104 and MCP were detected (Figure 8, 
lanes 8, 10, 12). In precipitates of mock, vector-transfected as well as IE1-transfected cells no 
specific proteins were observed (Figure 8, lane 2, 4, 6). 
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Figure 8: Analysing direct interactions. 293T cells were either transfected with 
pcDNA77-myc alone (mock, lane 1-2) or co-transfected with a combination of 
pcDNA77-myc and pcDNA3.1/HisC (vector, lanes 3-4), pcDNA77-myc and pHM123 
(IE1, lanes 5-6), pcDNA77-myc and pcDNA56 (pUL56, lanes 7-8), pcDNA77-myc and 
pcDNA104 (pUL104, lanes 9-10) or pcDNA77-myc and pcDNAMCP (MCP, lanes 11-
12). Co-immunoprecipitation was performed 48h after transfection with pcDNA77-myc 
specific mAbMyc_m. Lysates were subjected to SDS-PAGE prior to immunostaining 
using mAbXpress specific for Xpress-tag (D-L-Y-D-D-D-D-K) of pcDNA56, pcDNA104 
and pcDNAMCP or pHM123. Extract (Extr. Lane 1, 3, 5, 7, 9, 11) and precipitate (Co-IP 
lane 2, 4, 6, 8, 10, 12) fractions are analysed. The arrows indicate the positions of the 
proteins IE1, pUL56, MCP, pUL104 and pUL77. The molecular weight markers (M) are 
indicated on the left. 
 
These data implicate physical interactions between the capsid-associated pUL77 and the 
structural proteins of the HCMV capsid, in more detail: (i) the large terminase subunit pUL56, 
(ii) the portal protein pUL104 and (iii) MCP. 
Therefore we hypothesise that interactions between pUL77 and the capsid proteins tested are 
a hint for a function of pUL77 in events connected to capsid assembly and/or DNA 
packaging. 
 
3.1.4 DNA binding of HCMV pUL77 
To further analyse whether pUL77 might be connected to DNA packaging its ability to bind 
dsDNA was examined. Therefore, in vitro binding studies were performed. [35S]-labelled 
pUL77 was loaded on a dsDNA cellulose column or heparin-sepharose which is used as a 
dsDNA analogue (18, 46, 162, 208). Scott et al. (208) described immobilised heparin to have 
two main modes of interaction with proteins; (i) it can operate as an affinity ligand, e.g. in its 
interaction with coagulation factors; or (ii) heparin functions as a high capacity cation 
exchanger, due to its anionic sulphate groups. The negative charge mimics the electrostatic 
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characteristics of dsDNA and therefore heparin-sepharose is used to bind DNA-binding 
proteins. 
 
Figure 9: Interaction of pUL77 with dsDNA. (upper panel) In vitro translated [35S]-
labelled pUL77 (in vitro translate, lane 1) was applied to a dsDNA-cellulose column. 
After the column was washed (wash, lane3), pUL77 was eluted with increasing NaCl 
concentrations (200-2000mM NaCl, lanes 4-8) and an additional boiling step (resin, lane 
9). (middle panel) In vitro translated [35S]-labelled pUL77 (in vitro translate, lane 1) was 
applied to a heparin-sepharose column. After the column was washed (wash, lane3), 
pUL77 was eluted with increasing NaCl concentrations (200-2000mM NaCl, lanes 4-8) 
and an additional boiling step (resin, lane 9). (lower panel) To control specificity of the 
method in vitro translated [35S]-labelled MCP (in vitro translate, lane 1) was loaded onto 
dsDNA-cellulose column. The column was washed (wash, lane3) prior to elution with 
increasing NaCl concentrations (200-2000mM NaCl, 4-8) an additional boiling step 
(resin, lane 9) (cf. 149). Molecular weight markers (M) are indicated on the left; the 
positions of the proteins are indicated on the right. 
 
After serious washing steps bound proteins were eluted with a NaCl-gradient (200-2000mM 
NaCl). Eluates were analysed by SDS-PAGE and autoradiography. The protein pUL77 could 
be detected in all eluted fractions in both experiments binding to dsDNA-cellulose as well as 
to heparin-sepharose columns (Figure 9. upper and middle panel). Still we detect a peak in 
elution at 400-800mM NaCl for the undefined dsDNA (Figure 9. upper panel, lane 5-6) and at 
400-1000mM NaCl for heparin (Figure 9. middle panel, lane 5-7). Thus, the results are 
implying an interaction of pUL77 with dsDNA. In contrast to this observation, there is no 
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significant signal for MCP, used as a negative control, detected (Figure 9. lower panel, lanes 
4-9(cf. 149)). These results indicate that pUL77 has the ability to bind dsDNA. 
 
3.1.5 HCMV pUL77 binds to dsDNA of at least 500bp in length 
To further analyse pUL77 binding to dsDNA the assay described above was adapted. To 
answer the question whether the DNA has to be specially designed to allow binding of 
pUL77, defined species of DNA were used. 
 
Figure 10: Testing known interactions. To oligonucleotides bio-pac in vitro translated 
[35S]-labelled pUL56 (upper panel, lane 1) or MCP (lower panel, lane 1) were added as 
positive and negative control. Column was subjected a serious washing step (lane 3) and 
to elution with increasing NaCl concentrations (lanes 4-8, (200-2000mM NaCl)) and an 
additional boiling step (lane 9 (resin)). Samples were analysed by 8% SDS-PAGE and 
autoradiography. Molecular weight markers (M) are indicated on the left, the positions of 
the proteins on the right. 
 
Either small fragments containing specific motifs by oligonucleotide synthesis (bio-pac) or 
longer ones by PCR (bio-250, bio-500, bio-1000) were obtained. The bio-pac oligonucleotide 
corresponds to the pac1 sequence (163). The motif is described as the recognition motif of the 
terminase complex (31). Bogner et al. used the very same specific 36-mer to analyse the 
interaction between pUL56 and pac1 in an electro mobility shift assay (31). As proof of 
principal and for testing specificity of the method the experiment described in the paper was 
reconstituted using the method optimised in this study. 
For pUL56 we detect binding to bio-pac. In detail, for pUL56 (Figure 10, upper panel, lane 3 
(wash)) we see an excess of protein being washed away while the rest of the protein binds so 
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tight to the sequence that it cannot be removed by elution with 200-2000mM NaCl (Figure 10, 
upper panel, lane 4-8 (200-2000mM NaCl)) alone. Only after an additional boiling step 
(Figure 10, upper panel, lane 9 (resin)) pUL56 is completely removed from the beads. In the 
case of MCP, that is known not to bind dsDNA, we detect no specific bands in the elution or 
resin fractions (Figure 10, lower panel, lanes 3-9). In addition, experiments using bead 
material alone does not show interactions with the proteins applied (data not shown, cf. 149). 
 
Figure 11: HCMV pUL77 binds to defined dsDNA. (A) The binding reaction was carried 
out by incubation of dsDNA oligonucleotide 36-mer bio-pac containing pac1 motif (lanes 
1-9) with avidin-agarose resin followed by addition of in vitro translated [35S]-labelled 
pUL77. Washing and elution steps were carried out as described previously. Briefly, 
column was subjected a serious washing step (lane 3), to elution with increasing NaCl 
concentrations (lanes 4-8, (200-2000mM NaCl)) and an additional boiling step (lane 9 
(resin)). (B) The binding reaction was carried out by incubation of dsDNA 
oligonucleotides 250-mer bio-250 (upper panel, lanes 1-9), 500-mer bio-500 (medium 
panel, lanes 1-9), 1000-mer bio-1000 (lower panel, lanes 1-9), respectively. Washing and 
elution steps were carried out as described in A. Samples were analysed by 8% SDS-
PAGE and autoradiography. Molecular weight markers (M) are shown on the left; the 
positions of the proteins are indicated on the right. 
 
Since it is possible to detect specific interactions between proteins and rather short dsDNA 
fragments (36-mer bio-pac) on bead material, this method was used in further experiments. 
Because the pac-sequences are the only motifs on the HCMV genome described so far to 
facilitate specific interactions to viral proteins involved in packaging, we were testing whether 
pac-sequences might mediate binding of pUL77 to dsDNA. In contrast to pUL56 (Figure 10, 
upper panel) we did not find any specific binding for pUL77 to bio-pac (Figure 11. A). 
Therefore we hypothesise that not a specific motif but the DNA itself being a negatively 
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charged species facilitates the interaction. The amount of charge provided from the 36-mer is 
not sufficient to facilitate an interaction. 
Hence, we constructed longer DNA-species resulting in higher negative charge and applied 
them to this assay. Figure 11. B shows that only after applying an oligonucleotide of 500bp or 
longer a specific binding similar to pUL56/bio-pac could be detected. In other words, a 
specific band for pUL77 is detected in the resin fraction of bio-500 (Figure 11. B, middle 
panel, lane 9) and bio-1000 (Figure 11. B, lower panel, lane 9). 
To draw further conclusions from these findings a quantification of the results is necessary. 
Therefore a factor needs to be defined that reflects the relative strength of the interaction 
between protein and DNA. In our study we defined the band intensity detected by Bioimager 
in resin (Figure 9, Figure 10 and Figure 11, lane 9) relative to the input (Figure 9, Figure 10 
and Figure 11, lane 1) as binding efficiency (BE). This number has nothing to do with global 
binding constants measured by physicochemical methods like stop-flow or Biacore but serves 
to help us setting the results of this assay in ratio. In other words, the quantification allows us 
to analyse differences in the binding between different proteins and DNA species tested in this 
assay. The results of this quantification are summarised in Table 1. 
Table 1: Quantification of DNA-binding. Using the binding efficiency (BE) defined by the formula 
on the left hand side DNA-binding reactions were quantified. BE is defined 10 for binding 
between pUL56 and bio-pac1. BE < 1 is defined as no binding. Values were obtained in three 




pUL56 bio-pac1 10±0.53 
MCP bio-pac1 0.2±0.40 
pUL77 bio-pac1 0.2±0.03 
pUL77 bio-250 0.5±0.45 
pUL77 bio-500 2.2±0.41 










BE  ...binding efficiency 
Iresin...Intensity of 100% resin 






We defined the interaction between pUL56 and pac1 as BE=10, for the interaction is known 
from literature to be specific, long-lived and strong enough to allow the terminase to perform 
its specific cut to separate one unique length genome from the other (31). In contrast to that 
all interaction BE<1 were defined as not specific, e.g. for the interaction between MCP and 
pac1, pUL77 and pac1 as well as pUL77 and bio-250. In comparison to pUL56 and pac1, BE 
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from the interaction between pUL77 and bio-500 is 80% reduced, whereas with bio-1000 only 
50% and with the genomic DNA approximately 20%. This findings show that the interaction 
between pUL77 and dsDNA seems to get stronger with longer interacting DNA fragments, 
thereby strengthening the hypothesis that we are analysing an electrostatic effect. Taken 
together, we could show that we designed a method that can be used to quantitatively analyse 
binding between proteins and specifically designed DNA species. Applying this method to 
further analyse the DNA binding abilities of pUL77 we could show that this interaction is 
dependent upon a certain length of the provided DNA. 
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3.2 Functional characterisation of HCMV pUL71 
3.2.1 Identification of the protein pUL71 
To generate a specific antibody against pUL71 a similar approach as described for generation 
of pAbUL77 was used. Since Beghetto et al. published that pUL71 causes a strong 
immunogenic response in HCMV patients (27), the sera of high titre HCMV positive 
individuals was applied to column affinity chromatography against rpUL71_Ecoli. The 
purified fractions were tested for monospecificity prior to further usage in this study.  
Figure 12. A shows blots probed with rpUL71_Ecoli and stained with either purified antibody 
pAbUL71 (Figure 12. A, lane 1 (pUL71)), Cytotect (Figure 12. A, lane 2 (HCMV+ Serum)) or 
mAbUL44 (Figure 12. A, lane3 (pUL44)). Only pAbUL71 and the positive control Cytotect 
reacted with the recombinant protein. Using the commercial strips containing for different 
immunogens (Mikrogen Diagnostics, Neuried, cf. pAbUL77 purification 3.1.1) we found 
Cytotect (Figure 12. B, lane 2 (HCMV+ Serum)) and mAbUL44 (Figure 12. B, lane 3 
(pUL44)) but not pAbUL71 (Figure 12. B, lane 1 (pUL71)) reacting. This finding is hinting 
towards the specificity of the antibody against its target. To further analyse specificity we 
transfected a 6x His-tagged (H-H-H-H-H-H) pUL71 expressed from pcDNA71 in 293Ts and 
reacted the blot with either mAbHis or pAbUL71. Both antibodies visualised a single band at 
approximately 55kDa further hinting on the monospecificity of the antibody (Figure 12. C). 
Further the antibody was used to detect pUL71 in mock-infected and AD169–infected HFFs 
separated by either SDS-PAGE or NATIVE-PAGE. In SDS-PAGE we detected a single band 
at 55kDA in infected cells (Figure 12. D, lane 1). Whereas, in NATIVE-PAGE a higher 
molecular weight species was detected (Figure 12. E, lane 1) hinting on a possible 
oligomerisation tendency of the protein that will be further discussed in this study (3.2.8). No 
specific band was detected in the mock fractions under both conditions (Figure 12. D and 
Figure 12. E., lane 2). 
Taken together we conclude that (i) with pAbUL71 we generated a monospecific antibody 
against pUL71 that (ii) reacts in infected and transfected cells in one band of approximately 
55kDa under denaturating conditions and (iii) a higher molecular weight band that might 





Figure 12: Identification of the pUL71. (A) The generated antibody pAbUL71 was tested 
for specificity. Purified rpUL71_Ecoli was separated by 10% SDS-PAGE and subjected 
to immunostaining using pAbUL71 (pUL71, lane 1), Cytotect (HCMV+ Serum, lane 2) 
and mAbUL44 (pUL44, lane 3). (B) Commercially available immunoblot stripes 
(Mikrogen Diagnostics, Neuried) containing immunodominant epitopes of IE1 (53 kDa), 
pp150 (50 kDa), pUL44/pUL57 (45 kDa), pp65 (31 kDa), gB1 (25 KDa) and gB2 (18 
kDa) were reacted with pAbUL71 (lane 1), Cytotect (HCMV+ Serum, lane 2) and 
mAbUL44 (lane 3). Positively reacted control stripe is shown on the right. (C) Cell 
extracts of transiently expressed pUL71 fused to a 6x His-tag (H-H-H-H-H-H) was 
analysed using specific antibodies against pUL71 (pAbUL71, lane1) and 6x His-tag 
(mAbHis, lane2). (D) Extracts from AD169-infected (lane 1) or mock-infected cells (lane 
2) were separated by 8% SDS-PAGE prior to immunostaining with pAbUL71. (E) 
Extracts from AD169-infected (lane 1) or mock-infected cells (lane 2) were subjected to 
8% NATIVE-PAGE followed by immunostaining with pAbUL71.Molecular weight 
markers (M) are indicated on the left. Markers for NATIVE-PAGE: β-GAL: β-
galactosidase 130kDa; PYG: phosphorylase 100kDa; BSA: bovine serum albumin 




3.2.2 Association of pUL71 with tegument fraction 
Extracellular virions were isolated from the supernatant of AD169-infected cells 96h p.i and 
subjected to fragmentation using detergent treatment prior to multiple ultracentrifugation 
steps. The content of each fraction was analysed by immunostaining and Coomassie staining. 
 
Figure 13: Association of pUL71 with the tegument. (A) Mock-infected (mock, lane 1) 
and AD169-infected cell extracts (Inf., lane 2) as well as extracellular virions (lane 3), 
purified envelope (lane 4), tegument (lane 5) and capsid (lane 6) fractions were analysed 
by immunostaining using pAbUL71 (pUL71, upper panel) and antibodies mAbgB for 
envelope (gB, second panel), mAbpp28 for tegument (pp28, third panel) or mAbMCP for 
capsid fraction (MCP, lower panel). (B) As a control for protein content, samples used for 
the immunoblot in A were subjected to 8% SDS-PAGE prior to Coomassie staining. 
Molecular weight markers (M) are indicated on the left side, the proteins are indicated by 
arrows. 
 
To analyse the association of pUL71 to the virions the specific antibody pAbUL71 (Figure 13. 
A, upper panel (pUL71)) and marker proteins for each fraction were used similar to 3.1.2, e.g. 
antibodies mAbgB for envelope (Figure 13. A, second panel (gB)), mAbpp28 for tegument 
(Figure 13. A., third panel (pp28)) or mAbMCP for capsid fraction (Figure 13. A, lower panel 
(MCP)). 
Immunostaining shows pUL71 to be found in AD169-infected cells (Figure 13. A, upper 
panel, lane 2 (pUL71)) as well as in extracellular virions (Figure 13. A, upper panel, lane 3 
(pUL71)). After fractionating of extracellular virions, pUL71 is exclusively detected in the 
tegument fraction (Figure 13. A, upper panel, lane 5 (pUL71)). It was tested by staining 
against specific markers whether all fractions containing the proposed protein content. All 
marker proteins were detected in infected cells (Figure 13. A, all panels, lane 2) and 
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extracellular virions (Figure 13. A, all panels, lane 3) and gB exclusively in envelope (Figure 
13. A, second panel, lane 4 (gB)), pp28 exclusively in tegument (Figure 13. A, third panel, 
lane 5 (pp28)) and MCP exclusively in capsid fraction (Figure 13. A, lower panel, lane 6 
(MCP)). Taken together, this experiment shows that pUL71 is a structural protein associated 
to the tegument fraction of extracellular virions. 
 
3.2.3 Expression of pUL71 within the viral life cycle 
For a further functional characterisation of the protein it is important to know its temporal and 
spatial expression pattern. An expression kinetic study was performed analysing samples at 
specific time points throughout the infection. The samples were subjected to 
immunofluorescence and immunostaining. To assay growth the expression of several marker 
proteins for specific time points in the viral life cycle was tested in parallel. IE1, the major 
immediate early protein is expressed as one of the first proteins, pUL44 a member of the DNA 
polymerase machinery and MCP the major capsid protein expressed at a late stage in infection 
were chosen as markers. These proteins represent immediate-early, early-late and late 
expression kinetics. 
In the control section of Fig A (Figure 14. A, controls) the expression pattern of marker 
proteins are shown. IE1 (Figure 14. A, controls, lane IE1) is expressed from the earliest time 
point, 6h p.i., tested onwards throughout the whole experiment in the nucleus of AD169-
infected cells. Expression of pUL44 (Figure 14. A, controls, lane pUL44) starts in a few cells 
at 24h p.i but more pronounced from 48h p.i onwards in distinct replication centre like areas 
in the nucleus, whereas expression of MCP (Figure 14. A, controls, lane MCP) starts at 72h 
p.i in similar patterns.  
From 96h p.i. extracellular virions (91) can be detected in the supernatant therefore the 
replication cycle is thought to be completed. Experiment was continued until 168h p.i. when 
almost all cells were lysed. Expression of pUL71 (Figure 14. A, pUL71) is detected first in 
cells at 24h p.i. but generally from 48h p.i. onwards getting more pronounced over time in the 
cytosol showing a peak at 72h p.i.. The expression pattern is very distinct, forming a 
junxtanuclear round shaped complex that in some cells seems to rearrange the nucleus around 




Figure 14: Expression of pUL71 within the viral life cycle. (A) HFFs were infected with 
a MOI of 2 and fixed at indicated time points (0, 6, 12, 24, 48, 72, 96, 120, 168h p.i.) for 
immunofluorescence analysis. Cells were reacted wit DAPI and specific antibodies. 
Expression kinetic was obtained for pUL71 using pAbUL71 (green, pUL71) as well as 
for IE1 using mAbIE1 (red, controls lane IE1), pUL44 using mAbUL44 (red, controls 
lane pUL44) and MCP using mAbMCP (red, controls lane MCP). (B) HFFs were 
infected with a MOI of 2 and cells were harvested at indicated time points (0, 6, 12, 24, 
48, 72, 96, 120h p.i.), separated by 8% SDS-PAGE and analysed by immunostaining. 
Immunoblots were reacted with pUL71  (upper panel, pUL71), mAbIE1 (2nd panel IE1), 
mAbUL44 (third, panel pUL44), mAbMCP (fourth, panel MCP) and pAbβ-actin (lowest 
panel β-actin). (C) Influence of inhibitor substance PAA on pUL71 expression was 
analysed by immunofluorescence in MOI 2 infected HFFs at 72h p.i.. Cells were grown 
in the absence (upper panel) and presence (lower panel) of PAA. Protein expression was 
analysed using pAbUL71 (green, lane pUL71) mAbIE1 (red, lane IE1), mAbUL44 (red, 
lane pUL44) and mAbMCP (red, lane MCP). (D) The effect of PAA on pUL71 was 
further analysed using immunostaining. HFFs were infected with a MOI of 2 grown in 
the absence (lane1) and presence (lane2) of PAA, harvested 72h p.i., separated by 8% 
SDS-PAGE and analysed with pAbUL71. Arrows on the right side indicate the position of 
pUL71. Molecular weight markers (M) are shown on the left. 
 
For immunostaining a similar expression kinetic as in immunofluorescence studies is detected 
for all proteins tested, e.g. pUL71 (Figure 14. B, upper panel (pUL71)) IE1 (Figure 14. B, 
second panel (IE1)), pUL44 (Figure 14. B, third panel (pUL44)) and MCP (Figure 14. B, 
lower panel (MCP)). Expression of pUL71 (Figure 14. B, upper panel (pUL71)) is detected 
from 48h p.i. onwards increasing over time.  
To further determine the time of pUL71 expression within the programmed cascade of HCMV 
translation, a chemical compound phosphonoacetic acid (PAA) was applied that inhibits the 
expression of proteins dependent upon expression of the viral polymerase gene (UL54) (220). 
The expression of pUL71 (Figure 14. C, lane pUL71), IE1 (Figure 14. C, lane IE1), pUL44 
(Figure 14. C, pUL44) and MCP (Figure 14. C, MCP) at 72h p.i. was analysed in the absences 
(Figure 14. C, upper panel) and presence (Figure 14. C, lower panel) of PAA. Addition of 
PAA resulted in inhibition of expression of pUL71, pUL44 and MCP. Since pUL71 is 
expressed from 48 h p.i onwards but dependent on expression of viral DNA polymerase it is 
supposed to have an early late expression kinetic. These findings were further verified by 
immunostaining. Again pUL71 expression at 72h p.i. was analysed in the absence (Figure 14. 
D, lane 1) and presence (Figure 14. D, lane 2) of pUL71. In line with the previous 
observation, pUL71 was only detected in the absence of the inhibitor. Taken together, pUL71 




3.2.4 pUL71 and the assembly complex (AC) 
As shown in the previous immunofluorescence study (e.g. Figure 14. A, pUL71, 72h p.i.) 
pUL71 shows a very specific cytosolic expression pattern. Similar patterns are described in 
literature for pp28 (203, 209) and other proteins (202) involved in egress of viral particles as 
well as for cellular components of the endoplasmatic reticulum (ER) and Golgi apparatus 
(Golgi) (47, 70, 71, 101) in HCMV infected cells. To analyse if pUL71 is arranged or even 
directly interacting with these structures termed assembly complex (AC) (70) confocal 
immunofluorescence microscopy will be used. 
HFFs were mock-infected or AD169-infected and fixed 72h p.i prior to antibody staining 
against cellular (GM130, p230) and viral markers for AC (pp28). The localisation of the Golgi 
was analysed using mAbGM130 to stain for marker protein GM130 and of the trans-Golgi 
network (TGN) using mAbp230 for p230. In Figure 15. A, C these structures were analysed in 
mock-infected cells, whereas in Figure 15. B, D the reorganisation of those structures upon 
viral infection is shown. Fig. E and F shows the localisation of pp28- a large tegument 
protein- both in mock-infected or AD169-infected cellss using mAbpp28. All markers of the 
AC are stained in red; pUL71 is always stained in green. On the micrograph B we detect a 
similar distribution but not a spatial co-localisation between Golgi-markers and pUL71, the 
same is seen for the TGN-marker (Figure 15. D) and pp28 (Figure 15. F). Although some 
proteins spatially co-localise the overall distribution pattern shows no hint on a direct 
interaction. Taken together, we conclude that the junxtanuclear localisation of pUL71 is 
similar in shape and localisation to the AC. Still no direct interaction between pUL71 and the 
AC was observed with the three markers tested in this study. 
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Figure 15: Spatial localisation to the assembly complex (AC). HFFs were mock-infected 
or AD169-infected at a MOI of 2, fixed 72h p.i. and subjected to immunofluorescence. 
(A) Expression pattern of Golgi-marker GM130 in mock-infected cells. Nuclei were 
stained with DAPI and marker protein with mAbGM130. Micrograph represented as grey 
scale. (B) Expression pattern of GM130 in AD169-infected cells. Nuclei are stained with 
DAPI (blue), mAbGM130 (red GM130) and pAbUL71 (green pUL71). Micrograph 
represents merge image. Spatial co-localisation is indicated by yellow fluorescence. (C) 
Expression pattern of TGN-marker p230 in mock-infected cells. Nuclei were stained with 
DAPI and marker protein with mAbp230. Micrograph represented as grey scale. (D) 
Expression pattern of p230 in AD169-infected cells. Nuclei are stained with DAPI (blue), 
mAbp230 (red p230) and pAbUL71 (green pUL71). Micrograph represents merge image. 
Spatial co-localisation is indicated by yellow fluorescence. (E) Negative control of viral 
marker pp28 in mock-infected cells. Nuclei were stained with DAPI and marker protein 
with mAbpp28. Micrograph represented as grey scale. (F) Expression pattern of pp28 in 
AD169-infected cells. Nuclei are stained with DAPI (blue), mAbpp28 (red pp280) and 
pAbUL71 (green pUL71). Micrograph represents merge image. Spatial co-localisation is 
indicated by yellow fluorescence. 
 
3.2.5 Screening pUL71 against a cellular library 
To test whether pUL71 might bind to cellular factors that play a role in egress of HCMV 
virions, a Yeast-two-hybrid (Y2H) screen against a cellular library was performed. Used as a 
bait pGBUL71 was transfected into Y187 strain and mated with the cellular library (MEF: 
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Mouse Embryonic Fibroblasts in pACT2, Clontech) that was transfected into AH109 
previously. The mated colonies were applied to selective plates and analysed for growth and 
β- galactosidase activity. Unfortunately all clones selected in this screen turned out to be false 
positive after repeating the selectivity assays. A similar experiment was carried out in the 
group of Dr. Jens von Einem that resulted in not detecting any interaction partners of pUL71 
as well (Dr. Jens von Einem, personal communication). 
Therefore we conclude that, (i) either there are no interactions between pUL71 and cellular 
proteins occurring, which is rather unlikely taking the confocal images into consideration; or 
(ii) more likely, that the method is not applicable to detect those interactions. This could be 
either because of using a mouse library instead of a human derived one or the detection limit 
of the method is not sensitive enough to detect viral-host interactions of pUL71. 
 
3.2.6 Screening pUL71 against a viral library 
Since no interaction partners of pUL71 were found in the previous Y2H screen against the 
cellular library, an in-house library containing several viral proteins was constructed. This 
library was used in further screens. 
Table 2: Screening for viral interaction partners- Summary of results of Y2H screen 
against the in –house library. Briefly, pUL71 as bait or prey was screened against pUL56, 
pUL89, pUL77, MCP, pUL104 and empty vector controls in appropriate form (bait/prey). 
As a read-out either using β-Gal filter activity (β-Gal) or selective growth (-His, -Ade) 
was analysed. Positive readout is represented by +, negative by -. 
bait prey β-Gal -His -Ade 
pUL56 pUL71 - - - 
pUL89 pUL71 - + - 
pUL77 pUL71 + + - 
MCP pUL71 - + + 
pUL104 pUL71 + - + 
Vector pUL71 - - - 
pUL71 pUL56 - - - 
pUL71 pUL89 - + + 
pUL71 pUL77 - + - 
pUL71 MCP - + - 
pUL71 pUL104 - - + 
pUL71 Vector - - - 
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Again bait constructs were transfected into Y187, prey constructs into AH109 yeast strain and 
analysed upon reactivation. The constructs that were negative for reactivation were combined 
upon mating both strains. The mated, diploid yeast colonies were applied to selective plates 
and analysed for growth and β- galactosidase activity in a β-galactosidase filter shift assay. 
Table 2 outlines the results of 5 independent experiments. Not all interactions were detected in 
all readouts, but Sanderson et al. (10) introduced a method defining combinations of these 
results as trustworthy indicators for positive interactions. Growth on selective media deficient 
for adenine (–Ade) as well a combination of two or more other readout methods are good 
indication for positive interactions. According to that only interactions between bait pUL71 
and pUL77, MCP and 104 as prey, as well as pUL89 as bait and pUL71 as prey are 
trustworthy candidates for positive interactions. 
Therefore, we can conclude that the Y2H screen gives us hints on interactions between 
pUL71 and the capsid and capsid-associated proteins tested. We detected interactions between 
pUL71 and structural proteins pUL77, pUL104 and MCP that need to be further verified by 
another protein-protein interaction assay. 
The interaction between pUL71, that localises in the cytoplasm (3.2.3) and pUL89 that is 
exclusively found in the nucleus (228), is considered to have no biological relevance. 
Therefore, it was not further analysed in this study. 
 
3.2.7 Confirming interactions found in the Y2H screen 
In this experiment we tried to confirm interactions found in the Y2H screen between pUL71 
and the subset of proteins by co-immunoprecipitation in infected cells. HFFs were mock-
infected or AD169-infected. Cells were harvested 72h p.i. and extracts subjected to co-
immunoprecipitation against pAbUL71. 
The interaction partners were analysed by immunostaining against pUL104 (Figure 16. A), 
MCP (Figure 16. B), pUL77 (Figure 16. C), pUL56 (Figure 16. D) and IE1 (Figure 16. E) that 
served as a negative control.  
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Figure 16: Verifying interaction found in Y2H screen. Mock-infected or AD169-infected 
HFF lysates at 72h p.i. precipitated with pAbUL77 and subjected to 8% SDS-PAGE prior 
to immunostaining. Mock-infected cell extracts (Extract, lane 1) and precipitates (Co-IP, 
lane 2) as well as AD169-infected cell extracts (Extract, lane 3) and precipitates (Co-IP, 
lane 4) were analysed. Immunostaining was performed using antibodies (A) mAbUL104, 
(B) mAbMCP, (C) pAbUL77, (D) pAbUL56, (E) mAbIE1 and (F) pAbβ-actin. Arrows on 
the right side indicate the position of proteins. Molecular weight markers (M) are shown 
on the left side. 
 
The presence of pUL71 in the extract and precipitate was verified (Figure 16. F, lane 3-4) by 
staining with pAbUL71. No signal was detected in extract and precipitates of mock-infected 
cells (Figure 16. A-F, lane 1-2). In AD169-infected cells the extract fraction always contained 
pUL71 (Figure 16. F, lane 3) and the appropriated protein tested (Figure 16. A-E, lane 3). 
Only if the protein is detected in the precipitate as well, we will analyse a direct interaction. In 
this study pUL104 (Figure 16. A, lane 4), MCP (Figure 16. B, lane 4) and pUL77 (Figure 16. 
C, lane 4) was found in the precipitate but not pUL56 (Figure 16. D, lane 4) and IE1 (Figure 
16. E, lane 4). Thus, further verifying the interactions found in Y2H screen between pUL71 
and pUL104, MCP and pUL77. 
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3.2.8 Oligomerisation of pUL71 
The detection of the higher molecular weight band in the NATIVE-PAGE using pAbUL71 
(Figure 12. E) gave a hint on the putative oligomerisation tendency of pUL71. To further 
verify this finding baculovirus expressed recombinant protein rpUL71-Bac was purified by a 
combination of anionic exchange chromatography and gel filtration.  
 
Figure 17: Oligomerisation potential of rpUL71-Bac. (A) Chromatogram of gel filtration. 
Peak at 35ml represents the dead volume. Marker proteins are indicated below to connect 
elution volume with protein size. Void Volume (= 25 ml); Ferritin (85kDa = 38ml); OVA 
(45kDa = 55ml). (B) Negative stained particles from sample taken at 47.8ml analysed by 
EM. Molecular weight (kDa) can be calculated from size of the particles (77). Different 
oligomers formed from the sample. Monomeric forms (a-h), dimers or trimers (i-l) and 
higher oligomeric forms (m-q). Bar size =200nm. 
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In the gel filtration fraction at 47.8 ml was taken (Figure 17. A), later on used for electron 
microscopy (EM) analysis. The purified protein was negative stained and subjected to EM 
analysis. Species of different size were detected that were calculated to be monomeric (Figure 
17. B, a-h) as well as higher molecular weight forms of the protein (Figure 17. B, i-q) (cf. 77). 
These result hints on the ability of recombinantly expressed rpUL71-Bac to form higher 
ordered structures on its own. 
To further test the oligomerisation ability of pUL71, samples were analysed under different 
SDS-PAGE condition as described by Seo et al. (209). For pp28 dimerisation studies mock-
infected and AD169-infected HFF cells were harvested 72h pi. and treated under denaturating 
(2%SDS, 5% b-mercaptoethanol, 5’ 95°C) or non denaturating (0.1%SDS, RT) conditions 
prior to separation by SDS-PAGE and immunostaining. The experiment described by Seo et 
al. was repeated to test the functionality of the method under conditions in our lab (c.f. Figure 
18. A). As expected, we do not find any specific bands for pp28 in mock-infected cells (Figure 
18. A, lane 1-2). Whereas we detect several bands reflecting the monomeric form of the 
protein at 28kDa as well as higher molecular forms at 55kDa and above 170kDa in AD169-
infected cells under non-denaturating conditions (Figure 18. A, lane 3). On the other hand we 
could only detect a single band reflecting the monomeric form of pp28 in AD169-infected 
cells under denaturating conditions (Figure 18. A, lane 4). Therefore, we state that this method 
is suitable to test oligomerisation tendencies of HCMV proteins. 
In Figure 18. B the method was applied to test for oligomerisation of pUL71. Again no 
specific bands were found in mock-infected cells (Figure 18. B, lane 1-2). In contrast diverse 
bands were detected applying pAbUL71 to AD169-infected cells treated under non-
denaturating conditions. Thereby we detected a band at 55kDa that might represent the 
monomer, a faint band at 130kDa and a very prominent band above 170kDa representing a 
higher order oligomeric form of pUL71 (Figure 18. B, lane 3). In extracts treated under 
denaturating conditions only one specific band at 55kDa was detected (Figure 18. B, lane 4). 




Figure 18: Oligomerisation under different SDS-PAGE conditions. Mock-infected and 
AD169-infected HFFs were harvested 72h p.i. and equivalent samples were analysed by 
8% SDS-PAGE prior to immunostaining. Samples were prepared under different 
conditions. (A) Immunostaining against pp28 to analyse the oligomeric forms of pp28 in 
mock-infected (lane 1-2) and AD169-infected (lane 3-4) cells treated under non-
denaturating (0.1% SDS, lane 1,3) or denaturating (2% SDS, 5% ME, lane 2,4) 
conditions. (B) Immunostaining against pUL71 to analyse the oligomeric form of pUL71 
in mock-infected (lane 1-2) and AD169-infected (lane 3-4) under non-denaturating (0.1% 
SDS, lane 1,3) or under denaturating (2% SDS, 5% ME, lane 2,4) conditions. Molecular 
weight markers (M) are indicated on the left. Arrows indicate molecular weight forms of 
analysed proteins. 
 
3.2.9 The leucine zipper motif 
Since oligomerisation seems to be a characteristic of pUL71, we were interested in 
elucidating motifs in the amino acid (aa) sequence itself that serve as interaction domains. 
Therefore, several in silico analyses using programs Motif Runner Version 1.0 
(http://www.generunner.net/) and motif scan (http://myhits.isb-sib.ch/cgi-bin/motif_scan) 
scanning HAMAP profiles, PROSITE patterns, SMART, PFAM and FT-lines virtual motifs 
databases were performed. 
The results of those in silico motif scans are summarised in Table 3. The only motif with a 
potential to influence oligomerisation is the leucine zipper motif or also called bZip domain 
that was first described by Landschulz et al. (130) as an interaction domain in DNA binding 
protein GCN4 in yeast. O’Shea et al. (173, 174) described the motif to be composed of at least 
four heptads with hydrophobic amino acids at position 1 and 4 forming a hydrophobic core. In 
other words the leucine zipper motif facilitates dimerisation through parallel coiled-coil 
motifs and binds DNA through its hydrophobic domain. This domain is unstructured in the 
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absence of DNA and adopts a helical structure upon binding, thereby describing a class of 
DNA binding proteins (19, 45, 94, 121, 237). In more recent publication this motif is no 
longer restricted to DNA binding but generally accepted as a protein-protein interaction 
domain (141, 189). 
Table 3: Conserved motifs of pUL71. Table summarises the conserved motifs calculated by in 
silico analysis using Motif Runner Version 1.0 (http://www.generunner.net/) and motif scan 
(http://myhits.isb-sib.ch/cgi-bin/motif_scan) with HAMAP profiles, PROSITE patterns, SMART, 
PFAM and FT-lines virtual motifs databases. Resulted motif type and amino acid positions are 
indicated. 
Motifs Position (aa) 
Phosphorilation sites  
cAMP- and cGMP-dependent kinase 350-353 
Casein kinase II 51-54, 130-133, 148-151, 210-213, 301-304, 340-343
Protein kinase C 108-110, 285-287, 340-342 
Leucine zipper motif 34-55 
N-myristoylation site 173-178 
Herpes virus U44 protein (140) 21-166  (E-value = 4.6 10-19) 
 
To illustrate the domain in pUL71 aa 34-55 were represented in an alpha-helical wheel 
(Figure 19. A) and analysed its physicochemical properties using HeliQuest software (Figure 
19. B) (89). The classical leucine zipper motif is disturbed by asparagin (N44) on position 4 
(35). Though, we find a rather large hydrophobic face (L55, L37, L48, L41, L34, P52, F45) 
consisting of the leucines on position 1 and some other hydrophobic aa on positions 4 and 5 of 
the heptads (Figure 19. A and B). Therefore we conclude that this motif although not being a 
classical leucine zipper motif, still has potential to mediate hydrophobic interactions resulting 




Figure 19: Analysing physicochemical properties of the putative leucine zipper motif. (A) 
Representation of amino acids 34-55 in an alpha-helical wheel. Positions on the heptad 
are indicated by numbers 1-7. The important positions 1, 8, 15 and 22 are specially 
indicated. (B) Representation of physicochemical properties in an alpha-helical wheel 
using HeliQuest. Polar amino acids are represented in red (D, E: - charge) and blue (R, K: 
+ charge); Polar amino acids in pink/ violet (Q, N, T); Hydrophobic in yellow (F, L, I) 
and such that are not disturbing hydrophobicity are marked in grey (A) or in green (P) for 
their aromatic side-chain. The hydrophobic core spans from L-L-L-L-L-P-F. 
 
In a HCMV genome wide scan we analysed the abundance of such leucine zipper motifs. Out 
of 162 proteins expressed from HCMV (82, 239), in sequence NC_006273.2 (81) we detected 
only 11 proteins containing one or more leucine zippers. In other words, leucine zippers are 
found in 7% of all protein content reflecting a not highly abundant motif. (Figure 20). Most of 
these proteins, like pUL14, pUL50 (43, 200, 157, 158), pUS14 (70), pUS17 (69, 70), pUS20 
(160), pUS29 (160) are membrane associated. Some are related to DNA packaging like 
pUL51 (36), pUL104 (77, 78, 79) and for some the function is not fully elucidated yet 
(pUL48 (120, 254), pUL88 (23)). Since the exact function of the motif is not elucidated in any 
of those proteins one has to speculate that they serve different purposes within the proposed 
protein function by facilitating protein-lipid, protein-DNA and protein-protein interactions. 
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Figure 20: Abundance of leucine zipper motifs in the HCMV proteome. Schematically 
representation summarises results from HCMV proteome-wide leucine zipper motif scan. 
For in silico analysis motif scan (http://myhits.isb-sib.ch/cgi-bin/motif_scan) software 
was used. Resulting proteins are indicated. Name and function is marked on the left, 
sequence and position of leucine zipper motifs within the amino acid sequences are 
represented by a red squares shown on the right. 
 
Taken together, we conclude that such a leucine zipper motif is not completely unknown but 
not very abundant in HCMV proteins. Thus, hinting that the in silico prediction has resulted in 
a motif potentially present in the actual protein. 
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To identify whether the leucine zipper-like motif functions as an oligomerisation domain of 
pUL71 in vitro, different mutants as well as the full length protein were in silico analysed 
prior to applying it to protein-protein interaction studies. 
First a subset of alterations was introduced into UL71 affecting either individual amino acids 
or the whole motif. Five different constructs the wt UL71 71_wt, the three point single 
nucleotide change mutations L1 (L34A/L41A), L2 (L34A/L41A/L55A), L3 
(L34A/L41A/L48A/L55A) and deletion mutant ΔLZ (Figure 21. A, 1-5) were analysed. Prior 
to subjection to in vitro studies constructs were analysed using secondary structure prediction 
software p-coils, coils, psi-pred and quick2_d. (29). In Figure 21. B we see the results of p-
coils analyses. The exchange of two leucines into alanine at amino acids 34 and 44 resulted in 
loss of the predicted coiled-coil domain in the leucine zipper-like motif. While we see a peak 
of 0.2 on the probability scale [window 14] in 71_wt (Figure 21. B, 71_wt), none is detected 
in prediction for L1 (Figure 21. B, 71_L1). A loss of the predicted coiled-coil structure is 
observed as well for the more invasive mutations 71_L2, 71_L3 and 71_ΔLZ (Figure 21. B, 
71_L2, 71_L3 and 71_ΔLZ). 
The loss of the coiled-coil structure through the amino acid exchange hints on a 
corresponding loss in interacting ability of those mutants. To test this hypothesis the 





Figure 21: Mutational analysis of the leucine zipper-like motif in pUL71. (A) 
Schematically representation of leucine zipper-like motif (red bar). Exchanged amino 
acids are indicated in white. Constructs 71_wt (L R E L Q A F L D E N F K Q L E I T P A 
D L), 71_L1 (A R E L Q A F A D E N F K Q L E I T P A D L), 71_L2 (A R E L Q A F A 
D E N F K Q L E I T P A D A), 71_L3 (A R E L Q A F A D E N F K Q A E I T P A D A) 
are carrying two or more single nucleotide exchanges on heptad positions 1. Complete 
deletion of leucine zipper motif is constructed in 71_ΔLZ. (B) Analysis of coiled-coil 
structures using p-coils software. Result for 71_wt is depicted on the left, result for 71_L1 
on the right. Position of leucine zipper-like motif within the amino acid sequence is 




Figure legend for Figure 21 on page 94.  
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3.2.10 Analysis of the leucine zipper-like motif in vitro 
To test the predicted interaction domain the in silico analysed constructs (cf. Figure 21) were 
cloned into vectors expressing proteins fused to fluorophores and later on used in 
biomolecular fluorescence complementation (BiFC) assays. 
 
Figure 22: Optimising the BiFC-system. Hela cells were transfected with constructs later 
on used for BiFC: none- tagged pcDNA71 (71_wt), YN- tagged pcDNA71_wt-YN 
(71_wt-YN) and YC-tagged (i) pcDNA71_wt-YC (71_wt-YC), (ii) pcDNA71_L1-YC 
(71_L1-YC), (iii) pcDNA71_L2-YC (71_L2-YC), (iv) pcDNA71_L3-YC (71_L3-YC),  
and (v) pcDNA71_ΔLZ-YC (71_ΔLZ-YC) together with expression control pcDNA3.1-
GFP (GFP). (A) Cells were harvested 24h after transfection and analysed by 
immunostaining using specific antibodies against pUL71 (pAbUL71, upper panel), 
against the tags (mAbMyc_m, second panel; pAbHA, third panel), against GFP 
(mAbGFP, fourth panel) and to control equal protein amounts against β-actin (pAbβ-
actin, lower panel). (B) Cells were fixed 24h after transfection and analysed by 
immunofluorescence. Transiently expressed pUL71 forms 71_wt, 71_wt-YN, 71_wt-YC, 
71_L1-YC, 71_L2-YC, 71_L-YC and 71_ΔLZ–YC were stained with pAbUL71 in red, 
GFP-expression is detected in green and nuclei were stained with DAPI. 
 
Firstly, conditions were tested further used in BiFCs. To verify that IBiFC values measured later 
on are dependent upon interacting proteins, the level of transient protein expression was 
tested. Constructs were transfected together with a GFP-construct to assay the expression 
efficiency of the cells. The best results were obtained using following conditions: Hela cells at 
70% confluence were starved prior to transfection and grown 16h at 37°C follow by 30’ at 
32°C. Protein expression was analysed using immunostaining and immunofluorescence. 
Immunostaining shows that YN-tag on 71_wt-YN (Figure 22. A, lane 4) and YC-tags on 
71_wt-YC, 71_L1-YC, 71_L2-YC, 71_L3-YC and 71_ΔLZ-YC (Figure 22. A, lane 5-9) do 
not interfere with protein-expression compared to the none-tagged wild type form (Figure 22. 
A, lane 3). In line with that also mutations in the leucine zipper-like motif do not interfere 
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with protein-expression. Amounts of protein are comparable to 71_wt-YC (Figure 22. A, 
comparing lane 5 with lanes 6-9). In line with the immunostaining data intracellular 
localisation is not disturbed through tags or mutations (Figure 22. B) Therefore, we conclude 
that the conditions tested are applicable for BiFCs. 
Cells were grown on cover slips prior to transfection with both transient expression constructs 
fused to one half of the fluorophores YFP. Briefly, a combination 71_wt-YN fused to the N-
terminal and various species of pUL71 fused to the C-terminal part of YFP were expressed 
(71_wt-YC, 71_L1-YC, 71_L2-YC, 71_L3-YC and 71_ΔLZ-YC). In addition, a construct 
expressing mCherry was co-transfected. Cells were grown under conditions determined 
above, prior to fixation for immunofluorescence. 
Examples for raw data (Figure 23. A, upper panel left to right: vector-YC: pcDNA71_wt-YN/ 
pcDNA-YC + pcDNA3.1-mCherry; 71_wt-YC: pcDNA71_wt-YN/pcDNA71_wt-YC + 
pcDNA3.1-mCherry; 71_L1-YC: pcDNA71_wt-YN/ pcDNA71_L1-YC + pcDNA3.1-
mCherry; lower panel left to right: 71_L2-YC: pcDNA71_wt-YN/ pcDNA71_L2-YC + 
pcDNA3.1-mCherry; 71_L3-YC: pcDNA71_wt-YN/pcDNA71_L3-YC + pcDNA3.1-mCherry; 
71_ ΔLZ -YC: pcDNA71_wt-YN/pcDNA71_ΔLZ-YC + pcDNA3.1-mCherry) are given. 
Expression of YFP is indicated by arrows. The YFP-Intensity (IYFP) of each acquired 






using Axiovision  software 4.8 to allow quantitative  comparison of 
IBiFC between different cells. Results are represented in a histogram (Figure 23. B). IBiFC was 
set to 100% for 71_wt-YN/71_wt-YC. In comparison to the interaction between both wild 
type forms IBiFC was reduced to approximately 40% for all other interactions. This numbers 
are comparable to IBiFc detected for empty vector. Data is highly significant since between 47 
and 153 cells were analysed for each form and p-values were calculated. Thus, indicting that 
an alteration in the leucine zipper motif results in a loss of interaction between the two 




Figure 23: Analysing oligomerisation potential of pUL71 using BiFC. Cells were grown 
on cover slips prior to transfection with a combination of pcDNA71_wt-YN (71_wt-YN) 
and constructs pcDNA-YC (Vector-YC), pcDNA71_wt-YC (71_wt-YC), pcDNA71_L1-
YC (71_L1-YC), pcDNA71_L2-YC (71_L2-YC), pcDNA71_L3-YC (71_L3-YC) or 
pcDNA71_ΔLZ-YC (71_ΔLZ-YC). Additionally a construct expressing mCherry was 
transfected. Cells were fixed 24h after transfection and analysed using 
immunofluorescence. (A) Immunofluorescence data. Expression of YFP (YC+YN) is 
detected in yellow, mCherry in red. (B) Quantification of BiFC results. IBiFC is set to 
100% for interaction 71_wt-YN/71_wt-YC. Other interactions are set in ratio. Error bars 
on the histogram are ± standard deviation from three independent experiments. Statistical 
analysis was performed and p-values were calculated using paired Student’s t-test. 
Significance is indicated by p-value; n: number of analysed cells. 
 
To further verify those results, a different in vitro method was applied to analyse whether the 
leucine zipper motif serves as the oligomerisation domain in pUL71. For co-
immunoprecipitations pUL71 species previously tested by in silico analysis and further by 
BiFCs were inserted into pcDNA3.1HisC and pHM1580 and transfected into 293T cells. The 
cell type is changed because in contrast to BiFCs a strong protein over-expression is needed to 
produce sufficient protein amounts for co-immunoprecipitation. 
For precipitation a specific antibody against the Myc-tag (mAbMyc_r) of 71_wtmyc or 
71_L1myc, 71_L2myc, 71_L3myc and 71_ΔLZmyc was used prior to immunostaining against 
Xpress-tag of 71_wtxpress. Empty vectors pHM1580 (Vectormyc) or pcDNA3.1+ (Vectorxpress) 
were transfected additionally. The extract fractions were stained with both antibodies to test 
the expression of Myc-tagged and Xpress-tagged proteins. Using mAbMyc_r we detected 
protein directly bound to the beads in precipitates (Figure 24. A, lane 3, mAbMyc_r). 
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Whereas if mAbXpress was used, a band representing 71_wtxpress would only be detected in 
the precipitate in the sample in which 71_wtmyc was co-expressed (Figure 24. A, right panel, 
mAbXpress, 71_wtmyc/ 71_wtxpress), thus confirming an interaction only between wild type 
proteins. In precipitates of vector-transfected as well as mock-infected cell extracts no specific 
proteins were precipitated. 
Further we analysed whether the YFP-tagged constructs used in BiFCs could be directly 
applied to co-immunoprecipitations. 
 
Figure 24: Analysing oligomerisation potential of pUL71 using Co-IPs. (A) 293T cells 
were transfected with a combination of pcDNA71 (71-wtxpress) and pcDNA71-myc (71-
wtmyc), pcDNA71_L1-myc (71-L1myc), pcDNA71_L2-myc (71-L2myc), pcDNA71_L3-
myc (71-L3myc) or pcDNA71_ΔLZ-myc (71-ΔLZmyc). As controls pcDNA71 or 
pcDNA71-myc were transfected alone or together with the empty vectors pHM1580 
(Vectormyc) or pcDNA3.1+ (Vectorxpress). Cells were harvested 48h after transfection and 
subjected to precipitation against mAbMyc_r. Extract (Extr., lane 1) and precipitate (Co-
IP, lane 3) fractions were analysed using mAbXpress (upper panel) and mAbMyc_r 
(lower panel). Lane 2 was left empty to prevent contamination upon loading. (B) 293Ts 
cells were transfected with constructs used for BiFCs. A combination of pcDNA71_wt-
YC (71_wt-YCHA) and pcDNA71-myc (71-wtmyc) as well as pcDNA71_wt-YN (71_wt-
YNmyc) was transfected, respectively Further, pcDNA71_wt-YN (71_wt-YNmyc) was 
combined with pcDNA71_wt-YC (71_wt-YCHA), pcDNA71_L1-YC (71_L1-YCHA), 
pcDNA71_L2-YC (71_L2-YCHA), pcDNA71_L3-YC (71_L3-YCHA) or pcDNA71_ΔLZ-
YC (71_ΔLZ-YCHA). Cells were harvested 48h after transfection and subjected to 
precipitation against mAbMyc_m. Extract (Extr., lane 1) and precipitate (Co-IP, lane 3) 
fractions were analysed using mAbHA (upper panel) and mAbMyc_m (lower panel). 
Again lane 2 was left empty to prevent contamination upon loading. 
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Hence, mAbMyc-m against 71_wtmyc or 71_wt-YNmyc was used for precipitation, 
respectively. For immunostaining mAbHA against the HA-Tag (Y-P-Y-D-V-P-D-Y-A) of YC-
tagged pUL71 was used. Similar results are obtained by subjecting constructs used for BiFCs 
to co-immunoprecipitations, in comparison to the not YFP-tagged proteins (Figure 24. B). 
Only pUL71 that is not altered in its leucine zipper-like motif can interact, e.g. between 
71_wt-YCHAand 71_wtmyc as well as between 71_wt-YCHAand 71_wt-YNmyc (Figure 24. B. 
71_wt-YCHA/ 71_wtmyc; 71_wt-YCHA/ 71_wtmyc): The C-terminal fused fluorophores YC or 
YN do not seem to interfere with the precipitation reaction by covering the interacting 
domains. 
These data implicates physical interactions, which are a prerequisite for oligomerisation, are 
only present between two wild type pUL71. If alterations in this motif like an exchange of 
two hydrophobic amino acids (L1) or more invasive ones (L2, L3, ΔLZ) are caused, this 
function is lost. Thus, confirming the leucine zipper-like motif to facilitate direct protein-
protein interaction. 
 
3.2.11 The leucine zipper motif is associated with pUL71 function 
The previous in vitro studies revealed that pUL71 has an oligomerisation tendency dependent 
upon an intact leucine zipper-like motif. Further we wanted to know whether the abolishing of 
oligomerisation influences viral replication. Therefore, mutations were introduced into 
recombinant HCMV 71_wt-BAC by BAC-Mutagenesis (231) resulting in the deletion mutant 
71_ΔLZ-BAC or in the single nucleotide exchange mutant 71_L1-BAC, analogous to 
constructs pcDNA71_ΔLZ or pcDNA71_ΔLZ-YC and pcDNA71_L1 or pcDNA71_L1-YC 
both tested in vitro. 
First, the influences of such mutations on viral replication were determined. HFFs were 
infected at MOI of 1.5 with the three viruses 71_wt-BAC, 71_ΔLZ-BAC and 71_L1-BAC. At 
indicated time points (0-168h p.i.) supernatants were harvested and titres were determined. 
The shedding of virus started 48h p.i. for all three viruses confirmed by an increased detection 
of infectious particles. Though in the following, a decreased shedding between 72h p.i. and 
120h p.i of about two log phases for mutant viruses 71_ΔLZ-BAC and 71_L1-BAC (titre:~105) 
is observed compared to 71_wt-BAC (titre: ~107). Still both mutant viruses can overcome this 
inhibition from 120h p.i onwards. This effect results in a growth deficiency between 72h p.i. 
and 120h p.i, comparing the three growth kinetics (Figure 25, 71_wt-BAC, 71_ΔLZ-BAC, 
71_L1-BAC). Therefore the results indicate that alterations in the leucine zipper motif 




Figure 25: Growth kinetics of wt and mutant viruses. HFFs were infected at MOI of 1.5 
with 71_wt-BAC, 71_ΔLZ-BAC and 71_L1-BAC for growth kinetics. Supernatants were 
harvested at indicated time point and progeny virus titres were determined. Error bars in 
the histogram indicate the standard deviation from three independent experiments. 
Growth of 71_wt-BAC is represented by grey diamonds, 71_ΔLZ-BAC by open and 
71_L1-BAC by the closed circle. pfu: plaque forming units. 
 
While performing the plaque assays for the growth kinetic, we observed that the plaques of 
mutant viruses 71_ΔLZ-BAC and 71_L1-BAC are significantly smaller than the ones produced 
by 71_wt-BAC. Therefore, we decided to analyse this observation in more detail. We infected 
HFFs on cover slips with one of the three viruses 71_wt-BAC, 71_ΔLZ-BAC and 71_L1-BAC 
at a MOI of 1.5 and grown 216h p.i. in viscous medium containing methocel. The cells were 
fixed, probed with specific antibody against IE1 (mAbIE1) and analysed using 
immunofluorescence. By analysing the plaque size we get hints about the cell-to-cell spread 
activity of the virus (212). 
Size of the plaques is dependent on number of neighbouring cells infected via direct cell-to-
cell spread. In case of the mutated viruses 71_ΔLZ-BAC and 71_L1-BAC this cell-to-cell 
spread seems to be reduced in comparison to 71_wt-BAC (Figure 26. A) 
In order to analyse this phenotype of reduced cell-to-cell spread more precisely, the effect was 
quantified by counting mean numbers of infected cells from each plaque. The results are 
represented in the histogram (Figure 26. B). Plaque size decreases about 80% comparing both 
71_ΔLZ-BAC (mean number 5 cells per plaque) and 71_L1-BAC (mean number 8 cells per 
plaque) to 71_wt-BAC (mean number 35 cells per plaque). 
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These results indicate that the reduced growth of mutant viruses 71_ΔLZ-BAC as well as 
71_L1-BAC compared to 71_wt-BAC observed in the growth kinetics is detected more 
pronounced in the cell-to-cell spread assay. Particularly, the reduction in viral growth seems to 
be even stronger when exclusively analysing cell-to-cell spread. 
 
Figure 26: Analysis of cell-to-cell spread. (A) HFFs were infected with 71_wt-BAC (left), 
71_ΔLZ-BAC (middle) and 71_L1-BAC (right) at a MOI of 1.5 and grown on cover slips 
216h p.i. in viscous medium containing methocel. The cells were fixed and subjected to 
immunofluorescence. Nuclei were stained with DAPI, infected cells with mAbIE1 (red) 
against IE1. A group of five or more neighbouring infected cells is defined as one plaque. 
Representative micrographs of plaques produced by 71_wt-BAC (left), 71_ΔLZ-BAC 
(middle) and 71_L1-BAC (right). (B) Numbers of infected cells from each plaque of 
corresponding virus 71_wt-BAC, 71_ΔLZ-BAC and 71_L1-BAC were quantified. Relative 
plaque size was analysed by setting mean plaque number of 71_wt-BAC to 100% and the 
others in ratio. Error bars on the histogram are ± standard deviation from three 
independent experiments. Significance of the results was determined by using paired 
Student´s t-test (p-values). 
 
To shed further light onto these observations the intracellular distribution of pUL71 in 
relationship to the localisation of other viral proteins was analysed using confocal microscopy. 
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HFFs were infected with viruses 71_wt-BAC, 71_ΔLZ-BAC and 71_L1-BAC at a MOI of 3 
until fixed for immunofluorescence at 120h p.i.. In all micrographs pUL71 was stained in 
green, while the tegument protein pp150 (109), representing maturing virions in the 
cytoplasm was stained in red (Figure 27. A). 
 
Figure 27: Intracellular localisation of pUL71 and other tegument proteins in mutants 
with alterations in the leucine zipper-like motif. (A) HFFs were infected with a MOI of 3 
with one of the three viruses 71_wt-BAC (left), 71_ΔLZ-BAC (middle) and 71_L1-BAC 
(right), respectively. Spatial distribution of viral proteins was analysed 120h p.i. by 
confocal microscopy using antibodies pAbUL71 against pUL71 (green) and mAbpp150 
against tegument protein pp150 as a marker for maturing virions (red). Arrows indicate 
distribution of maturing virions in contrast to pUL71 in micrographs 71_wt-BAC (left), 
71_ΔLZ-BAC (middle) and 71_L1-BAC (right), respectively. (B) In comparison to A 
micrograph of a virus lacking the whole UL71 (71_stop-BAC) is reproduced from the 
paper Schauflinger et al. (205) with permission. To mark distribution of maturing virions 
in the infected cell an antibody against tegument protein pp28 was used. Vesicular 
structures were marked by an antibody against endosomal protein CD3. 
 
In the micrograph 71_wt-BAC both pUL71 and the virions (pp150) are localised to the AC in 
the typical junxtanuclear pattern (Figure 27. A, left, 71_wt-BAC). Virions localise in a brood 
cycle (donut shape) within the spherical pUL71 pattern. In both mutant viruses 71_ΔLZ-BAC 
(Figure 27. A, middle, 71_ ΔLZ –BAC) and 71_L1-BAC (Figure 27. A, right, 71_L1-BAC) we 
see a disruption of this pattern. However, pUL71 somewhat localises in the junxtanuclear 
sphere whereas pp150 lost its typical distribution. A similar phenotype is described for viruses 
deficient for the whole UL71 open reading frame (71_stop-BAC) constructed on an AD169 
(248) or TB40E (205) backbone. 
Figure 27. B is a representation of the 71-stop mutant described by Schauflinger et al. (205) 
that shows a similar phenotype in immunofluorescence as 71_ΔLZ-BAC and 71_L1-BAC. In 
this micrograph localisation of virions is represented by pp28 (203), tegument protein 
encoded at UL99, stained in green. Endosomal markers CD3 are represented in red. 
In both cases virions seem to be stuck inside cellular structures that might represent vesicles if 
the leucine zipper motif is altered. This observation is in line with the deficiencies in growth. 
Therefore, we hypothesise that the function of pUL71 in the viral life cycle is dependent on 
intact oligomerisation that is facilitated through this motif. 
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To further analyse whether the observed growth defect of mutant viruses is based on a defect 
in virus morphogenesis ultrastructural investigations by electron microscopy were performed. 
Hence, HFFs were infected with one of the three viruses 71_wt-BAC, 71_ΔLZ-BAC or 71_L1-
BAC at a MOI of 3. Cells were harvested 120h p.i., fixed and embedded for EM-analysis to 
analyse secondary envelopment (cf. 205). 
We analysed 50 cells of each mutant virus on average and counted between 250 and 630 
virions in the cytoplasm. Virions in the nuclei were counted as well, but no significant 
differences between distribution of A-, B- and C- capsids could be detected between 71_wt-
BAC, 71_ΔLZ-BAC or 71_L1-BAC. Therefore we concentrated on the quantification of 
cytosolic particles and sub-classified them into five forms that were counted independently: 
(i) dense bodies, an accumulation of viral proteins enveloped by lipid membrane (=DB) (83, 
204), (ii) non-infectious enveloped particles (NIEPs), derived from B-capsids that have lost 
their DNA upon packaging but undergo morphogenesis (=NP) (108), (iii) and virions prior 
(naked) (=N), (iv) during (=E) or (v) that completed envelopment (=V) (152, 154) (Figure 28. 
J). Upon general inspection we find about 50-60% less cytosolic viral products in the mutant 
viruses 71_ΔLZ-BAC (Figure 28. D-F) or 71_L1-BAC (Figure 28. G-I) compared to 71_wt-
BAC (Figure 28. A-C). This might be due to the growth defect or simply due to the selection 
of cells since we do not detect differences in the number of capsids produced in the nucleus. 
The only striking finding is the accumulation of vacuoles in 71_L1-BAC (Figure 28. G-I) 
compared to the other viruses where we do not detect such an effect. 
Though we detect that infected cells are increasing in size due to the assimilation of virions 
and other viral products, we cannot detect any structure that might represent the AC found in 
immunofluorescence studies with EM analysis. 
Taking a closer look, we quantified different virion forms and detected that the ratio between 
enveloped virions and such that are prior or in the state of envelopment differ between 71_wt-
BAC and 71_ΔLZ-BAC or 71_L1-BAC (Table 4). This effect is obvious comparing 
percentages and as well as counted numbers. We detect 3 to 6 folds more mature enveloped 
virions in 71_wt-BAC than in the mutant viruses 71_ΔLZ-BAC or 71_L1-BAC. Comparing the 
ratio N:E:V in one population we find 1:1:5  in other words five times more mature virions in 
71_wt-BAC. In contrast, the ratio N:E:V is 2:2:1 for 71_ΔLZ-BAC or 2:1:2 for 71_L1-BAC 
showing a tendency of towards non-enveloped particles. Hence we hypothesise, that 
alterations in the leucine zipper-like motif lead to viruses with less efficient secondary 




Figure 28: Localisation of virions by transmission electron microscopy (TEM) of ultra 
thin sections. (A-C) Selection of electron micrographs from HFF infected with 71_wt-
BAC 120h p.i. Overview pictures are showing cytoplasm (Cyt) and partially nucleus 
(Nuc) to verify that the cells are infected. (D-F) Selection of electron micrographs from 
HFF infected with 71_ΔLZ-BAC 120h p.i. Overview pictures that show cytoplasm (Cyt) 
and partially nucleus (Nuc) to verify that the cells are infected. (G-I) Selection of electron 
micrographs from HFF infected with 71_L1-BAC 120h p.i.. Overview pictures that show 
cytoplasm (Cyt) and partially nucleus (Nuc) to verify that the cells are infected. Striking 
morphological changes like vacuoles are indicated by arrows. (J) Key of viral products in 
the cytoplasm: DB: dense bodies; NP: non-infectious particles; N: naked virions; E: 
virions during envelopment; V: enveloped virions. The scale bars correspond to the 
indicated magnifications. 
 
Additionally there might be a difference in protein production levels since we detect different 
percentages of dense bodies as well. In detail, while the number of dense bodies found in 
71_wt-BAC is around 45% of total viral products in the cytoplasm, the numbers decrease in 
71_ΔLZ-BAC to 14% and in 71_L1-BAC even to 2% (Table 4). In addition, the reduced 
number of viral particles detected could be an explanation for the growth deficiency in the 
mutant viruses. 
Taken together, in our ultrastructural investigations we observed that alterations in the leucine 
zipper-like motif cause a growth deficient phenotype that is dependent on insufficient 
secondary envelopment. 
Table 4: Quantification of viral content in the cytoplasm. Counted particle numbers and 
percentages of each fraction relative to the total number of viral products in the cytoplasm are 
obtained to allow comparisons between the three viruses 71_wt-BAC, 71_ΔLZ-BAC and 71_L1-
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To summarise the findings of the functional characterisation of pUL71 in the viral context we 
detected that the function of the protein is dependent upon a non altered leucine zipper-like 
motif. Since we verified previously that leucine zipper-like motif causes oligomerisation in in 
vitro studies, we conclude that protein function is dependent upon oligomerisation of pUL71. 
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If function of pUL71 is destroyed due to mutations in the leucine zipper-like motif we detect a 
phenotype for viruses 71_ΔLZ-BAC and 71_L1-BAC that is characterised by (i) a general 
deficiency in viral replication detected by growth kinetics assay, (ii) a diminished cell-to-cell 
spread, (iii) a spatial de-localisation of the virion marker pp150 from pUL71 towards 
vesicular structures in immunofluorescence and (iii) by insufficient secondary envelopment of 




4.1 Functional characterisation of HCMV pUL77 
One of the crucial steps of HCMV maturation and a potential drug target are all processes 
involved in DNA packaging into preformed capsids (30, 106, 107). Therefore a deepening of 
our understanding of this processes are necessary. So far we understand that viral packaging is 
a multifunctional process in which several gene products are involved. In the case of HSV-1 it 
is known that at least seven proteins, the gene products of UL6 (128, 166, 176), UL15 (20, 
253), UL17 (199, 230), UL25 (144, 222), UL28 (226, 253), UL32 (50) and UL33 (16), are 
required for DNA cleavage and packaging. Homologous proteins pUL104, pUL89, pUL93, 
pUL77, pUL56, pUL52 und pUL51 (52) are found in HCMV but the exact mode of action of 
each protein and the interplay between each other is not elucidated to date. 
In the present study the HCMV protein UL77 (pUL77), the structural homolog to -
Herpesvirinae pUL25, was characterised. Analyses were performed using an antibody against 
pUL77, pAbUL77, generated in this study. The antibody was purified from patients’ sera 
using column affinity chromatography. This is possible since pUL77 is present in sufficient 
amounts in infected individuals to cause host-dependent immune response. Furthermore 
pAbUL77 was successfully tested for monospecificity. On the one hand a subset of 
monospecific antibodies was reacted against the used antigen and on the other hand pAbUL77 
was reacted against commercially available immunoblot stripes containing recombinant 
polypeptides of the most abundant HCMV immunogens. 
In HCMV infected cells pAbUL77 precipitated a protein with a molecular mass of 
approximately 70 kDa. The same protein size was found in infected cells separated by SDS-
PAGE prior using pAbUL77 for immunostaining. For comparisons the calculated molecular 
mass of pUL77 is ~73kDa. 
The tendency of pUL77 to form oligomers was observed in NATIVE-PAGE as well as in 
SDS-PAGE for extracellular virions. Since the binding seems to be rather strong, not 
completely lost under denaturating conditions, it is likely that the oligomer formation occurs 
via covalent binding. Such strong interactions are not unlikely for proteins that have to face 
severe pressure or other harsh environmental conditions like structural proteins of viruses as 
well as archeal proteins. Peters et al (180) reported that tetramers of tetrabrachion, an archeal 
surface protein forms a very stable complex held together by covalent binding, could only be 
denatured by 70% sulphuric acid or heating to 130°C for 30 min in 6 M guanidine 
hydrochloride. Therefore we suggest that the stability of the pUL77 oligomer under 
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denaturing/reducing conditions is due to a coiled-coil structure. A coiled-coil motif was 
identified by in silico prediction and further analysed by in vitro protein-protein interactions 
studies by other members of this group and combined with data of this study for the 
publication by Meissner et al. (149) 
Further the subviral localisation of pUL77 was examined by ultracentrifugational separation 
steps of the virion fractions prior to immunostaining. Again pUL77 oligomers were detected 
in purified extracellular virions and capsids. Thus, demonstrating that pUL77 is a capsid-
associated structural protein. This is in agreement with several observations with the 
homologous proteins of -Herpesvirinae (118, 124, 229). The HSV-1 homologue has been 
analysed by ultrastructural methods and was found to be located at the vertexes of the capsid 
(64, 165). This localisation of pUL25 was described to play a role in stabilisation of capsids 
during DNA packaging against the pressure that is acting upon the capsids while DNA 
insertion (60, 171, 235). We are hypothesising that this is a function of HCMV pUL77 as well. 
In order to test our hypothesis, studies concerning interactions with DNA packaging motor 
components and structural capsid proteins were performed. Co-immunoprecitations in 
infected as well as transfected cells were carried out. In infected cells experiments were 
conducted vice versa to further verify the findings. Co-immunoprecipitations in transfected 
cells were performed to show that the interactions found in infected cells were direct and not 
dependent upon other viral proteins, that might facilitate the interaction of pUL77 to any 
given capsid or capsid-associated protein. In all three experiments we detected interactions 
between pUL77 and the major capsid protein (MCP) as well as the large terminase subunit 
pUL56, in contrast to all other known terminase subunits a structural component associated 
with the capsid, and the portal protein pUL104. The direct interactions with the DNA 
packaging motor components pUL56 and pUL104 support the proposed function of pUL77 
during DNA packaging (33, 78, 206). 
Recent findings indicate that the homologous proteins in α-Herpesvirinae do not interfere 
with DNA cleavage but are involved in later stages of packaging like generating a headfull 
signal to stop the packaging process or providing a cap to seal the portal and hold DNA within 
packaged capsids (15, 119, 144, 171, 222, 235). For HSV-1 pUL25 it has been shown that a 
UL25 null virus causes an accumulation of A-capsids because of deficient DNA packaging 
(144). Even more recent data implicates an additional function of HSV-1 pUL25 in entry (175, 
193). In these studies direct interactions between pUL25 and the nuclear pore were 
demonstrated that implicate that the protein facilitates the step of DNA release from the 
capsids into the nucleus (193). 
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Anyhow, short time DNA binding would be a prerequisite for both proposed functions. 
Therefore the DNA-binding ability of HCMV pUL77 was tested in several assays. Firstly 
binding to non-defined genomic DNA-cellulose was tested in an assay described previously 
(77) and in an optimised version using heparin-sepharose as target. Scott et al. (208) described 
the negative charge of immobilised heparin to mimic the electrostatic characteristics of 
dsDNA. Therefore heparin-sepharose can be used to bind DNA-binding proteins. Further 
different targets were supplied to pUL77 to answer the question whether the DNA has to be 
specially designed to allow binding. Either small fragments containing specific motifs by 
oligonucleotide synthesis (bio-pac) or longer ones by PCR (bio-250, bio-500, bio-1000) were 
obtained, labelled with biotin and covalently bound to avidin- sepharose beads. The bio-pac 
oligonucleotide corresponds to the pac1 sequence (163) and is used, because it is the only to 
date known motif to facilitate DNA-protein interactions in the process of packaging in 
HCMV. The motif is described as the recognition motif of the terminase complex (31). 
Bogner et al. used the very same specific 36-mer to analyse the interaction between pUL56 
and pac1 in an electrophoretic mobility shift assay (31). We verified that it is possible to 
detect specific interactions between proteins and rather short dsDNA fragments (36-mer bio-
pac) by applying pUL56 and therefore used the assay for further experiments. 
In the case of pUL77 we found that the protein binds dsDNA but in contrast to pUL56 in a 
sequence-independent manner though dependent on length of applied DNA. Our results are in 
line with the report of Ogasawara (171) showing that HSV-1 pUL25 binds to genomic DNA. 
In contrast to the terminase subunit pUL56 that only needs a 36-mer encoding pac1 the 
binding was only observed with the 500- and 1000-meric dsDNA. Possible explanation for 
this observation could be the different functions of both proteins. While the sequence specific 
DNA-binding of pUL56 is required to detect unique length genomes, subject them to 
endonuclease activity and insert them into the capsid, the association of pUL77 with DNA is 
more likely a temporary stabilisation. In addition, one could hypothesise that the observed 
effect is due to a different characteristic of the DNA. In our study we defined the relative band 
intensity detected on the blots by Bioimager as binding efficiency (BE) and used this for 
quantitative comparisons. Therefore we detected that binding between pUL77 and DNA 
seems to gets more pronounced with longer DNA fragments are applied. Since the 
enlargement of DNA fragments results in increasing negative charges we are hypothesizing to 
analyse an electrostatic effect. Now we wanted to know whether this effect is unspecific due 
to physico-chemical properties of the whole protein or a real effect. 
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Therefore we consider the isoelectric point (pI) of pUL77 that is 5.73, indicating the protein is 
negatively charged at the used physiological pH 7.3. Therefore the observed effect is not 
unspecific due to a positive charged protein. 
Taken together all observed functions of HCMV pUL77 like association to the virions as a 
structural capsid-associated protein, that directly binds to components of the DNA packaging 
motor and its DNA binding ability indicate a potential function during packaging or DNA 
release. Up to now, further studies will need to be performed aimed at deepening of our 
understanding concerning the role of HCMV pUL77 in the viral life cycle. To further 
investigate whether pUL77 plays a role in entry or processes related to DNA packaging it 
would be interesting to analyse the ultrastructural phenotype of a recombinant virus that is 
deficient for pUL77. Further it would be interesting to identify the DNA binding site and 
generate a mutant virus with alterations in this domain. To analyse the phenotype of both 
recombinant virus can give us information whether the function of the protein is exclusively 
connected to DNA-binding. 
 
4.2 Functional characterisation of HCMV pUL71 
As mentioned previously in this study (cf. 1.2.4.) DNA-packaged capsids have to leave the 
nucleus and undergo further steps of morphogenesis in the cytoplasm before being released 
from the cell as mature infectious virions. Several viral proteins are described to facilitate 
assembly and egress of the virions among them a number of tegument proteins (91). Thereby 
the virus interacts with cellular proteins of the endoplasmic reticulum (43), Golgi apparatus 
(101), endosomal recycling complex (123), multivesicular body (47, 87) and ESCRT 
(endosomal sorting complex required for transport) (225) to make use of cellular trafficking 
pathways for virus transport and morphogenesis. 
One potential candidate that might be involved in such processes is the HCMV protein UL71 
(pUL71), the homolog of -Herpesvirinae pUL51 (25, 131). In contrast to HCMV pUL77 and 
HSV-1 pUL25 we are not analysing a structural but a positional homologue. This means that 
both proteins do not share significant homology at the nucleotide or amino acid level. 
However, HCMV pUL71 and HSV-1 pUL51 are both members of the Herpesvirus U44 
superfamily, containing a conserved functionally unclassified U44 domain (140). 
Members of U44 superfamily can be found in all Herpesvirinae. While there is not much 
known about the function of HCMV pUL71, HSV-1 UL51 has been shown to be a 
palmitylated (169) tegument-associated, late protein (67) with putative involvement in egress. 
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To further characterise the protein an antibody against pUL71, pAbUL71, was generated 
similar to specific antibody pAbUL77, generated in the first part. The antibody was tested for 
monospecificity prior for further usage. A protein of 55kDa was detected in the 
monospecificity assay, in transfected and AD169–infected cells separated by SDS-PAGE. By 
analysing NATIVE-PAGE a higher molecular weight species was detected indicating 
oligomerisation potential of the protein.  
In α-Herpesvirinae, UL51 has been identified as a viral protein incorporated into viral 
particles (67, 119). HCMV pUL71 has also been characterized as part of the tegument of viral 
particles by mass spectronomy analysis (239). To further verify whether HCMV pUL71 is 
connected to virions, extracellular virions were isolated and subjected to fragmentation by 
ultracentrifugation. In this assay, pUL71 was detected both in extracellular as well as in the 
tegument fraction. This finding shows that pUL71 is a structural protein associated to the 
tegument fraction of extracellular virions and is in line with findings described for -
Herpesvirinae (67, 119). 
For further functional characterisation it is important to know the temporal and spatial 
expression pattern of HCMV pUL71 since previous genome analyses failed to result in a clear 
expression kinetics of pUL71 (49). 
We analysed the growth kinetics of HCMV pUL71 by several methods including, a time 
experiment and inhibitor studies by immunostaining and immunofluorescence, respectively. 
Our data show that pUL71 is expressed in the cytoplasm accumulating over time with an 
early-late kinetic. Hence, the protein is expressed from 48h p.i. onwards but dependent upon 
presence of viral inhibitor phosphonoacetic acid (PAA) and thereby the expression of the viral 
DNA-polymerase. A similar experiment was carried by another group defining the protein to 
be expressed with early kinetics, by applying the antiviral drug Foscarnet another inhibitor of 
the viral DNA-polymerase (205). Those inconsistent results are possible because both 
substances inhibit the viral DNA-polymerase using different modes of action; moreover 
pUL71 might use different promoters in our strain AD169 compared to TB40E used by this 
group (205). Therefore, these results might not be contradictory caused by minor 
inconsistencies of the experimental set up instead. 
In addition, our experiment showed that pUL71 is expressed in a very specific cytosolic 
expression pattern. A spherical rather large junxtanuclear structure is detected in the 
cytoplasm that seems to cause morphological changes such as a redistribution of the nucleus 
in a kidney –shaped form. Accumulation in comparable structures is described for a number 
of viral proteins (70, 99, 101, 129, 138, 202, 209, 227) during infection. These structures are 
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termed “assembly compartment” or “assembly complex” (AC) (101, 202). The AC was 
described to contain many vesicles derived from the trans-Golgi network, secretory, and 
endosomal pathway (66, 71, 87, 202, 233) because it combines all structures required for 
morphogenesis and final envelopment. In our confocal microscopy studies we could link 
HCMV pUL71 to distribution patterns of viral (pp28) and the cellular (GM130, p280) marker 
proteins for the AC. In line with our observations both PrV UL51 and HSV-1 UL51 are 
localized at Golgi membranes in transfected cells (169). The same is true for transfected 
pUL71 (this study, data not shown; Dr. Jens von Einem, personal communication). Since 
HCMV infection induces changes in the cellular membrane system such as a spatial 
reorganisation of the endosomal pathway components we can conclude that homologues in all 
three viruses might be involved in egress (71). 
This study in line with others (205, 248) showed that pUL71 is one of the viral proteins that 
localises in the AC. Still our data only reveals similar distribution pattern with the proteins 
tested; hence, it is not convincing to indicate any direct protein-protein interactions. Although 
some proteins spatially co-localise the overall distribution pattern shows no hint on a direct 
binding. This is likely since we only tested the three most prominent proteins described for 
the AC (71). 
To test whether pUL71 might bind to cellular or viral factors that play a role in egress of 
HCMV virions, Yeast-two-hybrid (Y2H) screens against different libraries were performed. 
Similar studies were performed by others as well using a cellular library (236) and a subset of 
viral libraries (181, 232). Our screen against the cellular library gave no positive interactions. 
This observation is in line with unpublished experiments carried out using a library described 
by Uetz et al. (236) that resulted in not detecting any interaction partners of pUL71 (Dr. Jens 
von Einem, personal communication). Therefore we conclude that, (i) either there are no 
interaction between pUL71 and cellular proteins occurring, which is rather unlikely taking the 
confocal images into consideration; (ii) or more likely, that the method is not applicable to 
detect those interactions. This could be either because of using a mouse library instead of a 
human derived one or the detection limit of the method is not sensitive enough to detect viral-
host interactions of pUL71 with cellular proteins. In a further study pUL71 will be screened 
again against a human derived library to elucidate whether the negative results have been 
caused by choosing the wrong library. 
Our library screen against our “in house” viral library resulted in detection interactions 
between pUL71 and pUL77, MCP, pUL89 and pUL104 according to the identification 
method for trustworthy positive interactions described by Sanderson et al. (10). 
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The interaction potential of pUL71 was also tested against different viral libraries by other 
groups. Phillips et al and To et al. performed two independent Y2H screens against different 
subsets of viral proteins (181, 232). However, Phillips et al. was not successful identifying 
interactions of pUL71 with a subset of capsid or tegument proteins because of difficulties 
with reactivation (181). In contrast, To et al. identified interactions between pUL71 and 
pUL26, a transcription factor, and pUL51, DNA packaging protein. Furthermore, the 
interaction between pUL71 and pUL89 was verified. In addition also the self-interaction of 
pUL71 was detected by Y2H (232). This finding is further hinting towards our hypothesis that 
pUL71 has a potential for oligomerisation. Interaction between pUL71, which localises in the 
cytoplasm, (3.2.3) and pUL89, pUL26 and pUL51, which are exclusively localised in the 
nucleus, are considered to have no biological relevance. Unfortunately Y2H screens prepare 
an artificial system that allows proteins to be expressed in Yeast nuclei independent of their 
natural distribution, folding, or abundance. This leads to high numbers of detected false 
positive interactions, observed unlikely to associate in vivo (246). Therefore all results need to 
be further verified by methods better reflecting in vivo conditions. 
The interactions that were considered to likely occur in vivo were analysed in co-
immunoprecipitations in infected cells. Y2H establishes a method of analysing direct 
interactions, without other viral proteins involved, apart from the ones transfected. Hence, we 
performed co-immunoprecipitations in infected cells under conditions in the viral context. 
Thus, verifying interactions between pUL71 and pUL104, MCP and pUL77. These proteins 
are components of the capsid and partially involved in DNA packaging. Since there were no 
interactions detected between pUL71 and pUL56 and because of pUL71’s cytosolic 
distribution we can exclude any influence of pUL71 in processes connected to DNA 
packaging that occur in the nucleus. Therefore it is more likely that pUL71 as a tegument 
protein is connected to the capsids at an early stage of morphogenesis. This observation might 
also be in line with the rather early expression in HCMV life-cycle (48h p.i.). The protein is 
present when egress starts 24h later at 72h p.i.. 
The oligomerisation tendency of pUL71 was discussed earlier by analysing the bands detected 
in NATIVE-PAGE. There we detected a band of higher molecular weight that could occur due 
to interactions with the virions or because of oligomerisation of the protein. In addition, the 
Y2H screen described by To et al. (232) provided evidence that pUL71 has a self-interacting 
and therefore oligomerisation potential. To further investigate that finding baculovirus 
expressed recombinant protein rpUL71-Bac was purified by a combination of anionic 
exchange chromatography and gel filtration prior to EM analysis of negative stained single 
particles. 
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Derived from a gel filtration fraction representing the monomeric form, the purified protein 
has the tendency to self-assemble. We detected several particles calculated to represent 
monomeric as well as higher molecular weight forms of the protein derived from this fraction. 
These result implicated that the recombinantly expressed rpUL71-Bac has the ability to form 
higher ordered structures without additional viral proteins involved. 
To verify those findings, more closely situated to in vivo conditions, studies under 
denaturating or non denaturating SDS-PAGE conditions were performed in infected cells. 
Thereby we detect that presence of pUL71 oligomeric forms is dependent upon non 
denaturating SDS-PAGE a finding that goes in line with observations for pp28 
oligomerisation (209). Since oligomerisation tendency of pUL71 was indicated by several 
independent methods analysing the protein alone as well as in the viral context, results can be 
considered to be applicable in vivo. 
To further analyse the oligomerisation potential of pUL71 first in silico analysis was 
performed. Scanning of a subset of frequent motif databases predicted a leucine zipper motif 
situated between aa 34-55 of the protein. Leucine zipper motifs are composed of at least four 
heptads of amino acids with hydrophobic ones at position 1 and 4 forming a hydrophobic 
core. (130, 173, 174). This motif was predominately described in DNA binding proteins but in 
more recent publication it is generally accepted as a protein-protein interaction domain (19, 
45, 94, 121, 141, 189, 237). 
Further investigations of the physico-chemical properties (89) revealed that we are not 
analysing a classical leucine-zipper motif rather a large hydrophobic face (L55, L37, L48, 
L41, L34, P52, F45) spanning over this area, termed leucine zipper like motif in this study. 
Still we hypothesise that this domain has potential to mediate hydrophobic interactions 
resulting in oligomerisation of pUL71. Such leucine zipper-like motifs are not conserved 
throughout UL71 homologues in the Herpesvirinae. In silico analysis of HSV-1 UL51 
predicted no such domain; still a large hydrophobic domain was predicted in the N-terminal 
part of the protein (p. 138). Further analysis in HSV-1 need to be preformed before any 
conclusions could be drawn from this in silico prediction. In both proteins we detect 
hydrophobic cores at comparable positions. However, continuative investigations need to be 
carried out to elucidate whether this is due to coincidence or a conserved region in all U44 
proteins. 
In silico analysis of the HCMV proteome predicted in the following proteins- pUL14, pUL48, 
pUL50, pUL51, pUL104, pUS17 and pUS29 – to contain similar leucine zipper motifs. In -
Herpesvirinae the only characterised predicted leucine motif zipper is the one in portal protein 
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of HSV-1 pUL6 the homologue of HCMV pUL104. This motif was described not to be 
involved in dimerisation of the protein and hypothesised to stabilise DNA during packaging 
(139) and more recently to facilitate binding to terminase subunits of HSV-1 (250). Those 
findings show that such a leucine zipper or other hydrophobic cores such as the leucine 
zipper-like motif of HCMV pUL71 mediate many functions. The function is not restricted to 
facilitate oligomerisation although in most cases such an interaction is a prerequisite for the 
actual function of the protein. Since the presence of such a motif is not a guarantee on having 
identified the oligomerisation domain of the protein, additional studies were performed to 
elucidate its function in pUL71. Therefore a series of in silico and in vitro experiments were 
performed. Coiled-coil motif analysis predicted that an alteration of the motif by single 
nucleotide exchanges (71_L1, 71_L2, 71_L3) or deletion (71_ ΔLZ) will result in a loss of the 
coiled-coil domain between aa 27-51. Since we are hypothesising that the leucine zipper-like 
motif is the oligomerisation domain of pUL71, a loss of the coiled-coil structure in this region 
would result in a corresponding loss in interacting ability of those mutants. Furthermore, 
biomolecular fluorescence complementation (BiFC) assays (116) and co-
immunoprecipitations were used to verify these predictions in vitro. Both assays indicated that 
alterations in the leucine zipper-like motif results in a loss of interaction between two pUL71 
proteins. Previously, Hu et al. analysed interactions between cellular bZip transcription factors 
in living cells using BiFC (102). Therefore we choose this method to help us solve our 
question concerning characterisation of leucine zipper- like motif in pUL71. BiFC data was 
quantified analysing relative YFP signal of at least >47 cells per experiment, to ensure 
producing statistical relevant data. The decrease in YFP signals of about 60% for mutated 
forms (71_L1, 71_L2, 71_L3 and 71_ ΔLZ) in comparison to 71_wt is comparable to 
experiments carried out applying 71_wt to the vector alone. The finding indicates that even 
exchange of 2 L to A at crucial position 1 of the heptads results in loss of interaction ability. 
The YFP signal will not be completely abolished due to several reasons: (i) the laser might 
cause cross-excitation of YC or YN though they should not emit light on their own resulting 
in background fluorescence or (ii) BiFC visualises not direct binding but spatial proximity 
therefore all tagged proteins that localise in close proximity will cause background 
fluorescence. 
For example all forms of pUL71 still co-localise because their localisation signal to AC (aa 1-
16, Dr. Jens von Einem, personal communication) was not altered in the constructs. Anyhow 
even empty vectors that express YC alone cause comparable background fluorescence. This 
could be due to the close proximity between protein factory of ER and pUL71 localisation. 
Because a 60% decrease in light intensity can be seen as significant enough no further 
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experiments with pUL71 lacking the cytosolic localisation domain (aa 1-16) were performed. 
However, vector experiments revealed that even proteins that have no co-localisation with 
pUL71 in proximity of Golgi/ER are causing comparable background signals. 
To verify those results with a method that detects physical binding co-immunoprecipitation 
experiments were carried out analysing none YFP-tagged as well as YFP-tagged constructs. 
These two subsets of experiments were performed, first to verify the BiFC results and further 
to ensure that the tags used in BiFC do not physically interfere with the binding domains. 
Both subsets of experiments gave comparable results. Still expression of none YFP-tagged 
proteins was more sufficient in 293Ts resulting in qualitatively better immunostainings. The 
oligomerisation of pUL71 was analysed as well by To et al. in their Y2H screen followed by 
verification in immunoprecipitations (232). In contrast to our experiments To et al. could not 
verify their results by co-precipitation using the Y2H constructs in U373 cells. This is likely 
because sufficient protein amounts might not be produced in this system using vectors 
constructed for expression in another species. Preliminary experiments in our lab using U373 
instead of 293Ts together with pcDNA3.1 constructs failed as well to detect interactions 
between pUL71 and capsid proteins because of insufficient protein expression levels (this 
study, data not shown). Taken together data of in vitro assays implicate physical interactions, 
which are a prerequisite for oligomerisation, are only present between two wild type pUL71. 
If alterations in this motif like an exchange of two hydrophobic amino acids (L1) or more 
invasive ones (L2, L3, ΔLZ) are caused, this function is lost. Thus, confirming the leucine 
zipper-like motif to facilitate direct protein-protein interaction. 
To analyse whether this loss of oligomerisation caused by alterations in the leucine zipper-like 
motif has any influence on viral maturation, similar mutations were induced into recombinant 
HCMV. Those mutations resulted in the deletion mutant 71_ΔLZ-BAC and in the single 
nucleotide exchange mutant 71_L1-BAC. Growth kinetic experiments were performed relative 
to wild type virus 71_wt-BAC. The recombinant viruses were constructed in cooperation with 
Dr. Jens von Einem. Revertant viruses were constructed and tested for all mutations induced 
but could not be implied in our experiments due to our cooperation requirements. Therefore 
all characterisation experiments of recombinant viruses were performed in parallel in our and 
in the lab of Dr. Jens von Einem. 
We characterised our viruses for growth, cell-to-cell spread, intracellular distribution of 
pUL71 in comparison to other tegument proteins and ultrastructural investigations by electron 
microscopy. 
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Growth kinetics were performed for the three viruses 71_wt-BAC, 71_ΔLZ-BAC and 71_L1-
BAC for 168h (7 days) at MOI 1.5. Additional experiments were performed using 71_wt-BAC, 
71_ΔLZ-BAC and 71_L1-BAC together with both revertants at high MOI (5) and low MOI 
(0.1) analysing shedded virus in the supernatant as well as cell associated virus (Dr Jens von 
Einem, personal communication). In all experiments growth impairments from 48-72h p.i. 
were observed indicated by reduced viral titres of about 2 to 3 log phases. Furthermore, we 
detected up to 80% reduced plaque size in 71_ΔLZ-BAC and 71_L1-BAC in comparison to 
wild-type. This observation indicates an impaired cell-to-cell spread activity. 
In line with our results, the phenotype of a HCMV mutant carrying a transposon insertion in 
UL71 is characterized by a small plaque phenotype and impaired viral growth (251). In 
addition, a HSV-1 UL51-null mutant is described with impaired viral growth reflected by 
reduced plaque sizes and a nearly 100-fold reduction in virus yield compared to wild-type 
virus (202). A similar phenotype was detected recently analysing HCMV 71-null mutants in 
strains AD169 and TB40E (205, 248). Comparing those published results from 71-null 
mutants to our phenotype caused by mutations in the leucine zipper-like motif of pUL71 we 
detect many parallels.  
Intracellular observations using immunofluorescence revealed that mutations in the leucine 
zipper like motif of pUL71 in 71_ΔLZ-BAC and 71_L1-BAC cause a reorganisation of other 
tegument proteins in infected cells compared to wild-type. While localisation of pUL71 does 
not seem to be altered, tegument protein pp150, used as markers for maturing virions, 
assembles on vesicular structures. This phenotype is comparable to phenotype described for 
viruses deficient for the whole UL71 open reading frame (HCMV 71-null mutants) 
constructed on an AD169 (248) or TB40E (71_stop-BAC, 205) backbone. Schauflinger et al. 
described those vesicles as multivesicular bodies and further identified them by ultrastructural 
analysis using EM (205). 
In line with literature we performed ultrastructural investigations by EM. Accordingly, HFFs 
were infected with one of the three viruses 71_wt-BAC, 71_ΔLZ-BAC or 71_L1-BAC. 
Cytoplasmic viral particles were quantified resulting in an accumulation of virions in a stage 
prior or during secondary envelopment. This effect is highly significant. We detect 3 to 6 folds 
more mature enveloped virions in 71_wt-BAC than in the mutant viruses 71_ΔLZ-BAC or 
71_L1-BAC. Therefore, we hypothesise, that alterations in the leucine zipper-like motif lead 
to viruses with less efficient secondary envelopment of HCMV particles. A similar growth 
defect has been reported for a UL51-deficient PrV (119). Large numbers of intracellular 
capsids in the cytoplasm lacking the envelope or at various stages of envelopment were found, 
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suggesting that envelopmental processes were affected in absence of PrV UL51 (119). A 
UL51-deficient HSV-1 has been shown to exhibit a 100-fold growth defect and to be defective 
for nuclear egress (170). 
Schauflinger et al. (205) argued that in their UL71-null mutant pUL71 is dispensable for 
events before cytoplasmic envelopment but required for correct morphogenesis of the AC (71, 
202, 203) and its associated vesicular system (248). A comparable phenotype is likely for our 
mutants because of similar results occurring for both in all experiments performed. Still we do 
not detect the multivesicular bodies in which the capsids accumulate described by 
Schauflinger et al. (205). Formation of these structures is maybe cell-type dependent. 
Schauflinger et al. (205) used HFFs for all described experiments but ultrastructural analysis 
was performed in MRC-5 (Human diploid fibroblasts) (59). In contrast we always used HFFs 
in all our experiments. Therefore it is possible that in MRC-5 it is more likely that those 
multivesicular bodies establish. The same is true for detection of the AC in ultrastructural 
analysis. We could never detect such accumulations in HFFs were they are highly abundant in 
MRC-5 (Dr. Jens von Einem, personal communication). 
None the less, an accumulation was found of capsids lacking the envelope or at various stages 
of envelopment in all those experiments. In experiments performed by Schauflinger et al. 
(205) this effect was easily detected upon sight, whereas in our experiments after statistical 
quantification. 
Therefore we conclude that the function of pUL71 in the viral context is dependent upon a 
non altered leucine zipper-like motif. Since we verified that leucine zipper-like motif causes 
oligomerisation in in vitro studies, we conclude that protein function is dependent upon 
oligomerisation of pUL71. In other words if the protein cannot oligomerise it cannot facilitate 
processes involved in secondary envelopment. Involvement in secondary envelopment brings 
the proteins into close contact with membranes composed from lipids. Since it is published 
that leucine zipper motifs facilitate protein-protein (141, 189), protein-DNA (19, 45, 94, 121, 
237) as well as protein-lipid interactions (240) through hydrophobic interactions, it would be 
interesting to elucidate whether pUL71 has the ability to bind lipid-bilayers by its 
hydrophobic core produced by the leucine zipper-like motif dependent oligomers. Taking this 
thought into consideration it would be interesting to investigate whether the function of 
pUL71 is to stabilise the process of envelopment by binding both the virions (by binding 
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Abbreviations for chemical compounds are found in the chemical list (2.1.1.1).  
35S Sulphur radioactive isotope 
aa amino acids 
AC Assembly compartment or assembly complex 
AIDS Acquired immune deficiency syndrome 
ATP Adenosine triphosphate 
BAC Bacterial artificial chromosome  
bp Base pair 
BE Binding efficiency  
BiFC Bi-molecular fluorescence complementation  
BSA Bovine serum albumin 
cAMP Cyclic adenosine monophosphate 
CCD Charged coupled device  
cf. lat. conferre, compare 
cGMP cyclic guanosine monophosphate 
cm2 Square centimetre  
DB Dense body 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide 
ds double strand 
EBV Epstein-Barr-Virus (Herpesvirus) 
ECL Enhanced chemiluminescence 
E. coli  Escherichia coli 
e.g. lat. exampli gratia, for example 
EGFR Epidermal growth factor receptor 
EM Electron microscope 
ER Endoplasmatic reticulum (cellular) 
ESCRT Endosomal sorting complex required for transport (cellular ) 
FCS Fetal calf serum 
g g-force (centrifugation)  
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g Gramm (10-3 kg) 
GST Glutathione S-transferase 
h hour 
HCMV Human cytomegalovirus 
HEK Human Embryonic Kidney cells 
HELF human embryonic lung fibroblast cells 
HFF Human foreskin fibroblast cells 
HHV-6 human herpes virus type 6 (Herpesvirus) 
HHV-7 human herpes virus type 7 (Herpesvirus) 
HHV-8 human herpes virus type 8 (Herpesvirus) 
HSV-1 herpes simplex virus type 1 (Herpesvirus) 
HSV-2 herpes simplex virus type 2 (Herpesvirus) 
IBiFC BiFC intensity  
ICTV international committee on virus taxonomy 
IgG Immunoglobulin G  
IF Immunofluorescence  
ImCherry mCherry (red) intensity  
IP Immunoprecipitation  
IRL Internal repeat long; region in Herpesvirus genome 
IRS Internal repeat short; region in Herpesvirus genome 
IYFP YFP intensity  
kb Kilo bases (1000 bases) 
kDa Kilo Dalton (1Da~ 1/ NA gram) 
kg Kilo gram 
L litre 
M Mole  
mA Miliampere, unit of electric current 
mCi Milicurie, unit of radioactivity 
mg Miligram (10-3 g) 
µg Micro gram (10-6 g) 
ml Mililitre (10-3 L) 
µl Micro litre (10-6 L) 
MOI Multiplicity of infection  
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mol Mole, mass entity of NA (Avogadro’s number ((6.02214179 ±3x 10
-7) x 1023 
mol-1) pieces 
MW Molecular weight 
NC Nitrocellulose membrane 
NIEP Non-infectious enveloped viral particle 
ng  Nanogram (10-9 g) 
nm Nanometre (10-9 m) 
OD600 Optical density 600 at nm 
ORF Open reading frame 
OVA Ovalbumine  
o/n Over night (16h) 
PAGE Poliacrylamide gel electrophoresis  
pAP Assembly protein precursor (encoded by HCMV UL80) 
PCR Polymerase chain reaction  
pH negative decimal logarithm of hydrogen ion activity in solution 
pI Isoelectric point 
p.i. Post infection  
PrV Pseudorabies virus (-Herpesvirinae in swine) 
RT Room temperature (~20°C) 
T Triangulation Number (T-Number) T = h2 + k2 + hk (h, k non-neg. integers) 
TEM transmission electron microscopy 
TGN Trans Golgi network (cellular) 
TRL Terminal repeat long; region in Herpesvirus genome 
TRS Terminal repeat short; region in Herpesvirus genome 
UL Unique long segment; region in Herpesvirus genome 
US Unique short segment; region in Herpesvirus genome 
V Volt, unit of electronic force 
VZV varizella zoster virus (Herpesvirus) 
WB Western blot (= immunostaining) 
WM Whatmann blotting paper 
Y2H Yeast two hybrid  
YC C-terminal part of YFP (used for BiFC) 
YFP Yellow fluorescent protein; Fluorophore in BiFC (=citrin)  
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YN N-terminal part of YFP (used for BiFC) 
‘ minute 
°C degree Celsius 
 
Herpes gene products and proteins (239) 
gB Glycoprotein B, encoded by HCMV UL55 
gCI Glycoprotein complex I 
gCII Glycoprotein complex II 
gCIII Glycoprotein complex III 
gH Glycoprotein H, encodes by HCMV UL75 
gL Glycoprotein L, encodes by HCMV UL115 
gM Glycoprotein M, encodes by HCMV UL100 
gN Glycoprotein N, encodes by HCMV UL73 
gO Glycoprotein O, encodes by HCMV UL74 
IE1/2 Immediate early gene 1/2, IE1 encodes by HCMV UL123 
IE2 encodes by HCMV UL122 
mC-BP minor capsid binding protein, encodes by HCMV UL46 
mCP minor capsid protein, encodes by HCMV UL85 
MCP major capsid protein, encodes by HCMV UL86 
pAP Assembly protein precursor (encoded by HCMV UL80) 
pp28 “Phosphor protein 28”; HCMV tegument protein, encoded by UL99  
pp65 “Phosphor protein 65”; HCMV tegument protein, encoded by UL83 
pp71 “Phosphor protein 71”; HCMV tegument protein, encoded by UL82 
pp150 “Phosphor protein 150”; HCMV tegument protein, encoded by UL32 
pPR Proteinase precursor (encoded by HCMV UL80) 
pTRS1 HCMV short terminal repeat gene product 1; Transcription-replication 
U44 Class of Herpesvirus proteins 
pUL14 HCMV type 1 membrane protein, encoded by UL14 
pUL31 -Herpesvirinae protein that facilitates nuclear egress 
pUL34 -Herpesvirinae protein that facilitates nuclear egress 
pUL44 HCMV polymerase co-factor, encoded by UL44 
pUL47 HCMV tegument protein, encoded by UL47 
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pUL48 HCMV large tegument protein, encoded by UL48 
pUL50 HCMV type 2 membrane protein, encoded by UL50 
pUL51 HCMV DNA packaging protein, encoded by UL51 
pUL52 HCMV DNA packaging protein, encoded by UL52 
pUL56 HCMV large terminase subunit, encoded by UL56 
pUL57 HCMV single strand binding protein, encoded by UL57 
pUL69 HCMV RNA-binding protein, encoded by UL69 
pUL71 HCMV tegument protein, encoded by UL71 (this study) 
pUL76 HCMV nuclear protein, encoded by UL76 
pUL77 HCMV capsid associated protein, encoded by UL77 (this study) 
pUL88 HCMV Tegument protein, encoded by UL88 
pUL89 HCMV short terminase subunit, encoded by UL89 
pUL93 HCMV capsid associated protein, encoded by UL93 
pUL97 HCMV viral kinase, encoded by UL97 
pUL104 HCMV portal protein, encoded by UL104 
pUS14 HCMV type 3 membrane protein, encoded by US14 
pUS17 HCMV type 3 membrane protein, encoded by US17 
pUS20 HCMV type 3 membrane protein, encoded by US20 
pUS29 HCMV putative membrane protein, encoded by US29 
RL5A HCMV envelope glycoprotein, encoded by RL5A 
RL13 HCMV membrane protein, encoded by RL13 
SCP small capsid protein, encodes by HCMV UL48A 
UL6 encodes HSV-1 portal protein (=HCMV UL104) 
UL15 encodes HSV-1 terminase subunit (=HCMV UL89) 
UL17 encodes HSV-1 tegument protein (=HCMV UL93) 
UL25 encodes HSV-1 capsid associated protein (=HCMV UL77) 
UL28 encodes HSV-1 terminase subunit (=HCMV UL56) 
UL32 encodes HSV-1 packaging protein (=HCMV UL52) 
UL33 encodes HSV-1 packaging protein (=HCMV UL52) 
UL36 encodes HCMV tegument protein pUL36 
UL70 encodes HCMV helicase-primase primase subunit pUL70 
UL71 encodes HCMV tegument protein pUL71 
UL72 encodes HCMV deoxyuridine triphosphatase pUL72 
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UL76 encodes HCMV nuclear protein pUL76 
UL77 encodes HCMV capsid-associated protein pUL77 
UL78 encodes HCMV envelope protein pUL78 
UL80 encodes HCMV scaffold proteins pAP, pPR 
UL131A encodes HCMV envelope protein pUL131A 
 
Amino acids 
A (Ala) Alanine 
D (Asp) Aspartic acid 
E (Glu) Glutamic acid 
F (Phe) Phenylalanine 
H (His) Histidine 
I (Ile) Isoleucine 
K (Lys) Lysine 
L (Leu) Leucine 
N (Asn) Asparagine 
P (Pro) Proline 
Q (Gln) Glutamine 
R (Arg) Arginine 
T (Thr) Threonine 













In silico analysis HSV-1 UL51 in comparison to HCMV UL71 
Psi-pred HHHHHHHHHH HHHCCCCCCC CCCCCCCCCC HHHHHHHHHH HHHCCCCCCC CHHHHHHCCC 
HCMV   1 mqlaqrlcel lmcrrkaapv adyvllqpse dvelrelqaf ldenfkqlei tpadlrtfsr 
HSV-1  1 masllgaicg wgarpeeqye miraavppse aeprlqeala vvnallpapi tlddalgsld 
Psi-pred CHHHHHHHHC CCCCCHHHHH HHHHCCCCCC CHHHHHHHHH HHHHHCCCC CCHHHHHHCHH 
 
Psi-pred CCHHHHHHHH HHHHHHHHHH HHHHHHHHHH HCCCCCCCCC HHHHHHHHHH HHHHHHHHHH 
HCMV  61 dtdvvnhllk llplyrqcqs kcaflkgyls egclphtrpa aeveckksqr ilealdilil 
HSV-1 61 dtrrlvkara lartyhacmv nlerlarhhp gfeaptidga vaahqdkmrr ladtcmatil 
Psi-pred HHHHHHHHHH HHHHHHHHHH HHHHHHHCCC CCCCCCCHHH HHHHHHHHHH HHHHHHHHHH 
 
Psi-pred  HHHHHCCCCC CHHHHHHHHH HHHCCCHHHH HHHHHHHHHC CCCHHHHHHH HHCCCCCCCC 
HCMV  121 klvvgefams eadslemlld kfstdqaslv evqrvmglvd mdceksayml eagaaatvap 
HSV-1 121 qmymsvgaad ksadvlvsqa irsmaesdvv medvaiaera lglsafgvag gtrsggigvt 
Psi-pred  HHHHHCCCCC CCHHHHHHHH HHHHHHHHHH HHHHHHHHHH HCCCCCCCCC CCCCCCCCCC 
 
Psi-pred  CCCCCEEECC CCCCCCCCEE EEEECCCCCC CCCCCCCCCC CCCCCCCCCC CCCCCCCCCH 
HCMV  181 ptppavvqge sgvredgetv aavsafacps vsdslipeet gvtrpmmslah intvscptv 
HSV-1 181 eapslghpht pppevtlapa arngdalpdp kpescprvsv prptasptap rpgpsraapc 
Psi-pred  CCCCCCCCCC CCCCCCCCCC CCCCCCCCCC CCCCCCCCCC CCCCCCCCCC CCCCCCCCCC 
 
Psi-pred  HHHHHHHHHC CCCCCCEEEE CCCCCCCCCC CCCCCCCCCC CCCCCCCCCCC CCCCCCCCC 
HCMV  241 mrfdqrllee gdeedevtvm spspepvqqq ppvepvqqqp qgrgshrrry kesapqetlp 
HSV-1 241 vlgq 
Psi-pred  CCCC 
 
Psi-pred  CCHHHHHHHH HHCCCCCCCC CCCCCCEEEC CCCCCCCCCC HHHHCCCCCC CCHHHHHCCC 
HCMV  301 tnhereildl mrhspdvpre avmsptmvti pppqipfvgs arelrgvkkk kptaaallss 
 
Psi-pred C 
HCMV  361 a 
 
p-coils: predicted coiled-coil motifs in orange 
Psi-pred: H...Helix, E.. strand, C..coil 
HSV-1 UL51 aa.31-52      Hydrophobic core: l45a31a38r49v42l35l46l39 (Heliquest prediction) 
HCMV UL71 aa. 34-55    Leucien zipper-like motif lrelqaf ldenfkqlei tpadl(Motif scan prediction) 
Hydrophobic aa. i..isoleucine, l..leucine in yellow 
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